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AchChEI Acetyl-cholinesterase inhibitor
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SPECT Single photon emission computed tomography
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Chapter 1: General Introduction
1. General introduction
This thesis explores the use of pharmacological functional magnetic resonance imaging 
(pharmacological fMRI or phMRI) within a clinical context.
1.1 MRI and fMRI
Magnetic resonance imaging (MRI) is a non-invasive imaging technique that is used in 
clinical practice to make high-resolution digital images of water-containing human tissues. 
Ever since its first appearance in hospitals in the 1980s, it has greatly enhanced the 
ability of clinicians to make accurate diagnoses by providing a detailed view of structural 
abnormalities occurring within normal appearing tissue. MRI scanners examine the 
effects of a wide range of tissue characteristics on the ability of atomic nuclei (usually 
protons) to absorb and emit radiofrequency radiation within a strong magnetic field. 
Functional magnetic resonance imaging (fMRI) is an extension of traditional MRI, in 
which the varying magnetic properties of the oxygen transporter molecule haemoglobin 
are exploited to examine brain function in human subjects (Jezzard et al., 2001).
When activity of neurons in neural tissue increases (e.g. subjects receive 
sensory stimuli), neurotransmitters and metabolites are released into the extracellular 
environment. This leads to an increase in local blood flow, volume and oxygenation levels 
through a process called ‘neuro-vascular coupling’ (Logothetis & Pfeuffer, 2004). Blood 
flow and oxygen concentrations are raised beyond a level necessary to compensate for 
local oxygen and energy demands (perhaps to facilitate oxygen extraction by raising 
the diffusion coefficient, or neurotransmitter washout by raising blood flow). The result 
is that active brain regions are characterised by increased blood oxygenation levels 
relative to their less active states. Haemoglobin with oxygen (oxyhemoglobin) has no 
significant magnetic properties of its own, and will not affect the static magnetic field 
of the MR scanner (i.e. oxyhemoglobin is ‘diamagnetic’). Haemoglobin without oxygen 
(deoxyhemoglobin), however, has magnetic properties that result in the formation of 
magnetic field gradients around blood vessels (i.e. deoxyhemoglobin is ‘paramagnetic’). 
Such gradients distort local magnetic field homogeneity, which decreases phase 
coherence of protons (shorten T2*) and reduces signal readout from such regions. 
Thus, decreased neural activity is accompanied by more local magnetic field distortions 
and therefore less MR signal. In contrast, increased activity of neural tissue leads to 
less magnetic field distortions and more MR signal.
Functional imaging experiments involve the recording of these blood oxygenation 
level dependent (BOLD) signal intensity changes in time, by scanning large numbers 
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of brain volumes in rapid succession (i.e. creating a movie, or ‘timeseries’). Special 
sequences of gradient field manipulations and proton excitation with non-ionising 
radiation within the radiofrequency range are required to optimise detection of significant 
BOLD signal intensity changes. One of the most popular and widely used sequences 
in fMRI imaging experiments is the echo planar imaging (EPI) sequence, which allows 
rapid and continuous acquisition of hundreds to thousands of brain volumes within 
minutes to hours (i.e. one brain volume every ~2s). A typical fMRI experiment lasts for 
several minutes and produces a time series consisting of several hundreds of brain 
volumes. Each of these volumes is made up of several thousands of volume elements 
(voxels), which represent the smallest unit of spatial resolution of the functional image 
(typically ~3 x 3 x 3mm for studies in individuals).
In most fMRI studies, subjects are scanned while performing a certain task (or 
‘paradigm’). In such paradigms, conditions of interest alternate with reference conditions 
to produce differences in BOLD signal intensity. Task conditions have to be repeated in 
order to reduce the effects of noise-variables and detect signal changes that correlate 
significantly with task stimuli. Two basic task designs are possible. ‘Block designs’ 
involve alternations of task conditions with relatively long durations (i.e. 30-40s). Such 
designs allow for detection of global functional effects of task performance in relatively 
short amounts of time. ‘Event-related’ designs involve alternations of discrete stimuli (i.e. 
0.1–5s), which allows analyses of isolated event types and subcomponent processes 
during task performance (Buckner et al., 1996).
Most commonly, a model-fitting approach is used that examines the degree to 
which actual changes in signal intensity measured at each voxel during task performance 
(in a single subject) conform to a user-specified hypothesis of signal behaviour (based 
on prior knowledge of the onset times of all stimuli in a particular task) (Jezzard et 
al., 2001). Based on this model, average signal intensity changes from baseline and 
corresponding standard deviations are estimated for each task condition in a voxelwise 
manner. Estimated mean signal intensity change is then divided by its standard deviation 
(i.e. noise), to produce a signal-to-noise ratio, which is expressed as a T-value. In order 
to facilitate between-voxel and between-session comparisons, this T-value is normalised 
with respect to its standard deviation, to produce a Z-value (Z-score; a normalised 
T-value). For technical reasons, fMRI is not well able to provide reliable measures of 
absolute signal intensity (the MR signal may show ‘drifts’ in time, the correction of 
which requires rapid online calibration). fMRI studies therefore usually report relative 
measures of signal intensity, which involve a comparison of average signal intensity 
changes from baseline between two conditions of interest. The assumption is made 
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that drifts in signal intensity equally affect signal intensity during both conditions, hence 
their subtraction should produce a stable value. The resulting ‘contrast maps’ are three-
dimensional functional images in which signal intensity at each voxel represents a new 
Z-score, which expresses the difference between estimated signal intensity changes 
calculated for both conditions of interest, corrected for the noise levels found under both 
conditions (e.g. hot colours indicate significantly stronger stimulus-related activation 
during one condition versus another (i.e. activations), and blue colours represent 
significantly lower stimulus-related activation for one condition than for another (i.e. 
deactivations). Since functional images are of low spatial resolution when compared 
to conventional anatomical images obtained with structural MRI, contrast maps are 
superimposed onto structural brain volumes for ease of localisation of the effects.
fMRI is a non-invasive imaging technique, which is important in terms of its further 
development as a clinical tool. When performed at conventional spatial resolution, fMRI 
produces functional neuroimages that reflect brain function at the level of neural networks 
and systems. This places it in a central position with respect to techniques examining 
similar effects at other levels of neural organisation (Figure 1). When compared to 
other non-invasive techniques used to examine brain function at a system level (e.g. 
electroencephalography (EEG), magnetoencephalography (MEG) or positron emission 
tomography (PET)), fMRI combines several unique features (Jezzard et al., 2001). These 
include:
A high spatial resolution (compared to EEG or MEG).
A good temporal resolution (compared to H2
15O PET). This allows event-related 
analyses of subcomponent processes during task performance (Buckner, 
1998).
The ability for repeated measurements in single subjects with no technical 
constraints put to the number and duration of the experiments, which makes 
it a highly flexible technique (PET investigations are limited by the half-life and 
cumulative dose of radioactive tracers).
Because of its high flexibility and ability for event-related analyses, fMRI has gradually 
replaced H2
15O PET as the non-invasive imaging technique of choice to examine brain 
function at high spatial resolution. Possible constraints of fMRI are its low signal-to-
noise ratios, its relative measures, and the fact that the BOLD signal is not a direct 
measure of neural activity. BOLD signal intensity changes may therefore be difficult to 
interpret in terms of underlying neurodynamics (Logothetis & Pfeuffer, 2004).
1.
2.
3.
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Figure 1. fMRI relative to other techniques used to examine brain function at different levels of 
neural organisation.
Ever since its first use in animals and humans in 1991, fMRI has proven to be a valuable 
extension to fundamental studies of brain function and behaviour. Event-related fMRI has 
meant an important advance particularly in studies of memory performance ((Buckner et 
al., 1998a; Buckner et al., 1998b); see below). So far, the clinical use of fMRI has been 
largely limited to localisation of language and sensorimotor regions prior to surgery 
in patients with neural or vascular damage (Powell & Duncan, 2005). Although more 
clinical applications are expected, fMRI currently remains a research tool, of which 
the full potential is still actively explored. The current thesis examines one promising 
application of fMRI, which concerns the imaging of pharmacological effects on BOLD 
signal intensity.
1.2 phMRI
Pharmacological fMRI (phMRI) examines the impact of pharmacologically induced 
neurochemical changes on BOLD signal intensity (Honey & Bullmore, 2004). Most 
phMRI studies use the same approach to detect significant effects of pharmacological 
16
Chapter 1: General Introduction
intervention on brain function: ‘main effects’ during task performance within a group of 
subjects (i.e. brain activation or deactivation as a result of task stimuli) are compared 
statistically between placebo and active medication conditions to produce group-
level contrast images of ‘treatment effects’. The field is still in its early stages. Since 
1999, some 60 articles have been published concerning the topic of phMRI. The first 
phMRI studies mainly involved feasibility studies in animals and fundamental studies 
of neurotransmitter system function in humans (e.g. neurotransmitter depletion or 
overexpression) (Shah & Marsden, 2004). Such studies showed that changes in brain 
function as a result of pharmacological treatment may be region-specific, process-
specific and even genome specific and depend on age and cognitive capacity (Honey 
& Bullmore, 2004).
Apart from studying fundamental processes, phMRI has been used to examine 
the effects of pharmacological intervention on brain function within a clinical context. 
So far, clinical phMRI studies mainly involved feasibility studies in patients, studies of 
pharmacotherapeutic mechanisms and the effects of certain vulnerability traits (such as 
substance abuse and addiction) on the functional response to an addictive substance. 
The (differential) diagnostic and prognostic value of phMRI has been addressed only 
recently and will be considered further in this thesis.
Knowledge of pharmacological effects on neural systems in vivo is still quite 
limited. PET studies (Gee, 2003; Moresco et al., 2001) and EEG studies (Fingelkurts 
et al., 2005) of pharmacological intervention have yielded important information, yet 
technical difficulties prevent a single technique from providing a comprehensive picture. 
Since the various imaging modalities are complementary rather than competitive (Rudin 
& Weissleder, 2003), it is hoped that a combination of high spatial and temporal 
resolution allows for an optimal view of the effects of pharmacological intervention on 
brain function in living subjects.
1.3 Aim of this thesis: exploring the use of phMRI in a clinical context
Given its combined qualities as a high-resolution, non-invasive imaging technique that 
allows for event-related analyses and repeated measurements within the same subject, 
fMRI can be used to answer several questions concerning pharmacological effects on 
brain function, which may be relevant to its use in a clinical context:
Does a pharmacological substance of interest indeed produce changes in the 
BOLD response?
Are treatment effects on the BOLD signal region- and process-specific?
Are functional changes specific to certain subgroups of subjects or patients (e.g. 
gender-specific, disease-specific)?
1.
2.
3.
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Are functional changes dependent on drug dosage and exposure duration?
Can fMRI be used to examine the treatment mechanism of a pharmacological 
substance?
Do the observed functional changes have (early, differential) diagnostic value, or 
predictive value for treatment response and eventual clinical outcome?
Following a tradition of memory research in relation to Alzheimer’s disease and related 
disorders, this thesis attempts to address these questions by studying effects of 
pharmacological substances on brain function in controls and patients during memory 
task performance. Studies were performed in collaboration with the departments of 
Neurology (Alzheimer Center), Radiology, Physics and Medical Technology, Statistics, 
and Endocrinology of the VU University Medical Centre, and with the department of 
Clinical and Experimental Psychology of the University of Amsterdam, the Netherlands.
Studying drug effects on memory function in controls and patients requires some 
knowledge of the neurochemistry that is modulated pharmacologically, its putative 
effects on the memory systems under investigation, and the pathological changes 
occurring in these memory systems in disease. The following paragraphs will therefore 
briefly address some of the key concepts of neuropharmacology in relation to functional 
neuroimaging studies of memory performance that provided the global context for the 
studies reported in this thesis.
1.4 phMRI: studying changes in neurotransmission
Most neuropharmacological substances exert their influence on brain function by 
interacting with neurotransmitter systems. Most classical neurotransmitter systems 
contribute to memory performance (for a recent meta-analysis, see (Myhrer, 2003)). 
The current thesis focuses on the pharmacological modulation of three neurochemical 
systems in relation to memory function within the central nervous system: the cholinergic, 
noradrenergic and the sex-steroid system.
The central cholinergic system originates in the brain stem and basal forebrain, 
where the neurotransmitter ‘acetylcholine’ is produced in discrete cholinergic nuclei 
(e.g. nucleus basalis of Meynert) and distributed diffusely across the brain (Selden 
et al., 1998). At the molecular and cellular level, acetylcholine interacts with nicotinic 
or muscarinic cholinergic receptors (ligand-gated ion channels) to modulate the 
transmembrane potential and induce protein synthesis through activation of G-protein 
coupled second messenger systems (Dani, 2001). Thus, in the short run, cholinergic 
activity provides the arousal state necessary for learning new information (McGaugh, 
2004), and for directing selective attention to relevant versus non-relevant stimuli (Sarter 
4.
5.
6.
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et al., 2005). In the long run, cholinergic activity contributes to memory formation by 
modulating the connection strengths of newly formed synapses and stabilising synaptic 
connections between networks that encode relevant associations (Mesulam, 1996; 
Little et al., 1998; Rezvani & Levin, 2001; Gu, 2002). A loss of cholinergic function 
may be observed in several clinical conditions including Alzheimer’s disease (AD). 
In AD, atrophy of the basal forebrain nuclei produces a cholinergic deficit, which is 
thought to contribute significantly to the symptomatology of the disease. Apart from 
memory impairment (Bartus, 2000), cholinergic dysfunction has been associated with 
neuropsychiatric symptoms such as attention deficits, sleep disorders, loss of verbal 
fluency, anxiety, depression, and psychosis (Assal & Cummings, 2002). Although 
the role of a cholinergic deficit in AD has been well established, the extent to which 
cholinergic function is impaired in AD, along with the time of onset of this impairment, 
are still subjects of debate. Recent results suggest that cholinergic function is intact 
and may even be upregulated in early stages of AD, such as mild cognitive impairment 
(MCI). MCI is defined as a slowly progressive memory decline without the involvement of 
another domain of cognitive function, that does not interfere significantly with activities 
of daily living (Petersen et al., 2001). MCI patients are at increased risk of developing 
AD, but clinical outcome may vary considerably at this stage. It has been hypothesised 
that conversion from MCI to AD (partly) reflects the inability of the cholinergic system to 
compensate for progressive memory deficits as a result of early hippocampal damage 
(DeKosky et al., 2002).
When compared to the cholinergic system, considerably less is known about 
the central adrenergic system. This system originates from discrete nuclei within the 
brain stem (mainly the nucleus coeruleus), where the neurotransmitter ‘noradrenaline’ is 
produced and transported diffusely across the brain. At the molecular and cellular level, 
noradrenaline interacts with alpha- and beta- adrenergic receptors (G-protein coupled 
receptors) to modulate the transmembrane potential and induce protein synthesis 
through activation of cyclic AMP related second messenger pathways (Waterhouse 
et al., 1991). The noradrenergic system is thought to be relevant to memory encoding 
and consolidation through a number of different actions, all of which result from the 
processing of (highly) emotionally relevant or meaningful information. These actions 
involve amygdala-mediated enhancement of cortical arousal, stimulation of the stress 
response, and stimulation of the cholinergic system in the brainstem (McGaugh, 2004). 
A loss of noradrenergic function (e.g. atrophy of the nucleus coeruleus) is thought to 
be relevant to a number of clinical conditions, including memory loss in AD, cognitive 
and movement disorders in Parkinson’s disease (Marien et al., 2004), anxiety and panic 
disorders, depression, and post-traumatic stress disorder (LeDoux, 1998).
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The effects of sex steroids (e.g. estrogen, testosterone, progesterone) on memory 
function are complex and still relatively unclear. Sex steroids are produced in male and 
female gonads as a result of the actions of a cascade of hormones that are produced 
in the hypothalamus and pituitary. They exert a broad range of effects across the entire 
human body, including the central nervous system (Pfaff, 2005), where they may have 
neuroprotective effects (Wise et al., 2005). At the molecular and cellular level, estrogens 
interact with alpha- and beta-estrogen receptors (ligand-dependent transcription factors) 
to produce a slow genomic effect, and with membrane-bound estrogen receptors to 
directly affect neural signalling (Vasudevan et al., 2005; Wolf, 2003; Bisagno et al., 
2003). Apart from affecting neural architecture during development, sex steroids have 
modulatory effects on the four primary neuromodulatory neurotransmitter systems (i.e. 
the cholinergic, noradrenergic, serotonergic and dopaminergic systems) (Bernardi et 
al., 2003; Korol, 2004). Thus, sex steroids are thought to be responsible for global 
differences in behaviour between the sexes (Cahill, 2003). A drop in estrogen levels 
during menopause has been implicated in an increased risk of postmenopausal women 
for mild cognitive impairment (MCI) and Alzheimer’s disease (AD) (Yaffe et al., 2005).
1.5 Memory tasks (‘paradigms’) used in the current study
To examine the impact of pharmacological intervention into noradrenergic, cholinergic 
and sex-steroid systems on brain function during memory performance, several fMRI 
paradigms were constructed. These paradigms activated brain structures relevant to 
different aspects of memory performance (for a review on the neuropsychology and 
taxonomy of memory, see (Gazzaniga et al., 2000)).
An n-letter back working memory task was used to examine brain function during 
short term working memory performance (see further descriptions in this thesis). In both 
controls and patients, this task reproducibly activates bilateral parietal and prefrontal 
brain regions with a preference for the left hemisphere. Brain function within these areas 
is thought to represent automatic maintenance and effortful manipulation of symbolic 
information (letters) in short term memory in the absence of the original stimulus (Owen 
et al., 2005).
Face encoding and -recognition tasks were used to examine (intermediate term) 
episodic memory performance for unfamiliar and emotionally neutral human faces (see 
further descriptions in this thesis). Face encoding and -recognition tasks are among the 
most established of memory tasks and have been widely used in functional neuroimaging 
studies to elicit reproducible patterns of brain function in both controls and patients 
(Small et al., 1999). Encoding tasks produce brain function related to the encoding 
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phase (naive situation) of memory performance. Recognition tasks produce brain 
function during retrieval of familiar or attempted retrieval of unfamiliar items (i.e.  during 
the non-naive situation, or ‘retrieval-mode’). fMRI allows event-related analyses of brain 
function related to distinct response types during retrieval (e.g. correct hits, correct 
rejections, false hits, and false rejections), which when contrasted allow further analysis 
of subcomponent processes during recognition, such as successful recognition and 
encoding during attempted retrieval (Buckner, 1998; Daselaar et al., 2003).
Finally, an encoding task was created using images from the international affective 
picture system (IAPS; see further descriptions in this thesis) (Lang & Bradley, 1997). 
This paradigm allows visualisation of brain function during encoding of aversive stimuli 
(i.e. disgusting, harmful or threatening information) into memory, and was developed 
in collaboration with Dr. A.H. van Stegeren and Prof. Dr. W.TA.M. Everaerd from the 
department of Clinical and Experimental Psychology of the University of Amsterdam. 
The primary function of this paradigm was to optimise detection of amygdala function 
during emotional memory performance.
1.6 Outline of this thesis
A total of three pharmacological substances were examined for their effects on brain 
function during memory task performance. These include propranolol, which is a 
centrally and peripherally acting blocker of beta-adrenergic neurotransmission (Ananth 
& Lin, 1986), raloxifene, which is a selective estrogen receptor modulator (SERM) of 
which the effects on brain function remain to be investigated (Heringa, 2003), and 
galantamine, which is a weak cholinesterase inhibitor with a strong sensitising effect 
on nicotinergic receptors and known efficacy in the treatment of memory deficits in 
AD (Raskind, 2003). Studies reported below are summarised in the order in which 
they appear in this thesis (subject and content of these studies partly mirror the rapid 
developments in the field of phMRI):
In Chapter 2, propranolol was used to block beta-adrenergic neurotransmission 
in the central nervous system of healthy young subjects. Since animal studies have 
shown that neurotransmission in the amygdala is predominantly noradrenergic, we 
hypothesised that a singe oral dose of propranolol in humans would interfere with 
normal amygdala function during encoding of emotionally charged information (IAPS 
pictures; see above) into memory. This phMRI study aimed to link functional and 
behavioural data on amygdala function in animals and humans by examining the influence 
of pharmacological impairment of beta-adrenergic neurotransmission on amygdala 
function in human subjects. The possibility that both sexes respond differentially to 
beta-adrenergic blockade is also discussed.
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In Chapter 3, two studies are presented that examine the effects of the SERM raloxifene 
on brain function. These studies examined long-term effects of raloxifene treatment while 
anticipating its clinical prescription in elderly males. Effects of long-term (three months) 
raloxifene treatment were examined during encoding (Chapter 3.1) and recognition 
(Chapter 3.2) of emotionally neutral human faces into memory. Predictions are made 
with respect to behavioural changes based on the observed effects of treatment, and a 
hypothesis is presented for a possible treatment mechanism of raloxifene.
In Chapter 4, three phMRI studies are presented that examine the effects of 
short-term galantamine exposure on brain function in patients with mild cognitive 
impairment (MCI) and Alzheimer’s disease (AD). Effects of galantamine challenge 
were evaluated at different exposure durations (i.e. acute (single dose) and prolonged 
(5 days) exposure) on brain function during face encoding, face recognition and n-letter 
back working memory performance. Effects of galantamine intake are first examined on 
brain function during face encoding and working memory performance in MCI (Chapter 
4.1) and AD patients (Chapter 4.2) separately. Similar effects are then examined on 
brain function during recognition, which are compared directly between MCI and AD 
patient groups (Chapter 4.3).
Chapter 4.1 examines the feasibility of detecting effects of pharmacological 
challenge in patients with MCI. Studies examining cholinergic system reactivity to 
pharmacological challenge in MCI patients may be used to assess the functional status 
of the cholinergic system in disease, which may be relevant in terms of predicting further 
memory decline, and possibly conversion to AD.
Chapter 4.2 examines effects of galantamine challenge in AD patients. Like 
chapter 4.1, cholinergic reactivity is evaluated with respect to brain function during face 
encoding and working memory performance. Differences with cholinergic reactivity of 
MCI patients are discussed, and effects of galantamine challenge on the shape of the 
BOLD response are investigated.
Chapter 4.3 examines MCI and AD patients for a differential response to 
galantamine challenge during face recognition. Such a differential response may indicate 
a difference in the functional status of the cholinergic system in both patient groups. 
The issue of region-, process- and disease-specificity of treatment effects is raised. 
Additionally, the possible clinical (e.g. diagnostic) value of a differential response to 
pharmacological challenge is highlighted.
In Chapter 5, findings from our phMRI studies are summarised and discussed 
within the context of the clinical potential of phMRI, after which suggestions are made 
for future studies.

Chapter 2
Effects of beta-adrenergic blockade on 
amygdala function in healthy young subjects
2.1 Noradrenaline mediates amygdala activation in men and 
 women during encoding of emotional material
Van Stegeren AH, Goekoop R, Everaerd WTAM, Scheltens P, Barkhof F, Kuijer JP, 
Rombouts SARB
Neuroimage. 2005; 24(3):898-909. PMID: 15652324 
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Abstract 
The amygdala is a pivotal structure in humans for encoding of emotional information, as 
shown by recent imaging studies. It is unknown which neurotransmitters are specifically 
involved in the human amygdala, although in animal studies noradrenaline was shown 
to be essential. In our study participants received the betablocker propranolol (which 
blocks the noradrenergic response) or placebo when watching neutral to highly negative 
arousing pictures. Amygdala activation, monitored with functional magnetic resonance 
imaging (fMRI), increased with emotional intensity of the pictures under placebo 
condition. Betablockade selectively decreased amygdala activation for emotional 
pictures of the second highest category, but not for the highest or lower (neutral) 
category pictures. Two findings add to the existing knowledge in this area. First, the 
activation pattern in the amygdala under placebo condition shows a non-linearity related 
to the emotional categories of the pictures. Secondly, propranolol disturbs this activation 
pattern in the amygdala. Explorations with respect to gender show a similar effect of 
betablockade on amygdala activation in both men and women, but a difference in its 
effect on long term memory for emotional pictures. This study supports the hypothesis 
that the neurotransmitter noradrenaline also mediates amygdala activity in humans when 
processing emotional stimuli and that betablockers can disrupt the normal activation 
pattern in the amygdala. 
Key words: amygdala; fMRI; noradrenaline; gender.
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Introduction
A critical function of the human amygdala is the processing of emotional information. This 
process varies from the perception of stimuli that have emotional significance (Anderson 
& Phelps, 2001) to the continuing stages in the memory process . Exposure to aversive 
stimuli in multiple sensory modalities induces activation of the amygdala. Several 
imaging studies using a variety of visual, auditory, olfactory or gustatory stimuli evoked 
amygdala activation in humans. Even unpleasant interoceptive or painful sensations 
appear to induce amygdala activation (Zald, 2003). Although the activation pattern 
of the amygdala was consistently found in reaction to aversive stimuli (Fischer et al., 
2003; Garrett & Maddock, 2001; O’Doherty et al., 2001; Phan, Fitzgerald et al., 2004; 
Phelps et al., 2001; Stark et al., 2003; Zald & Pardo, 2002), activation was also found 
in reaction to positively valenced stimuli from multiple sensory modalities (Garavan et 
al., 2001; Hamann et al., 1999; Lane, Chua, & Dolan, 1999; Lane et al., 1997). Recent 
findings also provide evidence for a role of the amygdala in reaction to visual sexual 
stimuli as contrasted with non-sexual stimuli (Canli & Gabrieli, 2004; Hamann et al., 
2004) as well as for an important role in regulating human sexual behavior (Baird et al., 
2004). It appears that all these responses are modulated by the arousal level, hedonic 
strength or motivational value of the stimuli. 
With respect to the role of the amygdala in memory processes this structure 
was shown to be active during the encoding of emotional stimuli (Adolphs et al., 2000; 
Cahill et al., 1996; Canli et al., 2000; Hamann et al., 1999) or emotional context (Erk 
et al., 2003). Other studies stressed the important role of the amygdala in enhancing 
the strength of long-term memory for emotional stimuli, hence its role in consolidation 
processes (Cahill et al., 1996; McGaugh et al., 1996). The role of the amygdala as part 
of a neural network in relation to emotional memory was put forward in several studies. 
Two of these recent reports stressed the importance of the interaction between the 
amygdala and hippocampus that appears to be essential for a successful encoding and 
consolidation of emotional stimuli and situations (Phelps, 2004; Richardson, Strange, & 
Dolan, 2004). A recent path analysis using structural equation modeling also addressed 
aspects of the ‘memory modulation hypothesis’. They showed increased functional 
connectivity between the amygdala and the ipsilateral parahippocampal gyrus and 
ventrolateral prefrontal cortex during emotional relative to a neutral film viewing condition 
(Kilpatrick & Cahill, 2003). Using event-related fMRI during encoding of emotional and 
neutral pictures Dolcos et al. (Dolcos, LaBar, & Cabeza, 2004) found support for the 
modulation hypothesis, stating that better memory for emotionally arousing events 
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(compared with non-arousing neutral events) is due to an effect of the amygdala on the 
medial temporal lobe (MTL) memory system. 
More anecdotal evidence shows that memories of emotionally arousing events tend to 
be more vivid and to persist longer than do memories of neutral events. Apparently, the 
relevance and salience of a stimulus is important in survival of the species. It seems 
likely that processing of emotional information is mediated by neurotransmitters that 
have a relation to arousal, such as noradrenaline. 
In animal studies noradrenaline was shown to be one of the essential 
neurotransmitters in the (basolateral) amygdala, related to emotional processing 
(McGaugh, 2000). Pharmacological findings indicate that activation of postsynaptic 
alpha1-adrenoreceptors potentiates beta-adrenoceptor-mediated activation of cAMP 
(cyclic Amino-Mono-Phosphate) formation (Ferry, Roozendaal, & McGaugh, 1999a). 
However, this has only been shown in animal studies, where noradrenergic agonists, 
such as clenbuterol, injected directly into the amygdala, improved memory performance 
in rats (Ferry & McGaugh, 1999). In contrast, noradrenaline antagonistic agents such 
as propranolol, atenolol or zinterol, not only injected directly into the amygdala but also 
in several nuclei around the amygdaloidal complex and projecting on the amygdala, 
had the opposite (i.c. deteriorating) effect on later memory performance (Quirarte et 
al., 1997). These data support the hypothesis that the memory-modulating effect of 
the amygdala adrenergic system is mediated, at least in part, by the activation of beta-
adrenoceptors in the amygdala. 
In humans central noradrenergic mechanisms appeared to be essential in 
memory performance for emotional material. Beta-adrenergic blockade with a central 
and peripheral acting agent (propranolol) did affect memory for emotional stimuli (Cahill 
et al., 1994; van_Stegeren et al., 1998), whereas a peripherally acting betablocker 
(nadolol) did not have the same memory disturbing properties (van_Stegeren et al., 
1998). And stimulation of the central noradrenergic system with yohimbine resulted 
in the enhancement, whereas blockade with the betablocker metoprolol resulted in a 
reduction of recall and recognition of emotional material in man (O’Carroll et al., 1999). 
Until now it has remained unclear where in the human brain these centrally acting 
noradrenergic receptors exert their effect. 
In this study we monitored amygdala activation with fMRI during encoding of sets 
of pictures after having taken a betablocker (a noradrenergic antagonist) on one day or 
a placebo on the second day. We wanted to test the specific hypothesis – known from 
the animal literature – that the amygdala is mediated by noradrenergic activation in the 
human brain as well. We hypothesized that if noradrenergic activation in the amygdala 
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is essential in processing emotional information, amygdala activation under betablocker 
condition should be lower than under placebo condition, when subjects are confronted 
with emotional stimuli.
Methods
Subjects
Thirty right-handed subjects (15 male, 15 females; mean age 20.93 ± 2.38, ranging 
from 18 to 28 years) without medical or psychiatric history were selected after an 
introduction interview, where they were screened with the Symptom Check List (SCL-
90) (mean score = 104.03 ± 9.48) and a biographic questionnaire. Screening with the 
SCL-90 was carried out and scored using normative ratings for a healthy population. All 
subjects fell in the “normal range” with scores ‘below average’ and ‘low’. This was done 
because in several studies psychopathological disorders were shown to affect volume 
as well as functioning of the amygdala (Hull, 2001). Subjects were all students of the 
University of Amsterdam and received course credit for their participation. The Medical 
Ethical Committee of the VU Medical Center (VUMC) approved the experiment and 
informed consent was obtained from all subjects.
Design, Material and Procedure
In this study we used a randomized, double blind, placebo-controlled event-related design. 
On two consecutive days subjects came to the fMRI department of the VUMC. After an 
acclimatization period of 15 minutes, heart rate (HR) was measured for baseline (BL) 
values, before they entered the scanner (Pre-scan) and immediately after the scanning 
procedure (Post-scan) on both days. Double blind they received either a placebo (PL) 
or betablocker (BB) in random order over the two days (PL-BB or BB-PL). Drug order 
was divided over the sexes and the days as follows: data of 14 males were included in 
the analysis; 6 of them received pills in the order BB-PL, 8 males in the reverse order 
PL-BB; data of 14 females were included and drug order was evenly divided. A resting 
period of 90 minutes was needed to have the drug reach peak plasma levels (Gilman 
& Goodman, 1996). Stimulus material consisted of two sets of 92 pictures (Set 1 and 
Set 3) selected from the International Affective Picture System (IAPS) (Lang et al., 
1997). Both sets were divided in four categories (CAT1-CAT4) that ranged conform 
IAPS norms in emotional valence from neutral (5.0) to extremely negative pictures (2.0) 
and in arousal from low (3.2) to highly arousing (6.2).
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To study memory performance the two stimulus sets were complemented with 48 
additional pictures each (Recognition Set 2 and Set 4) that served as foils that had 
similar valence and arousal properties (see Table 1 for details). These sets were tested 
and validated in an earlier study (van Stegeren & Everaerd, 2004) where the sets showed 
to be completely identical with respect to emotional judgment by the subjects, in evoking 
physiological reactions and having identical memorizing properties. One of the stimulus- 
and recognition sets (set 1 and set 2, with four additional slides) has been used in earlier 
fMRI experiments (Canli, Desmond et al., 2002; Canli et al., 2000) where amygdala 
activation was found during presentation of the more emotional negative pictures. Set 
order was counterbalanced across the subjects over the two test days. After pre-scan HR 
measurements subjects were positioned in the MRI scanner, where a structural scan was 
made first. Then the experimental (event-related) functional imaging started. Subjects 
were presented with blocks of 8 pictures containing random assortments of pictures 
across all four emotional categories. After each picture (presentation time 3 seconds), 
subjects were asked on screen (within 3 seconds) to indicate the emotional intensity of 
the previous picture by pressing one of four buttons with their right hand, with 1 being 
‘not emotional at all’ to 4 being ‘extreme emotional’. These individual emotional ratings 
were used to classify the pictures for further event-related fMRI analysis. This method 
of correlating the event-related activity in the amygdala to subjects personal ratings was 
used in earlier studies as well (Cahill, Uncapher et al., 2004; Canli, Desmond et al., 
2002; Canli et al., 2000). Phan v (Phan et al., 2003) specifically tested the hypothesis 
that incorporating subjective emotional ratings improved the sensitivity for detecting 
activation in regions including the amygdala, and found support for it. 
After a block of 8 pictures with 8 emotional ratings by the subject, 8 gray screens 
(presentation time 3 seconds) served as a resting (baseline) period, also presented 
as events and jittered (Donaldson & Buckner, 2001). This was done to allow amygdala 
activity, when evoked by emotional pictures, to return to baseline levels as much as 
possible and to contrast activation levels during stimulus presentation with baseline 
levels. The procedure on the second day was identical to the first – apart from the 
content of the drug they received. 
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Table 1: Normative ratings of valence (V) and arousal (A)
Set Stimulus Set 1 Stimulus Set 3 Recognition Set 2 Recognition Set 4
Category V (SD) A (SD) V (SD) A (SD) V (SD) A (SD) V (SD) A (SD)
Extreme emotional 
intense
4
2.02
(0.07)
6.16
(0.11)
2.04
(0.06)
6.19
(0.14)
2.03
(1.35)
6.08
(2.26)
2.06
(1.44)
6.31
(2.20)
3
3.15
(0.09)
5.33
(0.15)
3.12
(0.07)
5.08
(0.17)
2.82
(1.67)
5.35
(2.16)
2.84
(1.68)
5.37
(2.27)
2
4.18 
(0.07)
4.43
(0.23)
4.19
(0.07)
4.32
(0.28)
3.85
(1.94)
5.21
(2.07)
3.85
(1.88)
5.52
(2.05)
Not emotional  
at all
1
5.05
(0.04)
3.01
(0.18)
5.04
(0.04)
3.36
(0.26)
4.99
(1.62)
4.13
(2.07)
4.98
(1.28)
3.14
(2.04)
Normative ratings of valence (V) and arousal (A) with standard deviation (SD) of the stimulus sets used 
in this study and the categorization. Valence and arousal norms are taken from the IAPS, where valence 
varied between 1 (extremely negative) and 9 (extremely positive) and arousal ratings varied between 1 
(low) and 9 (high). Stimulus Set 1 with the accompanying recognition Set 2 were based on sets used by 
Canli et al. (2002). Stimulus Set 3 and accompanying recognition Set 4 were matched and validated in an 
earlier study (van Stegeren and Everaerd, sumbitted for publication).
Pills
The betablocker was propranolol (80 mg) and as a placebo Albochin was used, a similar 
looking agent. Both pills were prepared in the VUMC Pharmacological Department. The 
choice for a dose of 80 mg propranolol, which is twice as high as used in previous 
studies (Cahill et al., 1994; van_Stegeren et al., 1998), was based on a pilot where 
subjects without medication indicated that the scanning procedure (being in a scanner 
(twice) for about an hour), as well as the content of the stimulus material, was highly 
arousing. The dosage of 80 mg propranolol is used in clinical settings to definitely lower 
blood pressure and heart rate in patients with cardiovascular problems. A significant 
decrease in physiological arousal was a preliminary condition for the whole design, so 
led to the choice for this dosage. Very recently, colleagues of another lab (Maheu et al., 
2004) used a dose of 80 mg propranolol as well, with effects on emotional memory in 
line with our earlier findings (van_Stegeren et al., 1998), because they failed to find this 
same effect with a 40 mg dose of propranolol.
Memory test
Subjects returned after 2 weeks for a surprise memory recognition test (all subjects 
later indicated in the exit interview it had been completely unexpected). Subjects were 
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shown the recognition sets of (92 + 48) 140 pictures in the same set order as they had 
been offered on day 1 and 2 of the experiment and were asked after each picture to 
indicate whether they had seen that picture before by pressing one of three buttons. 
Possible answers were:1 = no, never seen before; 2 = it looks familiar, but I am not 
sure; and: 3 = yes, I have seen this picture before. Memory scores were calculated by 
counting the correctly recognized items (answers 2 + 3: ‘familiar’ and with certainty 
recalled pictures together) and were expressed as percentage correctly recognized 
pictures per category. Two subjects were excluded from analysis because their memory 
score was well below chance level (< 30%). False positive rates were around 17%, 
which is in line with earlier studies in this area. 
fMRI acquisition
Twenty-three slices positioned perpendicular to the long axis of the hippocampus and 
completely covering the amygdala and hippocampus were collected using a gradient-
echo echo-planar imaging pulse-sequence (in-plane voxel size 3 x 3 mm; 2.5 mm thick, 
0.5 mm gap; repetition time, 2130 ms; echo time, 50 ms; total number of scans in 
each subject ~620). A T1-weighted structural MRI-scan was also acquired (MPRAGE; 
inversion time: 300 ms, TR = 15 ms; TE = 7 ms; flip angle = 8°; 160 coronal slices, 
1 x 1 x 1.5mm voxels). Each subject’s functional images in the current experiment were 
first inspected to ensure adequate signal in both amygdalae.
fMRI Data Analysis
All MRI analyses were carried out using FEAT (FMRI Expert Analysis Tool) Version 
5.00, part of FSL (FMRIB’s Software Library, www.fmrib.ox.ac.uk/fsl). Pre-statistics 
processing included slice-timing correction using Fourier-space time-series phase-
shifting; motion correction (Jenkinson et al., 2002); non-brain removal (Smith, 2002); 
spatial smoothing using a Gaussian kernel of FWHM 8mm; mean-based intensity 
normalization of all volumes by the same factor; highpass temporal filtering (Gaussian-
weighted LSF straight line fitting, with sigma = 100.0s). Time-series statistical analysis 
was carried out with local autocorrelation correction (Woolrich et al., 2001), modeling 
in each subject the events using a double gamma hemodynamic response function and 
its temporal derivative. Then co-registration to high resolution scans and subsequently 
to standard space images was carried out (Jenkinson et al., 2002; Jenkinson & Smith, 
2001). Comparisons of interest were implemented as linear contrasts. Next a higher-
level analysis was carried out using a local analysis of mixed effects (Beckmann, 
Jenkinson & Smith, 2003). A repeated measures model was used with regressors 
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modeling betablocker (BB) and placebo (PL) scans separately. A regressor to correct 
for session effects (change between scan 1 and 2) was also included in the model. 
Main effects were calculated for the PL scans first, contrasting each emotional 
category to baseline. For these scans, Z (Gaussian T/F) statistic images were thresholded 
using clusters determined by Z > 2.3 and a corrected cluster significance threshold of 
p = 0.05 (Forman et al., 1995; Friston et al., 1994; Worsley et al., 1992). The amygdala 
was defined in standard space on the average structural scan of all subjects. First we 
determined amygdala activation during all of the (CAT > Baseline) comparisons. We 
determined based on the anatomy of the average structural scan of all subjects, which 
activations could be identified as being in the amygdalae. All these activated regions in 
the amygdalae were included in the further analyses of interactions as region of interest 
(ROI). The analyses testing for the interaction Drug x Category were again thresholded 
using clusters determined by Z > 2.3 and a cluster corrected significance threshold of 
p = 0.05.
Results
Physiological Measures
Heart rate was used as a marker to check for successful betablockade by propranolol. 
Heart rate was registered at baseline (BL), just before subjects entered the scanner 
(Pre-scan) and immediately after the scanning procedure (Post-scan) and was analyzed 
with a General Linear Model (GLM) (3 time x 2 drug). Baseline heart rate levels for 
all subjects were higher on day 1 compared to day 2 (p < .05), perhaps expressing a 
higher level of anticipation anxiety before the first scanning session began. Fortunately 
subjects were randomly allocated to each drug condition, so on both days the pill groups 
did not differ at BL measurement. Checking for the intended drug manipulation revealed 
that heart rate was significantly lower at Pre-scan and Post-scan measurements in the 
propranolol condition, showing that the betablocker was effective during the complete 
scanning procedure (Figure 1A). As had been found in earlier studies (Lang et al., 
1993; Suarez et al., 2004), men had significantly higher heart rate levels at BL than 
women on both days, but since men and women were as evenly as possible divided 
over the pill-order conditions, this also did not affect baseline HR levels between the 
drug conditions.
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Emotional Ratings
Subjects saw pictures varying from neutral images (CAT1) such as domestic items or 
tools to extremely negative emotional (CAT4) images, depicting mutilation or serious 
injuries. After each picture subjects were asked to rate the emotional intensity of the 
pictures to check for supposed differences in categories. Emotional ratings of the 
subjects were highly correlated with the original category classification (r = .99) and did 
not differ between drug groups (placebo r = .98 and betablocker r = .99; t-test: p > .10) 
(Figure 1B). There was a sex related difference in the emotional ratings consistent with 
those found in earlier studies (Cahill, Uncapher et al., 2004; Canli, Desmond et al., 
2002; Canli et al., 2000) (Figure 2). 
Figure 1. Successful manipulation of pill condition.
(A) and differences in emotional intensity (B) (A) Effect of betablockade on heart rate during scanning 
procedure. Heart rate between pill groups (PL = placebo and BB = betablocker) did not differ at baseline 
on both days (in beats/min ± standard error of mean). After taking the pill (BB or PL), subjects waited 1.5 
h to reach peak plasma levels before pre-scan measurement was carried out. Betablockers caused on 
both days a significant decrease in heart rate compared to placebo at pre- and post-scan measurements 
(interaction time x pill pre-scan: F(1,57) = 24; P < 0.001; post-scan: F(1,58) = 22; P < 0.001): The 
betablocker was active during the complete experiment. (B) Manipulation of emotional intensity. After each 
picture (presentation time 3 s), subjects were asked on screen to indicate the emotional intensity of the 
previous picture by pressing one of four buttons with their right hand, with 1 being ‘not emotional at all’ to 
4 being ‘extreme emotional intense’. Subjects rated pictures in emotional intensity in a way that was highly 
similar to standard norm groups (r = 0.99). Emotional manipulation succeeded.
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fMRI Results 
At first level mean activation (per subject per session) as measured with fMRI, was 
calculated for pictures of the same emotional category and contrasted with a baseline 
condition of gray screens. Then at higher level (across subjects) these contrasts were 
analyzed in a General Linear Model (GLM). In the placebo group, amygdala activation 
increased with emotional intensity of the pictures. There was no difference in amygdala 
activation between CAT1 and CAT2 pictures, but emotional pictures (CAT3 and 4) 
evoked more amygdala activation than neutral (CAT1) pictures under placebo condition 
(Figure 3A and 4A). The main purpose of this study was to test if amygdala activation 
was affected by betablockade. Amygdala activation was analyzed with a GLM with 
contrasts between subsequent emotional categories 1 to 4 (CAT2 with CAT1, CAT3 
with CAT1 etc.) and with ‘drug’ as between variable. In this way we tested how amygdala 
activation depended on the emotional intensity of the pictures, and – testing our main 
hypothesis – whether noradrenergic blockade with propranolol affects this activation 
pattern (Table 2). 
Figure 2. Emotional rating of the pictures by sex.
Classification of pictures done by men and women in this study, when asked to rate the emotional intensity 
of the pictures. Women appear to rate significantly more pictures as extreme emotionally intense (CAT4) 
than men, whereas men rated significantly more pictures as neutral (CAT1) than women (* = p <.05).
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Evidence to support the main hypothesis of this study was provided by these contrasts 
where amygdala activation under betablocker condition was subtracted from the 
activation under placebo condition. Increased amygdala activation for the emotional 
CAT3 pictures, compared to the neutral CAT1 pictures, was significantly lower when 
subjects had taken a betablocker (Z =  3.63; cluster corrected p < .05) (Figure 3B). 
But a remarkable image appeared for the pictures with the highest emotional intensity 
(CAT4): the (random) presentation of these highly negative pictures led to comparable 
amygdala activation in both drug conditions (Figure 4A and B). Secondly, it was 
noteworthy that no overall BOLD effect of the betablocker could be found (Figure 5): 
there was no effect of beta-adrenergic blockade on amygdala activity during presentation 
of pictures from the neutral and low emotional categories (CAT1 and 2). This strongly 
supports the idea that noradrenergic blockade selectively affects amygdala activation 
in humans when confronted with emotional, but not neutral stimuli. If the emotional 
intensity of the stimulus is too extreme, such as the CAT4 pictures in this study, the effect 
of betablockade on the amygdala might be overruled by the emotional or presumably 
the arousal properties of the stimulus. Based on these findings we hypothesized 
that this reaction could be explained in terms of a dose-response relationship of the 
noradrenergic system in the amygdala, where in the light of this study the ‘dose’ is 
referring to the emotional intensity of the pictures. To explore this line of reasoning 
we carried out some additional analyses where we explicitly predicted a linear versus 
a non-linear relationship between the emotional intensity of the stimulus material and 
amygdala activation. We hypothesized that if noradrenergic activation in the amygdala is 
characterized by a curvilinear relationship, and if betablockade is exerting its effect on 
beta-adrenergic receptors in the amygdala, then this type of relation should be disturbed 
in the betablocker condition. 
We created a linear contrast on first level (on subject per session level) that had to 
be entered in a demeaned format (–1.5; –0.5; 0.5; 1.5) as well as a non-linear contrast 
(–1.125; –0.125; 0.875; 0.375) (see figure 6A). Entering these contrasts in the higher-
level analysis we found a significant fit of a curvilinear relationship between stimuli and 
activation pattern in the amygdala under placebo condition more than under betablocker 
condition (see figures 6B + C). Direct comparison of both conditions showed a trend 
(p = .09) that showed that activation under PL condition more than the BB condition 
is fitting to a curvilinear activation pattern, herewith supporting our hypothesis of a 
curvilinear activation pattern in the amygdala for the placebo group. Testing the linear 
contrast revealed also a significant fit under PL as well as BB condition (PL: Z = 4.32 
in Right and Z =  4.51 in Left amygdala; p < .005) (BB: Z = 4.46 in Right and Z = 4.09 
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in Left Amygdala; p < .01). This linear contrast elicited an activation pattern in L and R 
amygdala that was not different between the drug groups in either direction (PL > BB nor 
BB > PL). It can be concluded first that amygdala activation is depending on emotional 
intensity of the stimulus material under placebo condition. Secondly, that this relationship 
fits to a linear as well as a curvilinear model and is mediated by noradrenergic activation. 
In this study particularly the presentation of CAT3 pictures led to significantly lower 
amygdala activation in the betablocker group. Finally, we conclude that betablockade is 
specifically disturbing the curvilinear activation pattern in the amygdala.
Figure 3. (A) Amygdala activation was significantly higher when subjects watched emotional CAT3 pictures 
than the neutral CAT1 pictures under placebo condition. Two large clusters in left and right amygdala were 
visible in this contrast (local maxima: right amygdala at coordinates 18, 0, –14; Z = 4.49; P<0.005;left 
amygdala at coordinates –16, –8, –12; Z = 5.05, P < 0.01). (B) No activation passed the threshold (of Z 
= 2.3, P < 0.05) when subjects had taken the betablocker. (C) Interaction between emotional intensity 
of CAT3 contrasted with CAT1 pictures x pill effect: fMRI scans showing remaining amygdala activation 
during CAT3 pictures when activation with betablockade is subtracted from activation with placebo, 
projected on the average transverse anatomical images. This is literally picturing the difference in activation, 
shown in the histogram of Figure 5 for CAT3 pictures, of clusters that pass the threshold (* = P < 0.05; 
cluster corrected). An independent radiologist identified this significant activation to be present in the left 
amygdala (maximal activation cluster on coordinate x = –16; y = –8; z = –12; Z = 3.63, cluster corrected 
P < 0.05). Right in images is left in brain.
Table 2. GLM of amygdala activation contrasting emotional intensity by pill. 
Contrasts
Pill CAT2 > CAT1 CAT3 > CAT1 CAT4 > CAT1 CAT3 > CAT2 CAT4 > CAT3
PL − ** ** * −
BB − − ** − */**
PL>BB − * − − −
PL = placebo; BB = betablocker; − = nonsignificant; ** = P < 0.01; * = P < 0.05; */** = Li/Re.
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Figure 4.
(A) In the placebo condition amygdala activation was significantly higher during the most emotional 
CAT4 pictures when compared with the activation during the neutral CAT1 pictures (local maxima in right 
amygdala at coordinates 10, –2, –12; Z = 4.22, p < .005 and in the left amygdala at –8, –10, –12; Z = 4.17, 
p < .01). (B) A comparable image appeared with beta-blockade for CAT4 pictures: significant clusters 
were found in right and left amygdala (local maxima: right amygdala at coordinates: 22, –6,– 18; Z = 4.56, 
p < .005 and in the left amygdala at –16, –8, –16; Z = 4.16, p < .01). Betablockade appeared not to affect 
amyg amygdala activation for this contrast.
Figure 5. 
Mean activation in arbitrary units (a.u.) in the region of interest (amygdaloidal complex L and R) under 
each pill condition. This reveals a pattern of increasing amygdala activity with emotional intensity with the 
expected pill effect (Betablocker < Placebo) for CAT3 pictures.
Memory Results
After two weeks recognition memory was tested and results were also analyzed as 
separate behavioral data in a GLM, repeated measures, with contrasts between 
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subsequent emotional categories 1 to 4 (CAT2 with CAT1, CAT3 with CAT2 etc.) and 
with ‘drug’ as between variable (4 emotional intensity x 2 drug). This revealed a pattern 
for memory performance highly similar to that of the fMRI data of amygdala activation 
(figure 7). A main effect of emotional intensity emerged (F(3,52) = 31.47; p < .001): 
memory performance under placebo as well as betablocker condition increased with 
emotional intensity of the pictures. But there also was a significant interaction effect 
(intensity x drug: F(3,52) = 2.42; p < .05): this was specifically found in the contrast 
between the more emotional CAT3 compared with CAT2 pictures. The increase in 
memory performance from CAT3 compared with CAT2 pictures was bigger when 
subjects had taken a PL than under BB condition (F(1,54) = 4.31; p <.05). 
Figure 6. 
(A) Predefined contrasts used on first level to test amygdala activation pattern: A linear contrast as well 
as a nonlinear (inverted-U shape) contrast was entered in the FSL analysis. A significant fit of a curvilinear 
relationship between stimuli and activation pattern in the amygdala under placebo condition (B) more than 
under betablocker condition (C) was found. (B) Higher-level activation in the placebo group fitting to the 
nonlinear contrast: Significant cluster corrected activation (thresholded at Z = 2.3, P < 0.05) in right and 
left amygdala was identified (local maxima in R amygdala at coordinates: 20, 0, —16; Z = 5.1, P < 0.005 
and in L amygdala at —16, —8,—12; Z = 5.2, P < 0.005). (C) Higher-level activation in the betablocker group 
fitting to this same nonlinear contrast: A cluster in the right amygdala was found (local maximum at x, y, 
z = 24, —4, —18; Z = 3.52, P < 0.05). 
The effects of betablockade on memory were not as robust however, as we have seen 
in previous studies using betablockade to affect emotional memory performance (Cahill 
et al., 1994; Maheu et al., 2004; O’Carroll et al., 1999; Strange, Hurlemann, & Dolan, 
2003; van Stegeren et al., 1998). This could be due to the high variance in memory 
scores in this study (standard deviations were around 20%). Furthermore, two groups 
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of 14 subjects might be regarded as sufficient with respect to the analysis of fMRI 
data, it is a relatively small group in memory studies, hence affecting the power of these 
outcomes. 
Figure 7. Memory scores of correctly recognized pictures by pill.
Memory performance of pill groups related to emotional categories of the pictures. Memory performance 
increases with emotional intensity (main effect of intensity: P < 0.001). A significant interaction effect of 
intensity × pill was found too (P < 0.05), specifically in the contrast of CAT2 with CAT3 pictures × pill. 
The placebo group recognized significantly more emotional (CAT3) compared to CAT2 pictures than the 
betablocker group (* = P < 0.05).
Gender Effects and Lateralization
Recently the effect of gender on brain activation patterns, and specifically on the 
amygdala related to memory performance has been studied (Cahill et al., 2001; Cahill, 
Uncapher et al., 2004; Canli, Desmond et al., 2002). In these studies human brain 
imaging evidence has begun to reveal a sex-related hemispheric lateralization of amygdala 
function with respect to memory for emotionally arousing material. It was concluded that 
for men predominantly the right amygdala and for women the left amygdala is involved 
in the successful encoding of emotional information. 
Having established the main point of this study with all subjects, we carried out 
additional analyses to explore gender specific effects in relation to lateralization as well 
as to a possible differential role of the noradrenergic system in the amygdala. 
In line with the studies mentioned (Cahill, Uncapher et al., 2004; Canli, Desmond 
et al., 2002; Canli et al., 2000) we first looked at the placebo group only and analyzed 
amygdala activation of successfully encoded pictures. We found significant activation 
clusters that passed the preset threshold (Z = 2.3; p < .05) in the left amygdala of 
women, but not men when subjects were watching emotional pictures that were later 
recalled (maximum at (–20, 0, –16); Z = 4.08; p = .05), corroborating the earlier findings 
(Cahill et al., 2001; Cahill, Uncapher et al., 2004; Canli, Desmond et al., 2002). This 
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was specifically so for CAT3 pictures and not, as in the above mentioned studies, in 
the most extreme negative emotional category (CAT4). Pictures of CAT4 that were later 
correctly remembered evoked significant activation in the left parahippocampal gyrus 
in women, but not men. In contrast to previous studies, we were not able to show right 
amygdala activation passing the threshold in men, when watching later successfully 
encoded emotional pictures. Merging all data (placebo and betablocker groups together) 
showed a similar image: left amygdala activation (–20, 0, –16) in women correlated with 
later recalled CAT3 pictures (Z = 3.46; p = .05); no significant activation in men could 
be shown. No effects for CAT4 pictures with respect to gender and memory could 
be found in this study, although we cannot exclude that the smaller number of items 
assigned to CAT4 as compared to CAT3, resulting in decreased statistical power for 
estimating CAT4 activation, may also have caused this.
In addition, we tested whether women and men differ in amygdala activation when 
watching emotional pictures under influence of a betablocker. We therefore analyzed 14 
men and 14 women separately with respect to the drug effect on amygdala activation 
for the specific contrast of CAT3 > CAT1 pictures, that we earlier found to reveal the 
drug effect for the whole group. Mean activation was calculated in the defined ROI’s 
for men and women separately and plotted (figure 8 A + B). For both men and women 
betablockade significantly decreased amygdala activation for CAT3–CAT1 pictures. 
Activation clusters in left (Z = 3.73, p < .01) and right amygdala (Z = 3.96, p < .05) 
present in the placebo group for women did not pass the threshold under betablocker 
condition. Also in men activation under placebo condition evoked clusters in left 
(Z = 4.53, p <.05) and right (Z = 2.89, p <.05) amygdala, but no clusters passed the 
threshold under betablocker condition. This means that betablockade is effective in 
decreasing amygdala activation evoked by CAT3 pictures compared with placebo in 
both men and women separately.
We also analyzed the behavioral memory data for men and women separately 
using SPSS and a GLM, with drug and emotional category as within factors. For both 
men and women memory performance increased with the emotional intensity (main 
effect of category: for both men and women: p < .001). But only in women there was 
a significant interaction between emotional intensity and drug (p < .05), specifically 
emerging between CAT2 and CAT3 pictures (figure 8 C+D). A remarkable similarity 
between these memory data and amygdala activation in reaction to the betablocker is 
visible in women (figure 8 A + C). For men separately virtually no effect of betablockade 
on memory was shown in this study. In women, the decrease in amygdala activation at 
encoding under betablocker condition when watching CAT3 pictures was accompanied 
by a decrease in later memory performance for this category of pictures. 
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Figure 8.
(A, B) Mean activation in arbitrary units (a.u.) for 14 women and 14 men separately in the ROI (amygdaloidal 
complex L and R) under each pill condition. For women, this reveals a pattern similar to that of the whole 
group: Amygdala activity increased in a nonlinear way with emotional intensity also showing the expected 
pill effect (Betablocker < Placebo) for CAT3 pictures. For both men and women, betablockade significantly 
decreased amygdala activation for CAT3–CAT1 pictures. Activation clusters in left (Z = 3.73, P < 0.01) 
and right amygdala (Z = 3.96, P < 0.05) present in the placebo group for women did not pass the threshold 
under betablocker condition. Also, in men, activation under placebo condition evoked clusters in left 
(Z = 4.53, P < 0.05) and right (Z = 2.89, P < 0.05) amygdala, but no clusters passed the threshold under 
betablocker condition. (C, D) Memory performance of women and men, analyzed in a GLM, with emotional 
categories as within factor and pill as between variable. A main effect of emotional intensity was found 
in women as well as in men (P < 0.001), but only in women the pill interacted with emotional intensity, 
specifically for the contrast of CAT3–CAT2 pictures (P < 0.05). In men, no effect of betablockade on later 
memory performance was found. 
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Discussion
The results of this study support our hypothesis about the role of noradrenaline in 
amygdala activation during the processing of emotional information. Neutral and very 
light emotional pictures do not activate the amygdala significantly compared with 
baseline levels, but negative emotional pictures lead to a significant increase in amygdala 
activation under placebo condition. When the (central and peripheral) noradrenergic 
receptors were ‘blocked’ with this dosage of 80 mg propranolol, amygdala activation 
monitored with fMRI decreased when subjects were confronted with the emotional 
(CAT3) stimuli. Memory performance deteriorated accordingly for the group, suggesting 
that the amygdala plays a role in the effective encoding, but possibly in the consolidation 
process of emotional stimuli as well. In two human studies was shown that the level of 
noradrenaline during memory consolidation was related to enhanced long-term memory, 
and that post-learning stress hormone-related activity interacts with arousal at initial 
encoding to modulate memory consolidation (Cahill et al., 2003; Southwick et al., 
2002). When we explored the relationship between emotion intensity and activation 
it appears that amygdala activation under placebo condition is best described by 
a curvilinear pattern, although a fit to a linear contrast was found as well. This was 
specifically so for the placebo group and not the betablocker group, showing that the 
betablocker evoked a differential activation pattern in the amygdala. In animal literature 
this curvilinear pattern of reactivity in brain nuclei has been shown several times. Most of 
the times this was seen in dose-response studies, where apart from a time-dependent, 
also a dose dependent U-curve or inverted U-curve was found (Ferry et al., 1999a; 
Ferry, Roozendaal, & McGaugh, 1999b; Roozendaal, Quirarte, & McGaugh, 2002). A 
hypothesis that is concordant with our findings would be that noradrenergic activity 
in the amygdala has a dose dependent character, visible as a curvilinear activation 
pattern. Propranolol, which is a competitive betablocker, is disrupting this pattern by 
occupying (part of the) beta-adrenergic receptors in the amygdala. An important other 
factor that cannot be ruled out is that other neurotransmitters or hormones interact 
with the noradrenergic system in the amygdala. A logical candidate for this scenario 
is cortisol that has an apparent relation with stressful stimuli and situations. Several 
animal studies showed that glucocorticoids interact with and influence the efficacy of 
noradrenergic stimulation in the basolateral amygdala (Ferry et al., 1999a; McIntyre et 
al., 2003; Roozendaal, 2002; Roozendaal et al., 2001; Roozendaal & McGaugh, 1996, 
1997a). The scanning procedure was long enough to have this part of the hypothalamic-
pituitary-adrenal (HPA) axis come into action. However, it should be noted explicitly that 
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the effect on amygdala activation during the CAT4 pictures is not a temporal effect: 
as already mentioned all emotional categories were randomly presented, so the effect 
should at least partly be related to the properties of this emotional category. 
A different type of explanation can be inferred from more fundamental and 
technical studies on principles of event-related fMRI. Friston et al. (Friston et al., 2000) 
pointed at the importance of nonlinearities in evoked responses in fMRI, particularly 
with the advent of event-related fMRI. These nonlinearities are commonly expressed 
as interactions among stimuli that can lead to the suppression and increased latency 
of responses to a stimulus that are incurred by a preceding stimulus. They used the 
Balloon/Windkessel model and showed that this is sufficient to account for nonlinearities 
observed in evoked fMRI responses. They also showed that the parameters responsible 
for this phenomenon were all biologically plausible. However, the analyzing post-
processing software used in our study (FSL) anticipates on these phenomena by 
adjusting the form of the hemodynamic response – in our study to a double-gamma 
hemodynamic response function (HRF). Elaborating on the above mentioned study 
Mechelli et al. (Mechelli, Price, & Friston, 2001) tried to investigate the dependence of 
BOLD responses on different patterns of stimulus input or neuronal changes, such as 
stimulus presentation rate. The estimated BOLD response dramatically decreases with 
increasing rates of presentation. The response to a stimulus is modulated by preceding 
stimuli to give a non-linear refractoriness that depends on the interstimulus interval or 
rate. In both studies of Canli (Canli, Desmond et al., 2002; Canli et al., 2000) and of 
Cahill (Cahill, Uncapher et al., 2004) stimuli were presented for a period of 2.88 s with 
an intertrial interval of 12.96 s, during which a fixation cross was presented. This could 
lead to a ‘back to baseline’ activation pattern after each stimulus. 
However, this parameter (presentation rate) is playing a role in every emotional 
category of the pictures and – because they were presented randomly with respect 
to the category – cannot solely account for the saturation effect of CAT4 related to 
CAT3 pictures. A specific other parameter, namely the amplitude of a stimulus, could 
be the factor to be responsible for this effect. Although Mechelli et al. (Mechelli et al., 
2001) used a model and did not use emotional material, they did show that the increase 
in BOLD response with stimulus amplitude shows a saturation effect, which can be 
explained in terms of hemodynamic refractoriness. Perhaps the combination of high 
presentation rate (compared to earlier studies) and the amplitude/intensity of the CAT4 
pictures lead to this saturation effect in the highest emotional category.
Recently the necessity to anticipate and account for the effect of sex in emotionally 
influenced memory research is put forward in several papers (Cahill, 2003b; Cahill et 
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al., 2003; Cahill et al., 2001; Cahill, Uncapher et al., 2004; Canli, Desmond et al., 
2002). This study underlines this requirement: although power decreased by splitting 
the group, it could be shown that women and men react differently when confronted with 
these emotional stimuli. As in earlier studies, the judgment of the emotional intensity of 
the stimuli differed in a way that women rate more pictures as highly emotional intense 
than men. So their personal judgment was used to categorize the pictures. Amygdala 
activation in both sexes increased with emotional intensity in the placebo group with a 
flattening in activation between CAT3 and CAT4 pictures (contrast was n.s. in either 
direction). Betablockade was efficient to reduce the increased amygdala activation in 
both men and women for the emotional CAT3 pictures, but memory performance two 
weeks later was only affected in women – analogous to their amygdala activation pattern. 
In men the amygdala activation pattern under placebo condition paralleled their later 
memory performance. But the decrease of amygdala activation during CAT3 pictures 
under betablocker condition did not go together with the expected decrease in memory 
performance of the emotional CAT3 pictures. Only a few studies to date have directly 
compared the activation pattern of men and women with respect to emotional information 
processing. This is – to our knowledge – the first study that directly shows the effect of 
betablockade on amygdala activation in both sexes and of a differentiation in the effect 
of betablockade on long term memory performance. It seems that the direct reactivity of 
the amygdala on emotional material is comparable for men and women. Because one of 
the main roles of the amygdala is commonly viewed as ‘labeling for danger and harm’ it 
is understandable that no gender difference is found in this signaling phase, since this 
information is of equal (survival) importance for both sexes. There is a differentiation 
however in the effect of betablockade on long-term memory performance. This effect 
can be explained by a different sensitivity for the effect of the central and peripheral 
acting betablocker propranolol. Several factors such as gender and specifically the 
phase of menstrual cycle and use of oral contraceptives in women affect the activity 
of the HPA-axis (Hampson, 1990, 1990). Propranolol blood concentrations are raised 
by the use of contraceptive pills, so help to optimize the pharmacological action of 
betablockers (Kendall et al., 1984). And high levels of estrogen enhance noradrenaline 
secretion and noradrenergic receptor sensitization (Herbison et al., 2000). 
In addition a point of attention is proposed for future studies: in animal research 
the dosage used to test for certain effects is almost always related to the body weight 
of the subject animal. In human studies, on the contrary, this is hardly ever done. In 
our study it might simply be so, that the relative dosage of 80 mg propranolol for men 
was lower than for women, since their body weight was higher than that of the women 
(mean ± s.e.m. = 75.3 ± 2.0 for men and 65.5 ± 2.1 for women; t-test: p <. 005). 
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Finally, women also appear to have a slower beta-blocker catabolism (Maheu & Lupien, 
2003) (Lupien_S, personal communication) that could be responsible for the memory 
data. If betablockade was active for a longer period in women than in men, than the 
consolidation phase of the encoded stimuli might be affected for a longer time in women 
than in men. The effect of noradrenaline appears to have its greatest impact at the 
time of encoding, but some studies found effects during the stage of consolidation too 
(Cahill et al., 2003; Southwick et al., 2002). If propranolol was effective in women for a 
longer period than in men, due to the difference in catabolism, then the consolidation of 
the emotional stimuli could be attenuated in women more than in men. This could be in 
line with our finding that men don’t show the decrement in memory performance for the 
higher emotional categories under betablocker condition, that could be due to a faster 
wash out time during the stage of consolidation. 
In fact this finding has similarities with the finding of Maheu et al. (Maheu et 
al., 2004) who were not able to show memory impairing effects of a 40 mg dose of 
propranolol in men. They used a narrated slide show, based on earlier work of Cahill et 
al. (Cahill et al., 1994) and Van Stegeren et al.(van_Stegeren et al., 1998), that covers a 
story with a mild emotional phase in between two neutral phases of the story line. They 
explained their lack of effect on memory by the composition of their subject group, which 
consisted of men only. They expanded the experiment with a higher dosage (80 mg) and 
did find an effect in men on (short and) long-term memory performance for the story. 
Bearing in mind that the stimulus set used in this study is much more stress evoking 
than the slide show and that the condition of being in a scanner for an hour is pretty 
stressful too, it could contribute to this lack of effect on memory in men, even with this 
higher dose of 80 mg propranolol.
Furthermore, in an interesting study Strange et al. (Strange et al., 2003) studied 
the effect of propranolol (40 mg) on (short-term) memory for emotional words that 
were presented embedded in a list of neutral words and report two remarkable and 
interconnected findings. They showed that enhanced memory for the emotional (E) 
words was connected with a significant decrement in memory performance for the 
words that preceded the emotional oddball words (E–1 words) and that these effects 
were more pronounced in women. Propranolol reversed both effects in a way that E 
words were equally remembered to neutral words and memory for the E–1 nouns was 
now better than the control words. Memory was significantly more impaired in women 
than in men, a phenomenon that the authors explain could reflect a higher sensitivity in 
females to the disruptive effect of noradrenaline on consolidation. They refer to animal 
models that demonstrate enhancing as well as impairing effects of noradrenergic 
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stimulation on memory reflecting an inverted –U function. Their data demonstrate that 
the same level of (nor)adrenergic activation can produce memory enhancement and 
impairment depending on the timing of that activation and that this effect was stronger 
in women. Although their findings were related to short-term memory effects, it would 
be well in line with the effects on long-term memory presented here.
An earlier study supported the hypothesis that emotional arousal enhanced 
long-term memory for central information in men via activation of the right amygdala/
hemisphere function. In women arousal would enhance long-term memory for peripheral 
details via activation of the left amygdala/hemisphere function (Cahill & van Stegeren, 
2003). Although is was impossible to check for central and peripheral details in the 
memory test of this stimulus material, part of these findings are in line with the idea 
that encoding of emotional information is accompanied by left amygdala activation in 
women. Whether this is due to the processing of central or peripheral details of the 
pictures cannot be answered in this study. 
What has been a remarkable and consistent finding in all studies on emotional 
memory that used betablockers (Cahill et al., 1994; Maheu et al., 2004; O’Carroll et al., 
1999; van Stegeren, Everaerd, & Gooren, 2002; van_Stegeren et al., 1998), is that the 
emotional rating of the stimulus material by the subjects is not affected by betablockade. 
Apparently the cognitive appraisal of the emotionality or intensity is not fully correlated 
with the emotional and/or physical reaction to that same stimulus. This strongly 
suggests that different neural mechanisms are responsible for the ‘cognitive’ judgment 
of a stimulus or situation versus the physical arousal reaction or the emotional labeling 
that takes place. Kensinger and Corkin (Kensinger & Corkin, 2004) used functional MRI 
and behavioral studies to show that distinct cognitive and neural processes contribute 
to emotional memory enhancement for arousing information versus valenced, non-
arousing information. They conclude that the effect of arousing information was strongly 
connected to an amygdalar-hippocampal network, whereas the valenced, non arousing 
information was supported by a prefrontal cortex-hippocampal network implicated in 
controlled encoding processes.
Although the choice for the use of subjects’ personal rating to analyze fMRI data 
with respect to emotional categories was a deliberate one, it remains unclear whether 
subjects (cognitive) rating of the emotional intensity of the picture is reliable with respect 
to gender. In a recent study Hamann and colleagues showed that men and women differ 
in brain activation although personal ratings of the experienced arousal was comparable. 
They compared fMRI responses of men and women to sexually arousing and neutral 
pictures. Men showed greater activation in the hypothalamus and amygdala, even when 
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females (in retrospective) reported greater subjective arousal (Hamann et al., 2004). 
These findings suggested that the amygdala mediates sex differences in response to 
positive and appetitive emotional stimuli. It is conceivable that personalized subjective 
ratings represent another dimension and also in the case of negative emotional stimuli 
represent a system that does not completely parallel the activation pattern in the 
‘emotional’ amygdala. It should be concluded that the cognitive judgment of emotionality 
of a stimulus is not mediated by a noradrenergic depending system.
In a recent article Hamann and Canli (Hamann & Canli, 2004) give an overview 
of functional brain imaging studies to show how individual differences among subjects 
might modulate neural responses during emotion processing. They make a plea for 
including individual differences to provide a new window into the field of neurobiology 
of emotion and memory, that can complement traditional approaches. 
This study was meant to establish a general principle in emotional information 
processing, namely the role of noradrenaline in the amygdala and to see if men and 
women differ in this process. It can be concluded that also in humans noradrenaline 
is needed to allow amygdala activation in reaction to emotional stimuli. Moderation of 
amygdala activation with betablockers as done in this study may have an impact on long-
term effects such as consolidation of emotional experiences. Using more personalized 
criteria to define stimuli and reactivity of the subjects can lead to interesting new 
findings and further complement missing parts of information. In this study again a 
strong argument was made to take participants gender into account in future studies. 
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Abstract
Raloxifene is a selective estrogen receptor modulator (SERM) that is prescribed in 
females only, but its use in male subjects is increasingly considered. With a growing 
number of patients having potential benefit from raloxifene, the need for an assessment 
of its effects on brain function is growing. Effects of estrogens on brain function are very 
subtle and difficult to detect by means of neuropsychological assessment. Functional 
imaging techniques, however, have been relatively successful in detecting such 
changes. This study used functional magnetic resonance imaging (fMRI) to examine 
effects of raloxifene treatment on memory function. Healthy elderly males (n = 28; 
mean age 63.6 years, SD 2.4) were scanned during performance on a face encoding 
paradigm. Scans were made at baseline and after 3 months of treatment with either 
raloxifene (n = 14) or placebo (n = 14). Treatment effects were analyzed using mixed-
effects statistical analysis (FSL). Activation during task performance involved bilateral 
parietal and prefrontal areas, anterior cingulate gyrus, and inferior prefrontal, occipital, 
and mediotemporal areas bilaterally. When compared to placebo, raloxifene treatment 
significantly enhanced activation in these structures (Z > 3.1), except for mediotemporal 
areas. Task performance accuracy diminished in the placebo group (P = 0.02), but 
remained constant in the raloxifene group ( P = 0.60). In conclusion, raloxifene treatment 
enhanced brain activation in areas spanning a number of different cognitive domains, 
suggesting an effect on cortical arousal. Such effects may translate into small effects 
on behavior, including effects on attention and working memory performance, executive 
functions, verbal skills, and episodic memory. Further neuropsychological assessment 
is necessary to test the validity of these predictions. 
Keywords: Raloxifene; SERM; estrogen; fMRI; memory; arousal. 
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Introduction 
Selective estrogen receptor modulators (SERMs) are compounds that display both 
agonist and antagonist effects on estrogen receptors in a tissue-selective manner 
(Riggs & Hartmann, 2003). Raloxifene is a SERM of which several beneficial effects 
have been reported in postmenopausal women, including a reduced risk of breast 
carcinoma (Cummings et al., 1999), a reduced risk of vertebral fractures (Ettinger et 
al., 1999; Delmas et al., 2002), and beneficial effects on markers of cardiovascular 
disease, such as serum lipids and coagulation factors (Delmas et al., 1997; Walsh et 
al., 1998; de Valk-de Roo GW et al., 1999). To date, raloxifene can be prescribed in 
postmenopausal women only, to counter effects of osteoporosis. Meanwhile, a growing 
number of beneficial effects of raloxifene treatment are reported that may also apply to 
male patients. Raloxifene treatment is therefore considered in males, which have already 
shown good tolerance to the substance (Blum et al., 2000; Doran et al., 2001). So far, 
however, research into the effects of raloxifene treatment in humans has lacked a more 
detailed assessment of its effects on brain function and mental performance. With an 
increasing number of patients experiencing a potential benefit from raloxifene, the need 
for such an assessment is growing.
A large body of evidence suggests that sex steroids may influence brain function. 
In both sexes, estradiol is thought to be primarily responsible for effects of sex steroids 
on neural excitability, with testosterone in male subjects first requiring conversion to 
estradiol in order to exert its effects (Longcope et al., 1969; MacDonald et al., 1979). 
Estrogen receptors occur throughout the brain in both male and female subjects. Gender 
differences may influence their pattern of expression, suggesting different functions 
in both sexes (Osterlund et al., 2000; Zhang et al., 2002; Kruijver et al., 2003). A 
consistent finding is that low sex steroid levels are associated with impaired memory 
performance in both sexes (Morley et al., 1997; Wolf et al., 1999; Barrett-Connor et al., 
1999; Maki & Resnick, 2001; Senanarong et al., 2002). In contrast, enhanced estrogen 
levels in both males and females correlate with increased memory function (Sherwin, 
2003a; Sherwin, 2003b). It has even been suggested that estrogen supplementation 
may prevent Alzheimer’s disease in postmenopausal women (Simpkins et al., 1997; 
Paganini-Hill & Henderson, 1996). However, randomized controlled clinical trials found 
no significant effects of estrogen treatment in dementia (Polo-Kantola et al., 1998). 
Instead, three recently published controlled clinical trials from the Women’s Health 
Initiative (WHI) examining effects of hormone therapy in postmenopausal women have 
found adverse effects of combined estrogen and progestin treatment on brain function, 
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including effects on mental performance and an increased risk of dementia (Rapp et 
al., 2003; Shumaker et al., 2003; Wassertheil-Smolleret al., 2003). Thus, estrogens 
affect mental performance under physiological circumstances, and the effects of long-
term pharmacological intervention into sex steroid systems are still unclear. Indeed, very 
little is known about the effects of estrogen agonists on male brain function (Sherwin, 
2003b). Future prescription of raloxifene in male subjects therefore requires additional 
study.
So far, research into the effects of sex steroid or SERM treatment on brain function 
has largely depended on neuropsychological studies of behavior. Such studies typically 
show only minimal changes in behavioral measures (Sherwin, 2003b; Sherwin, 2003a). 
In contrast, functional imaging techniques have shown relatively clear results after sex 
steroid treatment. Both estrogen and testosterone may increase brain activation in 
areas relevant to memory, reasoning, judgment and emotions (Azad et al., 2003; Maki 
& Resnick, 2001). Although the clinical significance of neurofunctional changes in the 
absence of behavioral changes may be questioned, the possibility that they bear some 
extra insight into behavior should not be dismissed (Wilkinson & Halligan, 2004). Hence, 
it has been suggested that functional imaging techniques may have greater sensitivity 
to the effects of sex steroids on brain function (and possibly behavior) than most 
neuropsychological assessment scales (Maki & Resnick, 2001; Neele et al., 2001). For 
this reason, we examined the ability of functional magnetic resonance imaging (fMRI) 
to screen for effects of raloxifene treatment on male brain function in a small group 
of subjects. Based on results from previous imaging studies (Maki & Resnick, 2001; 
Sherwin, 2003b) and the sparse amount of data on the effects of estrogens on male 
brain function (Sherwin, 2003b), we hypothesized that raloxifene would influence brain 
activation during visuospatial memory performance. A face encoding task was chosen to 
elicit brain activation, since sex differences have been reported for visuospatial memory 
scores in general (Sherwin, 2003b; Kampen & Sherwin, 1996) and face encoding and 
recognition scores in particular (Yonker et al., 2003). Such ‘sexual dimorphism’ with 
respect to visuospatial memory suggests an effect of sex steroids on neural function 
associated with this task, making it a potentially sensitive tool to detect effects of 
treatment.
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Materials and methods 
Study design 
Subjects were screened for participation in a randomized, double-blind, placebo-
controlled study design. fMRI was performed at baseline (BL; no medication; session 
1) and after 3 months of a once-daily oral intake of raloxifene 120 mg or placebo (TR; 
session 2). Both BL and TR sessions were performed on exactly the same time of 
day in each subject. If data acquisition failed, the subject’s consent was asked for an 
additional scanning visit, up until which time the relevant medication regime (raloxifene 
or placebo) was continued, to obtain a maximum number of complete data sets. Study 
period extension was not to exceed 10 days. 
Subject recruitment 
The medical ethical review board of the VU University Medical Center of Amsterdam 
approved the study. Thirty healthy, right-handed elderly male subjects, aged 60 to 70 
years old (mean 63.6 years, SD 2.4; range 60–69 years) were recruited by advertisement 
in local newspapers. All subjects provided informed consent during a screening visit 
in which the procedure was explained and contraindications were checked. Subjects 
were excluded if they had any significant medical, neurological or psychiatric illness, 
or if they were taking any medication or other substances that are known to influence 
cerebral functioning. Exclusion criteria to MRI involved the presence of metallic implants 
in high-risk areas and a history of claustrophobia. Formal education was determined 
using a Dutch system (low, middle, high). Functional MRI (fMRI)
Data acquisition
Imaging was carried out on a 1.5-T Sonata MR scanner (Siemens, Erlangen, Germany), 
using a standard circularly polarized head coil with foam padding to restrict head 
motion. For fMRI, an echo planar imaging sequence was used (echo time 60 ms, flip 
angle 908, matrix 64 x 64, field of view 192 x 192 mm), to obtain 21 transverse slices 
(thickness 5 mm, interslice-gap 1 mm). Task stimuli were projected on a screen located 
at the head end of the scanner table via an LCD projector located outside the scanner 
room. Subjects viewed the screen through a mirror located on the head coil. In each 
hand, subjects held an fMRI compatible response-box through which they were able 
to react to task stimuli by pressing a single button using one of their index-fingers. A 
T1-weighted structural MRI scan was obtained of each subject (MPRAGE; inversion 
time: 300 ms, TR = 15 ms; TE = 7 ms; flip angle = 88; 160 coronal slices, 1 x 1 x 1.5 
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mm voxels). Total scanning time including structural imaging on average was 21 min for 
each visit. 
Encoding task
A face-encoding task was used to examine brain activation related to episodic memory 
for visuospatial information. This task produces activation in bilateral prefrontal, bilateral 
parietal, anterior cingulate and (posterior) mediotemporal structures with a preference 
for the right hemisphere (Small et al., 1999), which is in correspondence with the 
visuospatial nature of this task (Kelley et al., 1998). Two different but comparable 
versions were constructed and randomized across the scanning sessions (BL, TR). 
A spare version was made in case data acquisition failed during one of the scanning 
sessions. The paradigm was practiced on a laptop computer to familiarize subjects with 
the procedure (1 day before the start of the first session and 5 min before the onset of 
the first measurements of each session, with subject in scanner). During the first 10.5s, 
subjects saw a circle indicating time left before the onset of the first condition. To avoid 
investigator’s bias, task performance data were only viewed after all scan visits had 
been completed. 
A block design was applied with two alternating conditions: Condition 1 
(ENCOD) consisted of 4 blocks of 42s, each containing six unfamiliar faces presented 
sequentially on a black background (presentation time 6s, followed by a 1-s delay). 
Condition 2 (FIX) consisted of four blocks of 44s each, in which a white fixation cross 
(X) was presented on a black background. Prior to scanning, subjects were instructed 
verbally to remember the faces for future testing and to classify each face according to 
its gender by pressing one of two buttons (instructions ‘Left: male’, ‘Right: female’ also 
appearing alongside the pictures). Male and female faces were balanced across the 
ENCOD blocks. The entire task thus consisted of eight alternating blocks of ENCOD 
and FIX conditions and was preceded by a 21s FIX condition. Mean reaction times for 
gender discrimination were recorded and a performance accuracy score varying from 
–1 to 1 (with 0 indicating chance levels) were calculated by subtracting false answers 
from correct answers and dividing the result by the total number of items (24). Total task 
duration was 6 min and 12s. 
Immediately after encoding, encoding success was assessed using a recognition 
task, while subjects were still in the scanner. Twenty-four faces were presented 
sequentially in random order, of which 12 had been shown during encoding and 12 were 
new (presentation time 5s for each face, followed by a white fixation-cross presented 
for 3s on a black background). Subjects indicated whether the presented faces were 
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familiar or unfamiliar by pressing one of two buttons (instructions ‘Left: familiar’ and 
‘Right: unfamiliar’ also appearing alongside the pictures). Similar performance measures 
were calculated as for gender discrimination. 
Statistical analysis of task performance data 
After first asserting that raloxifene and placebo groups did not differ in their mean 
performance measures at baseline (using a multivariate analysis of variance), task 
performance measures during BL (no intake) were subtracted from those after 3 months 
of treatment (TR). A multivariate analysis of variance was then performed using SPSS, 
in which differential scores were entered as dependent variables in an analysis of the 
medication effect with medication ‘regime’ (two levels: raloxifene, placebo) as a fixed 
factor and ‘test version’ (two levels: 1 and 2) as a covariate. If a significant effect of 
this covariate was found, the model was adjusted to contain it as a fixed factor in a 
subsequent analysis of the medication effect. Effects of the factor ‘regime’ were then 
considered representative of an effect of intervention with either raloxifene or placebo. 
Analysis of functional neuroimaging data 
Functional datasets were analyzed using FSL (fMRIB’s Software Library, http://www.
fmrib.ox.ac.uk/fsl). The first five volumes of each data set were discarded to account 
for T1-saturation effects. At first level (individuals), the following pre-processing was 
applied: non-brain removal, slice-timing correction using Fourier-space time series 
phase-shifting, motion correction and spatial smoothing using a Gaussian kernel of 
FWHM 8 mm, mean-based intensity normalization of all volumes by the same factor and 
high and low pass temporal filtering (Jenkinson et al., 2002; Smith, 2002). Registration 
of functional images to high resolution and/or standard images was carried out using 
an intermodal registration tool based on the correlation ratio (Jenkinson & Smith, 2001). 
After pre-processing, the following statistics were applied on a voxelwise basis on each 
time series, using local autocorrelation correction (Woolrich et al., 2001): signal change 
during the ENCOD condition was modeled as a box car, which had the same alternation 
frequency as the ENCOD condition and convolved with a gamma function, to model 
the hemodynamic response. The FIX condition was not modeled (except for the first 
FIX-period of 21s), to prevent overspecification of the model. Model fitting generated 
whole brain images of parameter estimates and corresponding variance, representing 
average signal change during ENCOD as compared to FIX levels (both for BL and TR 
regimes). These images were resampled to 2 x 2 x 2 mm in standard space and fed into 
in a second-level statistical analysis to examine treatment effects at group level. 
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At second (group) level, activation images of main effects during encoding were 
produced by summing all individual activation maps for each session and medication 
regime separately [i.e., BL (placebo), BL (raloxifene), TR (placebo) and TR (raloxifene)] 
and across all sessions and regimes [i.e., BL (placebo) + BL (raloxifene) + TR (placebo) 
+ TR (raloxifene)] in a mixed-effects higher-level analysis using clusters determined 
by Z >N 2.3 and a corrected cluster significance threshold of P = 0.05 (Woolrich et 
al., 2004; Friston et al., 1994; Worsley et al., 1992; Beckmann et al., 2003). Effects 
of medication were then calculated using a repeated measures model, in which two 
explanatory variables (EVs) contrasted BL and TR sessions of placebo and raloxifene 
groups, while assuming separate variances for these groups. Two additional EVs coded 
for effects of test version on signal response, thus removing effects of this possible 
confounder. The main contrasts of interest were [TR (raloxifene) – BL (raloxifene)] 
<> [TR (placebo) – BL (placebo)], testing for an interaction between raloxifene and 
placebo activation levels before and after treatment. This interaction analysis was 
restricted to activated regions only (by masking for main effects summed across all 
treatment conditions, see above). A Z value of 3.1 ( P < 0.001) was used as a threshold 
for significant brain activation, with a minimal cluster size of 80 mm3 to remove single-
voxel noise (Woolrich et al., 2004; Forman et al., 1995; Friston et al., 1994; Worsley et 
al., 1992). The model was then adjusted to contain separate regressors for recognition 
accuracy for both treatment groups. This allowed treatment effects to be analyzed for 
correlations with performance changes both for raloxifene and placebo groups separately 
and their interactions. Images were rendered on a 3D mean anatomical brain volume 
of all subjects in standard space (Talairach & Tournoux, 1988) for display purposes. 
Coordinates of local maxima were extracted and fed into the Talairach Daemon Client 
version 1.1 (Research Imaging Center; University of Texas, Health Science Center, San 
Antonio, TX) for identification of the activated brain structures. 
Results
Demographics 
Mean age of subjects was 64.1 (SD 2.4) year in the placebo group and 63.1 (SD 2.5) 
year in the raloxifene group. The placebo group contained two smokers versus one in 
the raloxifene group. Education level was equal in both groups. 
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Subject compliance and discontinuation 
One subject (placebo group) was claustrophobic and data quality was poor in another 
subject (raloxifene group). These data were removed from the analysis, yielding 28 
complete data sets containing both BL and TR data (14 in raloxifene group, 14 in placebo 
group). In one subject, the second (TR) scan was repeated after 7 days because of 
scanner errors during the second session. Subject compliance was good as assessed 
by the tablet counts and there were no dropouts. No significant side effects were 
reported. 
Task performance 
Mean overall task performance accuracy for male-female discrimination (encoding 
accuracy) was 0.99 (SD 0.04) and mean overall reaction time 1.03s (SD 0.29s) (Table 
3). Recognition accuracy was 0.67 (SD 0.20) with mean overall reaction time 1.64s (SD 
0.33s). A significant interaction was found between mean recognition accuracy scores 
of raloxifene and placebo groups at baseline and after treatment (P = 0.021): recognition 
accuracy in the placebo group decreased slightly after treatment (P = 0.022), whereas 
performance accuracy in the raloxifene group remained constant (P = 0.60). No other 
measures of task performance showed significant changes between raloxifene and 
placebo groups after treatment. 
Analysis of functional neuroimages 
Main effects of face encoding involved extensive activation in ventral and dorsal 
occipital (visual) areas, and bilateral parietal, bilateral prefrontal and anterior cingulate 
gyri areas, with a preference for the right hemisphere. Extensive bilateral activation of 
thalamic structures also occurred. Additional activation was found in bilateral posterior 
hippocampal areas (Figure 1; Table 1). Pairwise comparisons showed no significant 
differences in activation levels at baseline between raloxifene and placebo groups (data 
not shown). The main contrast (examining the interaction between activation levels of 
raloxifene and placebo groups before and after treatment) showed increased activation 
after raloxifene intake when compared to placebo (Figure 2; Table 2). Areas included 
bilateral middle frontal gyri, bilateral parietal lobules and anterior cingulate/superior 
prefrontal, left inferior frontal gyri and the lingual gyri. 
Raloxifene treatment produced increases, but not decreases, in activation levels 
when compared to placebo (Z = 3.1). Plots of percentual signal changes (relative to 
global mean values) of peak voxels of local maxima illustrate the size of signal changes 
for the main contrast of interest (Figure 2). When both treatment groups were examined 
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separately for their contribution to signal changes as observed in Figure 2, the raloxifene 
group showed significantly enhanced (but not reduced) activity in the left superior 
parietal lobule, left inferior frontal and right middle frontal and superior frontal gyri 
(Figure 3A). The placebo group showed only nonsignificant changes after treatment 
(Z = 3.1). At Z = 2.3, decreases (but not increases) were found in left and right middle 
frontal gyri, anterior cingulate (superior prefrontal), right parietal and left primary visual 
cortex after treatment (Figure 3B).
Table 1. Volume, Z scores and coordinates of peak voxels of local maxima of main effects during face 
encoding. 
Nr. Vox Z x y z Le/Ri Location
Confluent
areas
8.6 42 –84 –8 R Inferior Occipital Gyrus
8.3 –8 –88 –4 L Lingual Gyrus
8.0 –14 –86 –10 L Lingual Gyrus
7.9 –40 –56 –18 L Fusiform Gyrus
7.8 10 –96 –4 R Lingual Gyrus
7.6 40 –54 –20 R Fusiform Gyrus
7.4 24 –30 –26 R Posterior Hippocampus
7.4 –32 –28 –6 L Posterior Hippocampus
7.2 26 –58 42 R Superior parietal lobule
7.1 36 4 30 R Precentral Sulcus
7.0 –38 42 28 L Precentral Sulcus
5.4 –26 32 –6 L Inferior frontal gyrus
5.3 16 –18 6 R Thalamus
5.3 –18 –18 6 L Thalamus
5.2 34 34 14 R Inferior Frontal Gyrus
5.1 –28 –58 40 L Superior parietal Lobule
5.0 8 12 44 R Anterior Cingulate Gyrus
Nr. Vox: number of voxels in local maximum (no data is provided since all areas are confluent). Z: Z score of 
peak voxel. x, y, z: coordinates of peak voxel in left-to-right, rostral-to-caudal and ventral-to-dorsal directions 
respectively. Le/Ri: left or right hemisphere.
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Figure 1. Axial slices showing main effects for face encoding rendered on a mean anatomical brain 
volume of all subjects (Mean_anat_RALMEN). 
Left in the image is left in the brain. Effects are cluster corrected using Z = 2.3 and P < 0.05. Color scale 
extends from Z = 2.3 (red) to Z = 9.5 (yellow). (A) Placebo group at baseline and (B) after 3 months 
of treatment. (C) Raloxifene group at baseline and (D) after 3 months of treatment. Note the pattern of 
bilateral parietal, prefrontal and anterior cingulate activation, which is comparable between both groups 
at baseline.
Effects of raloxifene treatment versus placebo (Figure 2) were subsequently tested for 
possible correlations with (alterations in) performance scores. In the placebo group, 
decreased performance correlated significantly with decreased (but not increased) 
activation in bilateral motor and sensory areas. These areas, however, did not overlap 
with overall effects of treatment, as judged by masking for these effects (Figure 4A). In 
contrast, performance accuracy changes in the raloxifene group correlated significantly 
with increased activation. Here, effects did overlap with similar effects contained in 
the overall pattern of treatment (Figure 4B). Performance differences after treatment 
between raloxifene and placebo groups were then contrasted directly in a single 
correlational analysis, to examine the contribution of these differences to the overall 
pattern of treatment as reported in Figure 2. Performance changes contributed at 
least partly to these effects. Parietal activation disappeared from the original pattern of 
treatment as reported in Figure 2, and could now be explained as an effect of treatment 
relating to performance differences between raloxifene and placebo groups (Figure 4C). 
In contrast, areas in the left and right middle frontal and right superior parietal areas did 
not correlate significantly with performance differences between both groups (Figure 
4D). Thus, the overall pattern of treatment effects (Figure 2) could be partly dissociated 
into treatment effects with high (Figure 4C) and low (Figure 4D) correspondence with 
changes in performance. 
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Figure 2. Axial slices showing effects of raloxifene treatment as determined by the interaction between 
activation levels of raloxifene and placebo groups at baseline and after treatment (see Materials and 
methods).
Functional maps are rendered on a mean anatomical brain volume of all subjects (Mean_anat_RALMEN). 
Left in the image is left in the brain. Effects at Z = 2.3 for display purposes (all effects are significant at Z = 
3.1). Color scale extends from Z = 2.3 (red) to Z = 4.5 (yellow). Images: Increased activation is observed 
in middle frontal gyrus bilaterally, parietal lobule bilaterally, anterior cingulate gyrus bilaterally, left inferior 
frontal gyrus and lingual gyrus bilaterally (Table 1). Plots: Graphs depicting the interaction between mean 
percentual signal change of raloxifene and placebo groups at baseline and after treatment, as observed 
in peak voxels of local maxima of significant effects of medication. Means and SD (error bars) are shown. 
Arrows indicate the corresponding clusters of activation. 
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Figure 3. Axial slices showing effects of treatment with raloxifene (A) and placebo (B) as compared 
to baseline activation levels (i.e., separate contributions of both treatment groups to overall pattern of 
treatment effects reported in Figure 2). 
Images are masked for significant effects of treatment (Figure 2). Functional maps are rendered on a 
mean anatomical brain volume of all subjects (Mean_anat_RALMEN). Left in the image is left in the brain. 
Z = 2.3 for display purposes. Color scale extends from Z = 2.3 (red) to Z = 4.5 (yellow). (A) Raloxifene 
group. Significant increases are observed in all areas reported in Figure 2 (Z = 3.1), except left middle 
frontal gyrus and right superior parietal lobule, which were significant at Z = 2.3 only. (B) Placebo group. 
Nonsignificant decreases are observed in prefrontal cortex and lingual gyri.
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Table 2. Volume, Z scores and coordinates of effects of medication intake as determined by 
peak voxels of their local maxima. 
Corr. Perf. N-Vox Z x y z Le/Ri Location
NO. Figure 3A: Raloxifene group; TR > BL
 80 4.02 46 20 42 R Middle frontal gyrus 
 45 3.8 –44 40 6 L Inferior frontal gyrus
 38 3.7 –30 –58 34 L Superior parietal lobule
 11 3.29 –48 –70 12 L Lingual gyrus
 10 3.2 –4 44 44 L Anterior cingulate gyrus / superior frontal gyrus
  Figure 3B: Placebo group; TR <> BL (No significant effects) 
 Figure 2: Interaction RAL_PLAC_TR_BL
 80 4.02 46 20 42 R Middle frontal gyrus 
 38 3.72 –30 –58 34 L Superior parietal lobule
 34 3.71 –36 12 42 L Middle frontal gyrus
 21 3.66 2 46 44 R Anterior cingulate gyrus / Superior frontal gyrus
 16 3.47 –44 34 –2 L Inferior frontal gyrus
 13 3.66 –28 –64 0 L Lingual gyrus
 12 3.2 46 –60 40 R Superior parietal lobule
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Corr. Perf. N-Vox Z x y z Le/Ri Location
YES. Figure 4B: Raloxifene group: functional changes correlating with behavioral changes (TR > BL)
 17 3.6 30 40 –6 R Inferior frontal gyrus
 13 3.89 22 –82 –4 R Lingual gyrus
 11 3.14 36 4 44 R Middle frontal gyrus
 11 3.12 42 -42 68 R Superior parietal lobule
 Figure 4A: Placebo group: functional changes correlating with behavioral changes (TR > BL)
 68 3.75 -34 18 4 L Insula
 62 3.67 30 4 56 R Pre / postcentral cortex
 52 3.58 –52 18 30 L Pre / postcentral cortex
 10 3.41 10 12 48 L Anterior cingulate gyrus
 Figure 4C: Comparison functional effects of behavior; Raloxifene > Placebo
 80 4.06 –38 –74 –4 L Lingual gyrus
 60 4.06 44 18 42 R Middle frontal gyrus 
 16 3.47 –42 36 –4 L Inferior frontal gyrus
 16 3.47 36 40 –6 R Inferior frontal gyrus
 11 3.2 40 –58 46 R Superior parietal lobule
 Figure 4D: Interaction RAL_PLAC_TR_BL 
 60 4.06 44 18 42 R Middle frontal gyrus 
 20 3.62 –38 10 44 L Middle frontal gyrus
 21 3.66 0 48 42 R Anterior cingulate gyrus / Superior frontal gyrus
 16 3.47 –42 36 –4 L Inferior frontal gyrus
Effects of treatment are shown for raloxifene and placebo groups separately (Figures 3A, B) and for their interaction, corrected for 
baseline activation levels (Figures 2 and 4D; interaction RAL_PLAC_TR_BL). Results are shown for two separate analyses: one 
involving effects of treatment without correcting for performance scores (Corr. Perf.: NO.), and one in which these effects have 
been corrected for (Corr. Perf.: YES.). Functional effects correlating with performance changes are shown for the raloxifene and 
placebo group separately (Figure 4B,A), and for a comparison between these groups (Figure 4C). Effects at Z = 3.1, cluster size 
>10 voxels. TR > BL: treatment > baseline. Le/Ri: left or right hemisphere. Nr. Vox: number of voxels in local maximum (voxelsize 
2 x 2 x 2 mm). Z: Z score of peak voxel. x, y, z: coordinates of peak voxel in left-to-right, rostral-to-caudal and ventral-to-dorsal 
directions, respectively. Brackets indicate statistical relations between the effects.
Discussion 
This study shows that 3 months of treatment with raloxifene increased brain activation 
relative to placebo during encoding of complex visuospatial information (faces) into 
memory. By choosing a low-level reference condition (i.e., fixation cross), we aimed 
to maximize contrast between processing requirements for face encoding and 
fixation. Thus, we were able to study functional changes in a broad variety of brain 
areas, which we hoped would provide a global picture of treatment effects on brain 
function during memory performance. At baseline, activation was observed in bilateral 
prefrontal, bilateral parietal, anterior cingulate, occipital, pre- and postcentral areas, 
62
Chapter 3: Effects of raloxifene treatment on brain function in healthy elderly males
and posterior mediotemporal and thalamic structures. Studies have shown that these 
areas are involved in attentional, sensory motor, working memory and episodic memory 
processing (see below). Raloxifene treatment enhanced activation in this network, with 
a preference for cortical but not subcortical or mediotemporal areas. These effects 
may involve behavioral changes in a number of different functional domains. Changes 
in memory performance after treatment correlated significantly with treatment effects in 
posterior brain areas (Figure 4). These results will be discussed below.
Table 3. Means, standard deviations and differences between (mean) task performance scores 
for encoding (encod) and recognition (recog) task performance. 
BASELINE TREATMENT TR vs. BL
Mean SD Mean SD P value df
PLACEBO Acc. Encod 0.98 0.05 1.00 0.00 0.19 12
RTAV Encod 1.16s 0.40 0.99s 0.22 0.08 12
Acc. Recog 0.73 0.10 0.51 0.31 0.02 12
RTAV Recog 1.72s 0.29 1.63s 0.35 0.32 12
RALOXIFENE Acc. Encod 0.98 0.05 0.98 0.05 1.00 12
RTAV Encod 0.98s 0.22 1.01s 0.29 0.50 12
Acc. Recog 0.67 0.15 0.69 0.14 0.60 12
RTAV Recog 1.56s 0.26 1.62s 0.41 0.39 12
RAL vs. PLAC
P value Acc. Encod 1.00 0.18 0.45 26
RTAV Encod 0.16 0.81 0.67 26
Acc. Recog 0.19 0.05 0.02 26
RTAV Recog 0.15 0.94 0.18 26
df Acc. Encod 26 26 26
RTAV Encod 26 26 26
Acc. Recog 26 26 26
RTAV Recog 26 26 26
TR vs. BL: treatment versus baseline. RAL vs. PLAC: Raloxifene versus placebo. Acc.: mean accuracy 
score. RTAV: mean reaction time (s). P value: P value for the relevant comparison. df: degrees of freedom 
for the relevant comparison.
The current fMRI study confirms the occurrence of alterations in blood oxygenation levels 
during memory task performance after raloxifene treatment. Raloxifene increased signal 
response in areas reported in Figure 3A, while placebo intake produced nonsignificant 
decreases in areas reported in Figure 3B. These effects combined (interaction) produced 
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a significant signal increase in bilateral prefrontal, bilateral parietal, anterior cingulate, 
and left inferior prefrontal areas, along with activation of lingual gyri (Figure 2). Apart 
from neuronal activity, both testosterone and estrogen influence the muscular tone of 
cerebral vasculature and PET studies have repeatedly shown a general rise in signal 
intensity levels after estrogen challenge (Maki & Resnick, 2001; Maki & Resnick, 2000; 
Paganini-Hill & Henderson, 1996). Hence, it is possible that some of the observed 
signal changes represented a change in neurovascular coupling (D’Esposito et al., 
1999). Such vascular effects, however, usually involve changes in absolute global mean 
intensity levels, which were ignored in our analysis. Furthermore, it is very unlikely that the 
highly spatially localized (and stimulus-related) pattern of signal enhancement observed 
in this study was due to a selective effect of raloxifene on cerebral vasculature in these 
areas. The pattern of signal enhancement can be localized to functionally meaningful 
areas (see below) and strongly suggests that at least part of the effect of raloxifene 
treatment was of neurogenic origin. 
From fMRI data alone, it is difficult to judge whether the observed effects 
represent beneficial or adverse effects on brain function. Based on previous findings 
in Alzheimer’s disease and related dementias and pharmacological fMRI studies of 
cholinergic treatment of patients with Alzheimer’s disease, a trend has emerged to regard 
increased brain activation during memory performance as something beneficial (Furey 
et al., 2000; Kumari et al., 2003; Machulda et al., 2003). This observation, however, can 
by no means serve as a general rule. The impact of the observed neurofunctional effects 
on behavior therefore needs to be further evaluated, preferably by means of randomized 
placebo-controlled clinical trials involving large groups of patients.
Given the modest results of larger trials involving neuropsychological assessment, 
we did not expect any behavioral changes after raloxifene treatment to be significant in 
our population. Hence, no follow-up was done of the cognitive status of our subjects. 
Since the main aim of the present study was to screen for neurofunctional effects in a 
small number of subjects, our main focus was on the functional data. Quite unexpectedly, 
however, we found a significant decrease in recognition accuracy scores after 3 months 
of treatment in the placebo group (i.e., from 73% to 51% above chance levels, i.e., from 
87% correct to 76% correct; P = 0.02; Table 3), whereas performance levels in the 
raloxifene group remained constant ( P = 0.60). Such differences in performance may 
have been due to small sample size (n = 2 x 14) and a selective biasing of one group 
over the other. Since no follow-up of the cognitive status of the subjects was performed, 
it was not possible to assess whether the observed decrease in performance was part 
of a more solid trend, indicating a pathological decline in memory performance in the 
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course of 3 months. Such a trend seems unlikely, however, since a period of 3 months 
may be too short for a group of healthy elderly subjects to develop significant pathology 
of memory systems (Petersen et al., 2001). Alternatively, decreased performance 
in the placebo group may have reflected a process of habituation of subjects to the 
experimental context after repeating of the procedure (i.e., less arousal and stress) 
(Loubinoux et al., 2001). Sample size was small, however, and the amount of weight that 
can be put to such interpretations is limited.
Given these behavioral changes, the possibility existed that the observed 
differences in task performance accuracy between both groups were responsible for 
the observed effects of treatment. We therefore performed an additional analysis of 
the separate contributions of both treatment groups to the overall pattern of treatment 
as shown in Figure 2, along with the impact of their performance scores on this 
pattern (Figures 3A,B). As shown in Figure 3B, the placebo group only produced 
nonsignificant decreases in activation after treatment, suggesting that the observed 
drop in performance did not translate into treatment effects. Similarly, Figure 3A 
suggested that treatment effects were mainly produced by the raloxifene group. This 
was confirmed by a subsequent analysis directly examining the effects of performance 
changes on activation levels before and after treatment. In the placebo group, areas 
showing a significant relationship with performance changes did not involve treatment-
related areas (Figure 4A; Table 2). In contrast, areas correlating with performance 
changes in the raloxifene group did show activation in treatment-related areas (Figure 
4B; Table 2). When performance differences were directly compared between raloxifene 
and placebo groups within a single correlational analysis, these differences explained 
part of the observed neurofunctional effects of raloxifene treatment (Figure 4D; Table 
2). Posterior (bilateral parietal) effects correlated significantly with performance, while 
anterior effects (bilateral prefrontal, anterior cingulate and Broca areas) did not (Figure 
4C; Table 2). Hence, part of the observed effects of raloxifene treatment could be 
explained by differences in task performance levels. Rather than the placebo group, 
however, it was the raloxifene group that was largely responsible for generating these 
effects. It is therefore unlikely that the observed effects of treatment were produced by 
a (passive) drop in performance in the placebo group.
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Figure 4. Results of an analysis examining effects of treatment for correlations with task performance. 
Functional maps are rendered on a mean anatomical brain volume of all subjects (Mean_anat_RALMEN). 
Left in the image is left in the brain. All areas are significant at Z > 3.1. Z = 2.3 for display purposes. 
Color scale extends from Z = 2.3 (red) to Z = 4.5 (yellow). (A) Activation pattern showing areas in which 
changes in performance accuracy in the placebo group before and after treatment correlate significantly 
with changes in activation levels (‘performance-related pattern’). Red: positive. Blue: negative correlation 
with performance. Changes mainly occur in sensorimotor areas that are not relevant to overall effects of 
treatment (Figure 2; Table 2). (B) Performance-related activation pattern of the raloxifene group. Red: 
positive. Blue: negative correlation with performance changes. Images are masked for significant effects 
of treatment (Figure 2; Table 2). (C) Activation pattern showing the result of the interaction between 
performance-related activation levels of raloxifene and placebo groups before and after treatment (panel 
B versus panel A). Images are masked for significant effects of treatment (Figure 2; Table 2). Clusters 
represent effects of treatment that correlate significantly with performance accuracy scores. (D) Activation 
pattern showing the result of the interaction between activation levels of raloxifene and placebo groups 
before and after treatment, corrected for treatment-effects on performance-related activation levels (effects 
in panel C). Images are masked for significant effects of treatment (Figure 2; Table 2). Clusters represent 
effects of treatment that do not correlate significantly with performance accuracy scores.
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The results of these functional–behavioral associations are compatible with the 
existence of an active process in the raloxifene group (as judged by enhanced activation 
in treatment-related areas) that may have maintained performance in this group at a 
certain level, whereas the absence of such a process in the placebo group may have 
produced a drop in performance (not translating into treatment effects). Hence, 
although perhaps unlikely, it is possible that raloxifene intake actively blocked a normal 
decrease in performance as a result of habituation. A canceling of training effects has 
been reported previously in male subjects receiving testosterone injections, and may 
involve effects of estrogens on attentional levels (Wolf et al., 2000). However, because 
of small sample size, further study is necessary to corroborate these findings.
The locations of the brain areas activated by raloxifene intake may provide a clue 
as to the nature of the affected functions. The observed pattern of signal changes after 
raloxifene treatment appears to be an enhancement of the activation pattern already 
observed during task performance (the main effects; Figure 1; Table 1). Such effects 
are almost invariantly observed during performance on any task that requires active 
processing of complex visuospatial information. A typical combination of bilateral 
parietal, bilateral prefrontal and anterior cingulate activation is produced that remotely 
resembles a ‘cloverleaf’ pattern (Figure 1). Previous studies have found that bilateral 
parietal activation within this pattern is related to automatic processing (i.e., working 
memory performance; (Rowe et al., 2000)), whereas activation in bilateral (pre)frontal 
areas usually involves more effortful processing (i.e., executive functions including 
response selection; (Fink et al., 1999; Rowe et al., 2000; Badre & Wagner, 2004) 
and activation of the frontal eye fields (i.e., gaze shifting; (Luna et al., 1998)). Anterior 
cingulate activation may mediate between effortful (prefrontal) and automatic (parietal) 
processing streams by selecting the most relevant of incoming stimuli, shifting conscious 
attention to this stimulus and directing effortful processing strategies against it, in order 
to generate a response that may alter the situation. This process has been referred to 
as ‘cognitive control’ in various neuroimaging studies (Badre & Wagner, 2004; Braver & 
Barch, 2002; Fink et al., 1999; Li et al., 2004b; Weissman et al., 2003). Thus, raloxifene 
intake may have affected a number of neural functions related to this process.
Apart from affecting the cortical ‘cloverleaf’ pattern, raloxifene treatment enhanced 
brain activation in the left inferior prefrontal cortex, in or near Broca’s area (Figures 2 
and 3A). Activation in this area is suggestive of increased verbal processing, possibly 
reflecting increased use of verbal strategies to encode the presented visuospatial 
information into memory. Increased verbal memory is a commonly reported finding after 
estrogen exposure (Rice & Morse, 2003). Although still a matter of debate, estrogens 
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may influence the lateralization of neural processing, possibly by enhancing verbal 
processing strategies that are dominantly represented in the left hemisphere at the 
cost of visuospatial processing strategies represented in the right hemisphere (Dietrich 
et al., 2001; Kelley et al., 1998). Data from this study therefore predict an effect of 
raloxifene on verbal performance, which may require additional study by means of 
neuropsychological assessment. 
Raloxifene treatment enhanced activation in cortical, but not subcortical or 
mediotemporal areas (Figures 2). This lack of mediotemporal activation may be due to 
a biasing effect in the sense that, for several reasons, mediotemporal (and especially 
hippocampal) activation has proven hard to image (Greicius et al., 2003). In a previous 
study, however, we used the same face encoding task as described in the current study 
to examine effects of cholinergic stimulation on brain activation in patients with mild 
cognitive impairment. Enhancement of hippocampal activation was observed, showing 
that this task may detect changes in mediotemporal activation even in patients with some 
hippocampal damage (Goekoop et al., 2004). Data from this study therefore suggests 
a preference for cortical, but not subcortical or mediotemporal activation changes. 
Thus, raloxifene treatment may have affected neocortical functions, rather than episodic 
memory itself, which depends largely on subcortical (limbic) and mediotemporal 
structures (Schacter & Wagner, 1999). Such a conclusion is supported by results 
from previous studies. (Shaywitz et al., 1999) examined changes in brain activation 
during both verbal and visuospatial memory performance after estrogen treatment of 
postmenopausal women for 3 weeks as compared to placebo.
Similar to results from the present study, enhanced activation was found in bilateral 
parietal and prefrontal structures, but not in subcortical or mediotemporal structures. 
Results were explained as an action of estrogen on cortical processes such as (verbal) 
working memory, but not episodic memory. Additionally, based on a review of a large 
number of studies, it has been suggested that effects of estrogens on memory and 
cognition represent a preferential targeting of neocortical areas, especially the prefrontal 
cortex, rather than memory circuits in subcortical or mediotemporal areas (Keenan 
et al., 2001). This conclusion is further supported by results from the current study, 
showing that raloxifene treatment produced no activation in the fusiform gyri, which 
are key structures in the processing of facial stimuli and activate strongly during task 
performance (Tarr & Gauthier, 2000) (Table 1). An effect of raloxifene might therefore 
have been expected in these areas. Instead, lingual gyri showed a small increase in 
activation. These structures are involved in visual perception, and activation changes in 
these structure may represent an effect on visuospatial attention (Bentley et al., 2004; 
68
Chapter 3: Effects of raloxifene treatment on brain function in healthy elderly males
Lawrence et al., 2002; Rezvani & Levin, 2001). However, their involvement should be 
viewed within the context of the main effects during task performance (Table 1). Face 
encoding produced maximum intensity signal changes in the lingual gyri, which may 
have made them disproportionally sensitive to effects of treatment. Thus, effects of 
raloxifene treatment during memory performance mainly involved higher cortical areas, 
but not mediotemporal areas. This makes it less likely raloxifene treatment has a direct 
effect on episodic memory during encoding.
Overall, raloxifene intake increased activation levels in brain areas spanning a 
number of different cognitive domains (see above). Such a multitude of affected 
regions makes it unlikely that raloxifene exerted a specific influence on each of these 
structures separately. Instead, the observed pattern of treatment effects is suggestive 
of a nonspecific effect of raloxifene on brain function. Such an effect may involve an 
influence on cortical arousal. Estrogens are known to exert a global influence on all 
primary neuromodulatory neurotransmitter systems (i.e., serotonergic, dopaminergic, 
nor-adrenergic and cholinergic systems), which are crucially involved in regulating 
arousal processes across the entire cortical mantle (Bernardi et al., 2003; McEwen, 
2002). Indeed, in patients with Alzheimer’s disease, cholinesterase inhibitors are used 
to stimulate the cholinergic system, which results in a small but therapeutic increase 
in episodic memory. This effect is thought to be secondary to a nonspecific effect of 
acetylcholine on cortical arousal and attention (Freo et al., 2002; Coull, 1998). fMRI 
studies have shown that modulation of cholinergic, dopaminergic and nor-adrenergic 
systems affects activation levels in a multitude of brain areas (Coull, 1998; Thiel, 2003; 
Strange & Dolan, 2004). Based on such findings, it has been suggested that many 
of the discrepancies in the literature on the behavioral effects of estrogens may be 
accounted for by assuming a context-dependent effect of estrogens on cortical arousal 
(Morgan et al., 2004). In this view, estrogens may exert a global effect on cortical 
arousal through their actions on multiple neurotransmitter systems, with small effects 
on behavior as secondary phenomena. Such a mechanism may explain previous results 
of PET studies showing a generalized increase in global activation levels after estrogen 
treatment (Maki & Resnick, 2001; Maki & Resnick, 2000; Paganini-Hill & Henderson, 
1996), and the modest changes in behavior usually associated with such treatment. In 
addition, it may explain the activation of multiple brain areas after raloxifene treatment 
as observed in this study. 
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Both estrogens and SERMs have been described as potent neuroprotectors, which may 
decrease ischaemic damage after injury and reduce cell death in neurodegenerative 
diseases, such as Alzheimer’s and Parkinson’s disease. Such effects may involve 
pathways that are only partially understood. Recent findings of adverse effects of 
estrogen treatment in postmenopausal women, including an increased risk of stroke 
and Alzheimer’s disease, have added to the controversy over the role of estrogens and 
SERMs in neuroprotection (Murphy et al., 2003). Estrogens, however, exert their effects 
on a variety of different levels, including effects on brain structure (organizational effects) 
and function (activational effects) (Bisagno et al., 2003). Both beneficial and adverse 
effects of chronic estrogen treatment may be unevenly balanced across these domains, 
and may also be context-dependent (see above). Hence, both structural and functional 
effects need to be studied separately, in order to obtain an integrated picture of the 
effects of (partial) estrogen agonists on mental functioning. This study has focused 
on the functional domain, showing that raloxifene treatment enhances activation in a 
variety of brain areas. Such changes may translate into behavioral changes that can 
be detected using neuropsychological assessment scales. Since they may represent 
secondary effects of raloxifene as a result of enhanced cortical arousal, such behavioral 
changes are likely to be small. This exploratory study predicts enhancement of working 
memory performance, executive functions, verbal skills and possibly episodic memory 
performance. Further neuropsychological assessment is necessary to test these 
predictions. Together with studies on the effects of estrogen agonists on brain structure, 
such knowledge may provide a comprehensive view on the effectiveness of SERM 
treatment in elderly subjects. 
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Abstract
Raloxifene is a selective estrogen receptor modulator that may delay the onset of 
mild cognitive impairment in elderly women. Effects of raloxifene treatment on mental 
performance in males remain to be investigated. In a previous functional magnetic 
resonance imaging (fMRI) study, we showed that raloxifene treatment enhanced brain 
activation in elderly males during encoding of new information (faces) into memory. The 
current study used fMRI in the same group of subjects to screen for effects of raloxifene 
treatment on brain function during face recognition. Healthy elderly males (n = 28; mean 
age 63.6 years, SD 2.4) were scanned at baseline and after three months of treatment 
with either raloxifene 120 mg (n = 14) or placebo (n = 14) in a randomized, double 
blind, placebo controlled study design. Functional data were analyzed in an event-
related fashion with respect to correct hits and correct rejections using FSL software. 
Performance data were analyzed with respect to recognition accuracy, latency, and 
response bias. Functional effects of treatment were found on brain activation related to 
correct hits only. When compared to placebo treatment, raloxifene treatment enhanced 
brain activation in the left posterior parahippocampal area (Z = 3.9) and right inferior 
prefrontal cortex (Z = 3.5). Recognition accuracy scores remained stable in the 
raloxifene group, whereas the placebo group showed a small but significant decrease 
in accuracy scores (p = 0.02). No significant effects were found on response bias 
or latency. In conclusion, raloxifene treatment affects brain function during memory 
performance in a way that may reflect increased arousal during initial encoding, with 
downstream effects on brain function during retrieval of information. Behaviorally, such 
neurofunctional effects may actively block decreased memory performance as a result 
of context-dependency. The validity of these predictions can be tested in large-scale 
clinical trials.
Keywords: fMRI;SERM; raloxifene; male; memory; recognition.
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Introduction
Raloxifene is a selective estrogen receptor modulator (SERM) that is used to treat 
osteoporosis in postmenopausal women (Heringa, 2003). Raloxifene has positive 
effects on cardiovascular risk factors, and is not associated with an increased risk 
of stroke and cardiovascular disease that is observed for regular estrogen treatment 
(Barrett-Connor et al., 2002). For such reasons, raloxifene treatment is considered an 
attractive alternative for prevention and treatment of osteoporosis and heart disease 
in male subjects as well (Doran et al., 2001; Blum et al., 2000). Recent results from 
a randomized controlled clinical trial show that raloxifene treatment at 120mg daily for 
three years may successfully delay the onset of mild cognitive impairment (MCI) and 
possibly Alzheimer’s Disease (AD) in elderly women (Yaffe eet al., 2005). Thus, the 
need for an assessment of the effects of raloxifene treatment on male brain function and 
mental performance is growing.
Estrogens and SERMs such as raloxifene may differentially affect mental 
performance, including memory performance, in both sexes (Cahill, 2003). It is 
therefore unclear whether the preventive effects of raloxifene treatment in women can be 
extrapolated to males. To our knowledge, no studies have been published that examined 
effects of raloxifene treatment on memory performance in male subjects. Such studies 
usually involve large-scale clinical trials in which subjects or patients are examined for 
several years in order to detect significant effects of pharmacological treatment on 
neuropsychological measures of behavior. While anticipating the results of such studies, 
the current study examined the effects of three months of raloxifene treatment on brain 
function during memory task performance using functional magnetic resonance imaging 
(fMRI). Task-related fMRI yields both functional and behavioral measures of treatment 
effects, which may serve as preliminary findings prior to large-scale investigations 
of similar effects in controlled clinical trials. fMRI may be more sensitive and less 
ambiguous to the effects of sex steroids on mental performance than conventional 
neuropsychological assessment scales (Maki & Resnick, 2001). Additionally, fMRI may 
provide an insight into the treatment mechanism of raloxifene. Treatment effects on brain 
function can be mapped to individual brain structures at high spatial resolution (Honey 
& Bullmore, 2004). The behavioral significance of such effects may be examined either 
by direct correlation of behavioral measures with such effects (Goekoop et al., 2005a), 
or by examining brain function associated with distinct response types during memory 
performance (e.g. correct hits, correct rejections) (Buckner et al., 1998a). This allows 
a detailed analysis of the effects of SERMs on memory function, which may eventually 
74
Chapter 3: Effects of raloxifene treatment on brain function in healthy elderly males
be relevant to the design and development of new SERMs that target specific aspects 
of memory performance, such as encoding and retrieval processes (Bernardi et al., 
2003).
In a previous fMRI study, we examined effects of raloxifene treatment versus 
placebo on brain function in healthy elderly males during encoding of new information 
(human faces) into memory (Goekoop et al., 2005a). Raloxifene globally enhanced brain 
activation during face encoding, with the exception of subcortical, medial temporal and 
visual structures. This was interpreted as a global effect of raloxifene treatment on cortical 
arousal, rather than a specific influence on each of the cognitive domains represented 
by this pattern (Goekoop et al., 2005a). Such effects are in line with findings from a 
large number of studies, suggesting that estrogens have a context-dependent effect on 
cortical arousal (Morgan et al., 2004; Cahill & Alkire, 2003). Based on the locations of 
treatment effects, we predicted small effects of raloxifene treatment on working memory 
performance, executive functions and verbal skills (Goekoop et al., 2005a).
Since no treatment effects were found in subcortical or medial temporal areas 
during encoding (despite activation of these structures during task performance), 
we considered an effect of raloxifene treatment on episodic memory to be less likely. 
However, the effects of raloxifene treatment on episodic memory could not be fully 
assessed, since only the encoding-phase of memory performance was examined. Since 
a growing number of imaging studies has shown that pharmacological substances 
affect brain function in process-specific manner (Honey & Bullmore, 2004; Thiel, 
2003), raloxifene treatment may have unique effects on brain function during encoding, 
consolidation or retrieval stages of memory performance. We therefore used fMRI to 
examine the effects of three months of raloxifene treatment on brain function during face 
recognition. Given the reported efficacy of raloxifene treatment in preventing the onset 
of memory impairment in elderly women, we hypothesized that raloxifene treatment 
would eventually affect brain function during retrieval of episodic information.
Methods
Study Design
Subjects were screened for participation in a randomized, double blind, placebo-
controlled repeated measures design. In each subject, fMRI was performed at baseline 
(BL; no medication; session 1) and after three months of a once daily oral intake of 
raloxifene 120 mg or placebo (TR; session 2). This dose was chosen because a previous 
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study showed no significant effects of raloxifene 60 mg on markers of bone turnover in 
males (Doran et al., 2001). BL and TR sessions were performed on the same time of 
day in each subject (margin 30 minutes). If data acquisition failed, the subject’s consent 
was asked for an additional scanning visit, up until which time the relevant medication 
regime (raloxifene or placebo) was continued, to obtain a maximum number of complete 
datasets. Study period extension was not to exceed 10 days.
Subject recruitment
The medical ethical review board of the VU University Medical Center of Amsterdam 
approved the study. Thirty healthy, right-handed elderly males, aged 60 to 70 years 
(mean 63.6 years, SD 2.4; range 60–69 years) were recruited by advertisement in local 
newspapers. This was the same study population that was examined previously for effects 
of raloxifene treatment on brain function during face encoding . All subjects provided 
informed consent during a screening visit in which the procedure was explained and 
contraindications were checked. The mental status of subjects was assessed by means 
of a structured clinical interview. This interview involved questions regarding the subjects’ 
general health, mental health, social status, history and intoxications. Exclusion criteria 
involved (a history of) psychiatric disease (i.e. any diagnosable disorders according to 
DSM-4-TR criteria (American Psychiatric Association, 2000), any neurological illness 
(memory complaints in particular), and the use of any medication or other substances 
that are known to influence cerebral functioning (including > 0.5 pack of cigarettes, 
> 4 glasses of alcohol). Elaborate physical examination and laboratory tests were 
performed to back the clinical interview. Exclusion criteria to MRI involved the presence 
of metallic implants in high-risk areas and a history of claustrophobia. Formal education 
was determined using a dutch system (low, middle, high). On the day of the second 
scanning session (after 3 months), a similar structured clinical interview was performed 
with a particular focus on side-effects of treatment. Compliance was assessed by pill 
counts and the subjects’ comments.
Functional MRI (fMRI)
Imaging was carried out on a 1.5 T Sonata MR scanner (Siemens, Erlangen, Germany), 
using a standard circularly polarized head coil with foam padding to restrict head 
motion. For fMRI, an echo planar imaging sequence was used (echo time 60 ms, flip 
angle 90°, matrix 64 x 64, field of view 192 x 192mm), to obtain 21 transverse slices 
(thickness 5 mm, interslice-gap 1 mm). Task stimuli were projected on a screen located 
at the head end of the scanner table via an LCD projector located outside the scanner 
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room. Subjects viewed the screen through a mirror located on the head coil. In each 
hand, subjects held an fMRI compatible response-box through which they were able to 
react to task stimuli by pressing a single button using one of their index-fingers. A T1-
weighted structural MRI-scan was obtained of each subject (MPRAGE; inversion time: 
300 ms, TR = 15 ms; TE = 7 ms; flip angle = 8°; 160 coronal slices, 1 x 1 x 1.5mm 
voxels). Total scanning time including structural imaging on average was 21 minutes for 
each visit.
Face recognition task 
Immediately after face encoding, which involved the presentation of four blocks of 
unfamiliar faces (24 in total), alternating with blocks of fixation (Goekoop et al., 2005a), 
a recognition task was administered. Total scanning time was 6’12’’ minutes for the 
encoding task and 3’40’’ minutes for the recognition task. Hence, minimum delay 
between items presented during encoding and recognition tasks was ~1 minute, and 
maximum delay ~10 minutes. During the first 10.5s of each memory-task, subjects 
saw a circle indicating time left before the onset of the first condition. During face 
recognition, 24 faces, of which 12 had been shown during encoding and 12 were new, 
were presented sequentially in random order on a black background. Presentation time 
was 5s for each face, followed by a white fixation-cross presented for 3s on a black 
background. We chose to contrast faces with a ‘low level’ fixation cross (X) in order to 
maximize contrast between processing demands for both conditions, which would result 
in a large number of brain areas being activated for faces > fixation contrasts, including 
visual and sensorimotor areas. This would increase chances of finding significant effects 
of treatment. Subjects were instructed verbally to indicate whether the presented faces 
were familiar or unfamiliar by pressing one of two buttons (written instructions “Left: 
familiar” and “Right: unfamiliar” also appeared alongside the pictures). Mean reaction 
times and the number of hits and misses were recorded. To avoid investigator’s bias, task 
performance data were only viewed after both scanning visits had been completed.
Two comparable versions of each paradigm were constructed and randomized 
across subjects and scanning-sessions (baseline, treatment), to reach equal numbers of 
subjects receiving test versions 1 and 2 in both treatment groups. A third ‘spare’ version 
was available in case data-acquisition might fail during one of the scanning sessions. 
Each paradigm contained unique items (faces), to avoid any overlap or interference with 
previously observed items at the time of the second scanning session. Paradigms were 
practised extensively to minimize effects of skill learning in the course of the scanning 
sessions. A practicing task was used that was similar to tasks used for neuroimaging, 
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but contained less items (practicing items did not overlap with those of tasks used for 
scanning purposes). A day before the onset of the first scanning session, subjects 
visited the hospital and practiced both encoding and retrieval tasks. On the day of 
the first scanning session, minutes before the onset of the first measurements, the 
tasks were again practiced with subjects in the scanner. On the day of the the second 
scanning session, subjects practiced the procedure within the scanner only. Total time 
for one scanning visit including instructions of memory tasks was approximately one 
hour.
Statistical analysis of task performance data
Post-hoc sorting of response types yielded a number of true positive (TP, correct hits), 
true negative (TN, correct rejections), false positive (FP, false hits), false negative (FN, 
false rejections) and forgotten items (Forgot). Based on these responses, an overall 
performance accuracy score (‘Pr’) was calculated by using the following formula: 
Pr = FP – TP (Corwin, 1994). This measure was divided by the total number of new 
items (12) to correct for 50% chance levels, yielding scores between –1 and 1. A 
‘false-alarm rate’ (‘FAR’) was calculated using the following formula: FAR = (FP + 0.5) 
/ 13. A measure of response bias ‘Br’ was then calculated using the following formula: 
Br = FAR / (1–Pr). This measure indicates the chance that subjects will guess that 
tested items are targets when they are in an uncertain state. High values of Br indicate 
a tendency to produce high numbers of false positive responses, whereas low values of 
Br indicate high uncertainty (Corwin, 1994).
Three independent variables were examined for effects of raloxifene versus 
placebo treatment: i.e. accuracy (Pr), latency (RTav) and response bias (Br). For each 
variable, a single mixed effects (ME) linear model was specified using SPSS 12.0, with 
‘group’ (2 levels: RAL, PLAC), ‘scanorder’ (2 levels: session 1, session 2) and ‘test 
version’ (2 levels: 1 and 2) as fixed factors, ‘scanorder’ being the repeated factor, and 
‘subjectnr’ defining linked measurements from the same subject. This model allowed 
calculation of significant effects of raloxifene versus placebo treatment (interaction 
group*scanorder), as well as effects of raloxifene or placebo treatment separately 
(custom contrasts examining ‘placebo: session 2 – session 1’, and ‘raloxifene: session 
2 – session 1’) and differences in performance between raloxifene and placebo groups 
at baseline and after treatement (custom contrasts examining ‘session1: RAL – PLAC’, 
and ‘session 2: RAL – PLAC’). Effects were examined using a threshold for significance 
defined by p < 0.05, Bonferroni corrected for multiple comparisons. The advantage 
of this model is that it is more accurate than conventional models, allows calculation 
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of all effects of interest within the confines of a single statistical model, and is closely 
related to the model used for analysis of the functional data. Since our previous analysis 
of the same performance data used the conventional but less accurate (multi-model) 
approach, the significance of the observed effects as reported in the current study may 
vary to some degree with those reported earlier (Goekoop et al., 2005a). However, the 
basic trends remain the same (see results section).
Analysis of functional neuroimaging data
Functional datasets of individual subjects were analyzed using FSL 3.2 (Smith et al., 
2004). The first five volumes of each dataset were discarded to account for T1-saturation 
effects. At first level (individuals), the following pre-processing was applied: non-brain 
removal, slice-timing correction using Fourier-space time-series phase-shifting, motion 
correction and spatial smoothing using a Gaussian kernel of FWHM 8mm, mean-based 
intensity normalization of all volumes by the same factor and high and low pass temporal 
filtering (Jenkinson et al., 2002; Smith, 2002). Functional neuroimages of each subject 
were coregistered to corresponding structural images in native space, and structural 
images were registered to structural Talairach standard images (Talairach & Tournoux, 
1988) defined by the Montreal Neurological Institute standard brain supplied with FSL. 
The same transformation matrices used for structural-to-standard transformations were 
then used for functional-to-standard space transformations of coregistered functional 
images. All registrations were carried out using an intermodal registration tool based 
on the correlation ratio (Jenkinson & Smith, 2001). After pre-processing, the following 
statistics was applied on a voxelwise basis on each time series, using local autocorrelation 
correction (Woolrich et al., 2001): signal change during face recognition was modeled 
in an event-related fashion, using separate regressors for TP, TN, FP, FN and forgotten 
response types (see above). Signal variance during fixation (X condition) was not 
modeled, to prevent overspecification of the model. Type and onset time of the events 
were determined by post-hoc sorting, based on the responses given by the individual 
subjects. Thus, all individuals obtained a unique model of signal response containing 
a regressor for each response type, which was convolved with a gamma function to 
model the hemodynamic response. Model fitting generated whole brain images in native 
space of parameter estimates and corresponding variance, representing average signal 
change during a particular condition (e.g. TP, TN, FP, FN, forgot) versus fixation (X, an 
implicit baseline condition). Because of a limited number of false responses, effects of 
raloxifene treatment versus placebo were examined on ‘TP’, ‘TN’, ‘TP > TN’ and ‘TN > 
TP’ contrasts only, i.e. false responses were ignored in further analyses. 
79
3.2 Effects of raloxifene treatment on brain function during recognition
Since our face recognition task contained both novel and familiar items, both encoding 
and retrieval processes occurred during task performance (Buckner et al., 2001). 
Such processes can be studied separately by means of event-related analyses of brain 
function during TP and TN items. TP and TN versus low-level fixation (X) contrasts (‘loose 
comparisons’) examine more general aspects of recognition memory performance, 
which are biased with respect to successful retrieval processes (TP > X) and encoding 
processes (TN > X), respectively (Buckner et al., 1998a). TP > TN contrasts specifically 
examine brain areas where signal intensity during successful retrieval of familiar 
information was significantly higher than signal intensity during successful rejection / 
encoding of new information. Areas of significant signal differences are therefore thought 
to represent ‘successful retrieval’ processes. Conversely, the reverse contrast TN > TP 
examines brain function related to ‘encoding during attempted retrieval’ (Daselaar et al., 
2003). TP <> TN contrasts (‘tight comparisons’) thus provide additional information 
concerning specific subcomponent processes during retrieval. Contrast images were 
resampled to 2 x 2 x 2 mm in standard space and fed into in a second-level statistical 
analysis to examine effects of raloxifene treatment on (distinct aspects of) brain function 
during retrieval.
Activation images of main effects during recognition were produced by calculating 
an average activation map based on all individual activation maps for each session, 
medication regime and event-type separately (i.e. BL (placebo), BL (raloxifene), TR 
(placebo) and TR (raloxifene)) in a mixed effects higher level analysis (Woolrich et 
al., 2004) using clusters determined by Z < 2.3 and a corrected cluster significance 
threshold of P = 0.05 (Forman et al., 1995; Friston et al., 1994; Worsley et al., 1992). 
Main effects at baseline were first tested for significant differences between raloxifene 
and placebo groups using the following contrasts: BL (RAL) <> BL (PLAC), at Z = 3.1 
(p < 0.001). Effects of treatment were then calculated using a repeated measures model, 
in which two explanatory variables (EVs) contrasted BL and TR sessions of placebo and 
raloxifene groups, allowing separate variances for both groups. Two additional EVs (one 
for each treatment group) coded for effects of test version on signal response. The main 
contrasts of interest were [TR (raloxifene) – BL (raloxifene)] <> [TR (placebo) – BL 
(placebo)], testing for an interaction between raloxifene and placebo groups before 
and after treatment. Analyses were performed using a threshold of Z = 3.1 (p < 0.001). 
Images were rendered on a mean anatomical brain volume of all subjects in standard 
space (Talairach & Tournoux, 1988) for display purposes.
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Results
Demographics
Mean age of subjects was 64.1 (SD 2.4) year in the placebo group and 63.1 (SD 2.5) 
year in the raloxifene group. The placebo group contained two smokers versus one 
in the raloxifene group. Education-level was equal in both groups (Chi square 
= 0.26; p = 0.88).
Subject compliance and discontinuation
One subject (placebo group) was claustrophobic and data quality of both sessions 
was poor in another subject (raloxifene group). These data were discarded, yielding 28 
complete datasets containing BL and TR data (n = 14 raloxifene group, n = 14 placebo 
group). Rescanning was performed once in a single individual (placebo group) because 
of poor data quality during the second scanning session. Subject compliance was good 
as assessed by tablet counts and there were no dropouts. No significant side effects 
were reported.
Task Performance
Numbers and percentages of all response types (i.e. TP, TN, FP and FN responses) 
are shown in Table 1A. Mean overall recognition accuracy was 0.60 (SD 0.20) above 
50% chance level, with mean overall reaction time 1.63s (SD 0.33s). Table 1B displays 
the significance of the difference between mean performance values (accuracy, latency 
and response bias) across both groups and scanning sessions. The placebo group 
showed significantly better mean recognition accuracy scores at baseline than the 
raloxifene group (p = 0.022). This trend was reversed after treatment (p = 0.052). 
After treatment, recognition accuracy increased significantly in the raloxifene group (p 
= 0.046), but decreased in the placebo group (p = 0.003), with the interaction being 
significant at p = 0.003. Response latency was not significantly affected in both groups. 
Response bias showed a trend toward a decrease in the placebo group (p = 0.08), 
but remained stabile in the raloxifene group (p = 0.086), with the interaction being non 
significant (p = 0.17). No significant effects were found of the covariate test version, or 
its interactions with other factors, on measures of task performance.
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Brain function
Main effects of face recognition (correct responses) involved activation of ventral and 
dorsal occipital (visual) areas, bilateral inferior parietal, parahippocampal, superior 
temporal, prefrontal areas and the lateral sulci (Figure 1, Table 2). These effects 
were very similar to previous patterns of brain function observed during delayed 
recognition memory performance (Rugg et al., 2002). Activation patterns for TP and 
TN decisions differed significantly: TP > TN contrasts showed activation bilaterally in 
primary visual cortex, anterior and posterior cingulate cortex, inferior parietal lobes and 
insula, whereas unilateral activation was observed in right motor cortex, right basal 
ganglia, left cerebellum, and left inferior, middle and superior frontal cortex (Z > 2.3 
cluster corrected (cluster threshold Z = 3.1); Figure 1). The lateralization in precentral 
areas likely represents increased motor activity of the right hand and fingers during TP 
decisions when compared to TN decisions. In contrast, only left motor cortex showed 
increased activation in TN > TP contrasts (Figure 1).
The main contrast examining the interaction between raloxifene and placebo 
groups at baseline and after treatment showed significant increases in activation during 
TP decisions only. Effects occurred in the left parahippocampal area and right inferior 
prefrontal cortex (Figure 2C; Table 3; Z > 3.1). Nearly identical effects were found on 
brain function during TN decisions, but these were not significant at Z > 3.1 (Figure 2D; 
Z > 2.3). When studying the separate contributions of each group to treatment effects 
reported in Figure 2, the raloxifene group contributed mostly to the observed effects of 
treatment (Figure 2A, 2B). No significant effects were found of placebo intake on brain 
function. No significant treatment effects were found on contrasts describing TP <> TN 
activation differences. No decreases in activation were observed after treatment with 
either raloxifene or placebo. No significant differences were found at baseline between 
activation levels of raloxifene and placebo groups within areas of significant treatment 
effects (Z > 3.1). Plots of percent signal change (from global mean values) of peak 
voxels of local maxima illustrate intensity changes in both groups before and after 
treatment (Figure 2).
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Figure 1. Axial slices showing main effects during face recognition rendered on a mean 
anatomical brain volume of all subjects. 
Left in the image is left in the brain. Effects after cluster correction at Z = 2.3 and p < 0.05. Colour scale 
extends from Z = 2.3 (red) to Z = 8.3 (yellow). Effects during correct hits (TP), correct rejections (TN) 
and TP <> TN activation differences. Baseline: brain activation at baseline. Treatment: brain activation 
after three months of treatment. Ral: raloxifene group. Plac: placebo group. Visual inspection suggests an 
enhancement of activation after raloxifene treatment for TP items. See also text and Table 2.
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Table 1. Performance measures in raloxifene and placebo groups before and after treatment.
A
Group TP TN FP FN Forgot Total
PLAC BL 142 148 18 25 3 336
PLAC TR 112 143 25 52 4 336
RAL BL 132 148 20 36 0 336
RAL TR 134 150 18 34 0 336
Single subject TP TN FP FN Forgot Total
PLAC BL 10.1 10.6 1.3 1.8 0.2 24
PLAC TR 8 10.2 1.8 3.7 0.3 24
RAL BL 9.4 10.6 1.4 2.6 0 24
RAL TR 9.6 10.7 1.3 2.4 0 24
Percentage %TP %TN %FP %FN %Forgot %Total
PLAC BL 42.3 44 5.4 7.4 0.9 100
PLAC TR 33.3 42.6 7.4 15.5 1.2 100
RAL BL 39.3 44 6 10.7 0 100
RAL TR 39.9 44.6 5.4 10.1 0 100
B
  Time Significance 
  Baseline  Treatment Treatment versus Baseline
Group Mean SE Mean SE T, df P value
Placebo Accuracy 0.69 0.030 0.47 0.060 -3.2, 42.2 0.003*
 Latency 1.76s 0.076s 1.66s 0.094s -1.3, 6.1 0.252
 Resp. Bias 0.47 0.059 0.35 0.058 -1.8, 18.5 0.083
Raloxifene Accuracy 0.59 0.030 0.64 0.060 0.79, 42.2 0.043*
 Latency 1.59s 0.076s 1.61s 0.094s 0.25, 6.1 0.810
 Resp. Bias 0.40 0.059 0.41 0.058 0.18, 18.5 0.858
Significance  T, df P value T, df P value F (num, den) P value
Raloxifene Accuracy –2.5, 21.9 0.022* 2.0, 24.0 0.052 7.85 (1,42.2) 0.008*
versus Latency –1.6, 20.8 0.125 –0.38, 24.0 0.706 1.15 (1,6.1) 0.324
Placebo Resp. Bias –0.88, 21.2 0.393 0.79, 24.0 0.440 2.03 (1,18.5) 0.171
A. Numbers of hits and misses during face recognition. ‘Group’: numbers for all subjects. ‘Single subject’: 
average numbers for single subjects. ‘%’: percentage of hits and misses for single subjects and group. 
‘PLAC’ : placebo. ‘RAL’: Raloxifene. ‘BL’: Baseline. ‘TR’: Treatment (3 months). ‘TP’: correct recognitions 
(true positives). ‘TN’: correct rejections (true negatives). ‘FP’: False recognitions (false positives). ‘FN’: 
false rejections (false negatives). ‘Forgot’: total number of cases in which presentation of a face was 
not followed by a key-press. ‘Total’: total number of presented items. B. Results of statistical analysis 
of task performance data (recognition accuracy, response latency, response bias) specified by group 
and timepoint of treatment. ‘Group’: treatment group (raloxifene, placebo). ‘Time’: time relative to onset 
of treatment (baseline, 3 months of treatment). ‘Accuracy’: recognition accuracy score (Pr); ‘Latency’: 
response latency (reaction time). ‘Resp. Bias’: response bias (Br). ‘Mean’: mean value of statistic. ‘SE’: 
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Standard error of statistic. ‘Significance Raloxifene versus Placebo’: significance of the effect of the factor 
‘group’, testing for a difference between raloxifene and placebo groups. ‘Significance treatment versus 
baseline’: significance of the effect of the factor ‘regime’, testing for any effect of treatment. ‘T, df’: T-value, 
with corresponding degrees of freedom for the relevant comparison (contrast). ‘F(num, den)’: F value, with 
numerator and denominator for the relevant comparison. ‘P value’: p value for the relevant comparison. 
Bottom right boxes show results of statistical analysis of the effect of the interaction group*time, testing for 
a significant effect of raloxifene treatment versus palcebo intake. Asterisks (*) indicate effects significant 
at the 0.05 level. See text for further details.
Table 2. Volume, Z-scores and coordinates of peak voxels of local maxima of main effects during 
correct recognition of familiar items (TP responses; averaged across baseline and treatment 
sessions of raloxifene and placebo groups).
Nr. Vox Z x y z Le/Ri Region
Confluent
areas 
9.7 2 –82 4 R Lingual gyrus
8.3 –31 –73 –10 R Fusiform gyrus
8 –30 –72 –12 L Fusiform gyrus
7.1 25 –35 –2 R Parahippocampal gyrus
6.6 –23 –38 2 L Parahippocampal gyrus
6 50 8 –3 R Superior temporal gyrus
6 48 10 –2 R Superior temporal gyrus
5.7 –40 4 0 L Lateral sulcus
5.4 0 –40 60 R Paracentral lobe
5 36 –62 40 R Inferior parietal lobe
4.7 –38 –62 39 L Inferior parietal lobe
4.2 –35 10 55 L Middle frontal gyrus
4.2 40 0 0 R Lateral sulcus
4 43 28 40 R Middle frontal gyrus
4 –40 28 42 L Middle frontal gyrus
3.9 –39 –10 54 L Precentral gyrus
3.7 –42 –23 55 L Postcentral gyrus
Similar regions were activated during TN responses. Effects after cluster correction at Z = 2.3 and p < 0.05. 
‘Nr. Vox’: number of voxels in local maximum. No data is provided since all areas are confluent. ‘Z’: Z-score 
of peak voxel. ‘x, y, z’: coordinates of peak voxel in left-to-right, anterior-to-posterior and ventral-to-dorsal 
directions respectively (mm, Talairach convention). ‘Le/Ri’: left or right hemisphere. See also text and 
Figure 1.
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Figure 2. Axial slices showing effects of raloxifene treatment on brain function during TP and TN 
responses (correct hits and correct rejections). 
Functional maps are rendered on a mean anatomical brain volume of all subjects (Mean_anat_RALMEN). 
Left in the image is left in the brain. Colour scale extends from Z = 2.3 (orange) to Z = 4.0 (yellow) for display 
purposes. No significant effects were observed after placebo intake (data not shown). A. Raloxifene group, 
TP items, contrast TR > BL. When compared to baseline, raloxifene treatment significantly increases brain 
activation in parahippocampal and right inferior prefrontal cortex. Effects are significant at Z > 3.1. B. 
Raloxifene group, TN items, contrast TR > BL (RAL). Effects are not significant at Z > 3.1, but are highly 
similar to treatment effects during TP responses at Z > 2.3. C. Raloxifene group versus placebo group, 
TP items, contrast (TR > BL (RAL)) > (TR > BL (PLAC)) (interaction). Increased activation is observed in 
parahippocampal cortex and right inferior prefrontal cortex (areas listed in Table 3). Effects are significant 
at Z > 3.1. D. Raloxifene group versus placebo group, TN items, contrast (TR > BL (RAL)) > (TR > BL 
(PLAC)) (interaction). Effects are not significant at Z > 3.1, but are highly similar to treatment effects during 
TP responses at Z > 2.3. The strong resemblance of treatment effects on TP and TN contrasts suggests a 
general effect of raloxifene treatment on brain function during recognition, rather than a selective effect on 
encoding or retrieval processes (see text). Plots: Graphs depicting the interaction between mean percent 
signal change of raloxifene and placebo groups at baseline and after treatment, as observed in peak voxels 
of local maxima of significant effects of treatment. Two reference voxels have been sampled in peak voxels 
of local maxima during face recognition in similar slices (10, –76, 16) and (2 –82 4), showing no significant 
interaction after treatment. Means and standard deviations (errorbars) are shown. Arrows indicate the 
corresponding clusters of activation. See also text and Table 3.
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Discussion
In a previous study, we reported effects of raloxifene treatment on brain activation during 
encoding of unfamiliar faces (Goekoop et al., 2005a). Results of the current study 
complement our previous findings by examining brain activation during recognition of 
the encoded items.
Effects of raloxifene treatment: behavioral data
An unexpected drop in recognition accuracy was observed in the placebo group 
after 3 months of treatment, whereas performance in the raloxifene group increased 
slightly (Table 1). The nature of this drop in accuracy scores is unclear, but a number 
of explanations are possible. First, although group size of the current study is large to 
fMRI standards, it is rather small in terms of behavioral studies. Such small groups may 
show random differences in mean performance measures (Wilkinson & Halligan, 2004). 
Second, a drop in recognition accuracy at time2 (retest phase) with respect to time1 
(test phase) is a regularly observed phenomenon in test-retest studies. Such effects 
are attributed to changes in context between test- and retest phases, and may involve 
‘true’ decreases in sensitivity to old or new items as well as a change in response bias 
(i.e. subjects perform worse when they are insecure, or in an unfamiliar environment) 
(Feenan & Snodgrass, 1990). We therefore considered the possibility that a change 
in response bias was responsible for the observed decline in performance accuracy 
in the placebo group. A trend was observed for a difference in response bias (Br) in 
the placebo group (p = 0.08), but no significant effects of raloxifene versus placebo 
treatment were found. The possibility therefore exists that a change in response bias 
explains the observed decline in performance in the placebo group, but group size may 
not have been large enough to produce a significant difference. A change in response 
bias may reflect the subject’s sensitivity to interference by changes in context between 
encoding and retrieval phases, practicing and scanning stages, or between first and 
second scanning sessions (e.g. no practicing round was held the day before the second 
scanning session). Since test items did not overlap between different test versions and 
the factor ‘testversion’ was no significant confounder of task performance scores, we 
consider it unlikely that specific test items or the use of different test versions acted as 
significant distracters. Since both groups were matched with respect to age, gender 
and education level, we considered problems of group matching to be an unlikely source 
of performance differences between raloxifene and placebo groups. Additionally, a 
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pathological decline of memory performance in the placebo group was considered 
unlikely, since these changes in performance occurred over a relatively short period of 
time (3 months) in otherwise healthy subjects (Goekoop et al., 2005a). Future studies 
may require to include more subjects and perform more detailed assessment of cognitive 
status (including measures of context-dependency), in order to evaluate the effects of 
pharmacological substances on brain function and mental performance.
Effects of raloxifene treatment: functional-behavioral relationships
Previous studies have shown that (small) behavioral changes do not necessarily translate 
into functional effects observed using fMRI at current group sizes (Wilkinson & Halligan, 
2004). To examine whether performance changes in each group separately were in any 
way related to the observed functional effects of treatment, we studied the separate 
contributions of raloxifene and placebo groups to the overall pattern of treatment effects 
on brain function during recognition. Treatment with placebo had no significant effect on 
brain activation. Indeed, treatment effects were mainly due to effects of raloxifene intake 
(Figure 2A, 2B). This indicated that the drop in performance observed in the placebo 
group was not a significant confounder of functional effects of raloxifene treatment 
versus placebo as reported in this study (Figure 2C, 2D). Similarly, we examined the 
separate contributions of both groups to effects of raloxifene intake versus placebo on 
brain activation during encoding in our previous study (Goekoop et al., 2005a). Only 
the raloxifene group showed significant increases in brain activation in treatment-related 
areas, again indicating that placebo intake and subsequent performance changes were 
not a significant confounder of treatment effects during encoding.
Although further studies are necessary to corroborate our current findings, 
our data are consistent with the hypothesis that a ‘normal’ decrease in performance 
accuracy as a result of the subjects’ sensitivity to a difference in context between test- 
and retest phases was countered by an active process related to raloxifene treatment 
(Goekoop et al., 2005a). A reduction in the variability of recognition accuracy scores 
has been observed previously in elderly women receiving estrogen treatment (Wegesin 
& Stern, 2004). Additionally, a canceling of learning effects has been observed in 
male subjects receiving testosterone injections (Wolf et al., 2000), which may involve 
estrogen-mediated mechanisms (Wolf, 2003; Longcope et al., 1969). Such effects 
may involve effects of estrogens on arousal and attentional levels rather than direct 
effects on episodic memory. Estrogens are thought to influence brain function through 
a context-dependent effect on cortical arousal (Morgan et al., 2004). Such effects 
involve well-documented effects of estrogens on the four primary neuromodulatory 
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neurotransmitters that regulate cortical arousal states (i.e. serotonin, dopamine, 
noradrenaline and acetylcholine) (Bernardi et al., 2003; Korol, 2004). An increase in 
cholinergic (or noradrenergic) arousal is known to reflect an increase in signal-to-noise 
levels in neural networks, which translates into enhanced attention and working memory 
performance in animals and humans (Sarter et al., 2005). This mechanism of action is 
thought to be an important factor underlying improvement of memory performance in 
patients with Alzheimer’s disease that are treated with cholinesterase inhibitors (Sarter 
et al., 2005). Similarly, raloxifene treatment may have improved memory performance 
by enhancing cortical arousal (signal-to-noise-levels) during initial encoding, thereby 
reducing sensitivity to interference as a result of context-changes. Future studies may 
require to examine effects of raloxifene treatment on physiological measures of arousal 
and attention in order to examine this hypothesis in more detail.
Effects of raloxifene treatment: encoding versus recognition 
During face encoding, signal intensity during task performance was enhanced 
symmetrically across a wide range of neocortical areas (Goekoop et al., 2005a). 
This rather generalized enhancement of cortical brain activation during face encoding 
was interpreted as a global effect of raloxifene intake on cortical arousal, rather than 
a specific effect of raloxifene treatment on all cognitive domains represented by this 
pattern (Goekoop et al., 2005a). Treatment effects observed in the current study 
showed both similarities and differences with treatment effects during initial encoding. 
During both phases of memory performance, raloxifene intake produced increases in 
brain activation. Although decreases may have been possible in theory, these were 
not observed. The reason for the absence of signal decreases is unclear, but may 
reflect effects of increased arousal, since enhanced arousal levels increase rather 
than decrease the reactivity of neural networks (Coull, 1998; Morgan et al., 2004). In 
contrast to face encoding, however, treatment effects during face recognition did not 
involve a widespread increase of main effects of task performance in cortical structures. 
Direct effects of cortical arousal may therefore not have been relevant to treatment 
effects during face recognition. Indeed, a recent study shows that noradrenaline and 
neural steroids such as cortisol may modulate memory consolidation by interacting with 
arousal levels at initial encoding, rather than recognition (Cahill & Alkire, 2003). Although 
raloxifene intake may have influenced brain function during recognition independently of 
encoding, it is therefore possible that the observed effects of raloxifene treatment during 
recognition represent indirect, or ‘downstream’ effects of treatment effects during initial 
encoding, or consolidation processes occurring between the two tasks. Clearly, more 
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research is needed to examine the neurodynamic changes underlying the observed 
effects of treatment, along with the possible interactions between treatment effects 
occurring at different stages of memory performance.
The current study shows that raloxifene treatment eventually affects brain function 
during memory retrieval. Since identical procedures of functional data analysis were 
performed, the asymmetric distribution of treatment effects across encoding and retrieval 
phases of memory performance suggests that the effects of raloxifene, like the effects 
of many other pharmacological substances, are process-specific (Honey & Bullmore, 
2004). A direct statistical comparison of treatment effects between encoding and 
recognition phases was not performed, however, since these tasks were too dissimilar 
(i.e. block versus event-related designs) to allow meaningful comparisons. We therefore 
report our findings of the effects of cholinergic challenge separately for both memory 
tasks. Although encoding processes during attempted retrieval may differ from encoding 
during attempted encoding (Reber et al., 2002; Rombouts et al., 2001), studies of brain 
function during retrieval allow analyses of encoding and retrieval processes within the 
same scanning session (see materials and methods), which avoids some of the potential 
confounds that may be introduced by across-session comparisons (e.g. differences in 
task design, subject positioning, motion artifacts).
Significant effects of raloxifene treatment were found on brain activation during 
TP decisions (familiar items), but not on TN decisions (unfamiliar items) (Figure 2C). 
Although this may indicate a preference for raloxifene treatment to influence successful 
recognition rather than encoding during attempted retrieval, the small number of items 
analyzed per subject somewhat limit these findings (Table 1). Indeed, when the threshold 
for significant brain function was lowered for contrast images representing treatment 
effects during TN decisions, treatment effects were found that were nearly identical to 
those observed for TP decisions (Figure 2D). This suggested that raloxifene treatment 
affected more general aspects of recognition memory function that are examined 
equally by ‘loose’ comparisons of brain function during TP and TN decisions versus 
fixation (see materials and methods). In order to explore this possibility in more detail, 
we studied the effects of raloxifene on ‘tight’ TP <> TN comparisons of brain function, 
which examine specific encoding and retrieval processes during task performance 
(see materials and methods). No significant effects of raloxifene treatment were found, 
supporting the view that raloxifene treatment affected general aspects of recognition 
memory performance, rather than specific subcomponent processes during retrieval. 
Brain areas showing treatment effects for TP items included the right inferior frontal 
gyrus and left parahippocampal cortex (Figure 2C, Table 3). These structures are 
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important to retrieval of episodic (visuospatial) information after some delay (Schacter 
& Wagner, 1999; Fletcher & Henson, 2001; Rugg et al., 2002). Enhanced activation 
of these structues may reflect direct effects of estrogen receptor stimulation on neural 
signaling and brain function (Bisagno et al., 2003), or sustained effects of estrogen 
receptor stimulation, which alters protein synthesis and enhances the outgrowth of neural 
spines in hippocampal areas, which is known to be associated with increased memory 
performance (Li et al., 2004a). Future studies may require to examine the relationships 
between functional effects of treatment and changes in (parahippocampal) spine density 
in vivo, by combining phMRI and molecular imaging techniques (e.g. PET). Based on 
the current results, we predict an effect of raloxifene treatment on delayed (visuospatial) 
memory performance in males.
Table 3. Volume, Z-scores and coordinates of peak voxels of local maxima of significant effects 
of medication intake (Z > 3.1), as determined by the interaction between activation levels of 
raloxifene and placebo groups at baseline and after treatment (see M&M).
Nr Vox Z x y z Le/Ri Region
33 3.53 –26 –38 –2 L Parahippocampal area
16 3.51 52 22 16 R Inferior frontal gyrus
‘Nr. Vox’: number of voxels in local maximum (voxelsize 2x2x2mm). ‘Z’: Z-score of peak voxel. ‘x, y, z’: 
coordinates of peak voxel in left-to-right, rostral-to-caudal and ventral-to-dorsal directions respectively 
(mm, Talairach convention). ‘Le/Ri’: left or right hemisphere. See also text and Figure 2.
Effects of raloxifene treatment: blood versus brain
In the absence of direct measurements of vascular changes (e.g. perfusion studies), 
only indirect arguments may serve to locate treatment effects on blood oxygenation 
level dependent (fMRI) signal reactivity more precisely to either the neural or vascular 
compartment (Honey & Bullmore, 2004). In the current study, vascular effects seemed 
less likely than neurogenic effects for several reasons. First, effects on blood vessels 
are likely to be similar across different mental processes, yet treatment effects differed 
between encoding and retrieval stages of memory performance. Second, effects on 
vascular tissue are likely to be generalized instead of localized, yet treatment effects 
were localized in our studies. Even during encoding, which showed a widespread 
pattern of signal enhancement, there were some highly vascularized and active brain 
structures (e.g. primary visual cortex) that did not show enhancement of signal intensity 
after raloxifene treatment. Finally, treatment effects were found in functionally meaningful 
areas only (e.g. not in white matter). Together, these observations strongly suggest that 
the effects of raloxifene treatment were of neurogenic rather than of vascular origin.
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Summary and conclusions 
Raloxifene treatment enhanced brain activation in male subjects during recognition of 
familiar items. A possible treatment mechanism involves enhanced memory retrieval 
as a result of increased cortical arousal during initial encoding, which reduces effects 
of context-dependency. Similar effects may underlie the ability of long-term raloxifene 
treatment to delay the onset of mild cognitive impairment in elderly women. Our combined 
studies on the effects of raloxifene treatment on episodic memory performance in male 
subjects predict the occurrence of small behavioral effects on working memory and 
delayed (visuospatial) memory performance, executive functions and verbal skills, 
which are secondary to enhanced arousal and attention during initial encoding. Further 
neuropsychological studies involving larger groups of subjects are necessary to test the 
validity of these predictions.
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Abstract
Mild cognitive impairment (MCI) often represents an early form of Alzheimer’s Disease 
(AD). In both MCI and AD, characteristic cholinergic changes may occur. Functional 
magnetic resonance imaging (fMRI) may help to examine neurochemical changes in 
early disease, by studying signal reactivity to pharmacological challenge. In this study, 
MCI patients (n = 28; mean age 73.6 ± 7.5; MMSE 27.0 ± 1.2) were scanned during 
task performance in a randomized trial under three different medication regimes: at 
baseline (BL; no GAL), after a single oral dose of GAL (SD) and after prolonged 
exposure (Steady State: SS). Memory tasks included an episodic face encoding task 
and a parametric n-letter back working memory task. Alterations in brain activation 
patterns before and after treatment were analyzed for both tasks using multi-level 
statistical analysis. Significant increases in brain activation from BL were observed after 
prolonged exposure only. For face encoding (n = 28), these involved left prefrontal 
areas, the anterior cingulate gyrus, left occipital areas and left posterior hippocampus. 
For working memory (n = 28), increased activation was found in right precuneus 
and right middle frontal gyrus, coinciding with increased accuracy-scores after GAL-
treatment. In conclusion, cholinergic challenge produces alterations in brain activation 
patterns in elderly MCI patients that can be detected with fMRI. This should encourage 
further functional imaging studies to examine the status of neurotransmitter systems in 
disease.
Keywords: fMRI; MCI; galantamine; challenge study; cholinergic system. 
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Introduction
Alzheimer’s Disease (AD) is characterized by progressive atrophy of medial temporal, 
frontal and parietal brain structures. These structural changes give rise to clinical 
symptoms such as amnesia, agnosia and aphasia (Braak et al., 1999; Geula, 
1998). Atrophy of basal forebrain nuclei is another major feature in AD, resulting in 
pathological neurochemical changes throughout the brain. Of these, low acetylcholine 
levels in particular are thought to contribute significantly to symptoms in AD (Bartus, 
2000; Mesulam, 2004). Current therapies against AD largely aim at restoring low 
acetylcholine levels with pharmacological agents (Lanctot et al., 2003; Trinh et al., 
2003). Functional imaging techniques are currently being investigated for their ability 
to detect neurochemical changes and monitor effects of treatment in dementia (Burn & 
O’Brien, 2003; Freo et al., 2002).
Mild cognitive impairment (MCI) represents a functional continuum between 
normality and the earliest signs of dementia (most commonly AD). Patients with MCI are 
at increased risk of developing AD, but clinical outcome may vary considerably (Petersen 
et al., 2001). Recent evidence shows that alterations in cholinergic system activity also 
occur in MCI patients. Markers of cholinergic function are upregulated in MCI, possibly 
to compensate for incipient neurofunctional defects (DeKosky et al., 2002). Functional 
imaging studies of cholinergic system (re)activity in MCI patients may therefore reveal 
important clinical information. First, such studies may link the functional status of the 
cholinergic system to the occurrence of symptoms in very early AD, indicating the 
necessity of starting cholinomimetic therapy (Volkow et al., 2001). Second, reactivity to 
cholinergic challenge may predict clinical responsiveness to cholinomimetic treatment, 
indicating the sensibility of starting a particular therapy (Volkow et al., 2001; Nobili et 
al., 2002; Doraiswamy et al., 2000). Thirdly, the ability of the cholinergic system to 
compensate for small decreases in neural function (by altering cerebral plasticity and 
changing signal-to-noise levels in neural networks) is now increasingly recognized (Parry 
et al., 2003; Mesulam, 2004; Burggren et al., 2002). If this is true, cholinergic system 
‘viability’ (Volkow et al., 2001), or residual function, may be a measure of ‘compensatory 
reserve’ (Mesulam, 2004) and may influence a patient’s prognosis.
In view of the above, we set out to study the feasibility of using fMRI to detect 
cholinergic system reactivity to selective pharmacological challenge in elderly 
patients with MCI. As a cholinomimetic agent, we used galantamine (GAL), which 
is a cholinesterase inhibitor with known therapeutic potential and has an additional 
modulatory effect on nicotinergic receptors (Raskind, 2003). To study the distribution 
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of GAL effects across memory systems, memory tasks were used that examine both 
episodic and working memory (WM) performance. To study the onset time of the effect, 
fMRI was performed after both a single dose challenge with GAL and after prolonged 
exposure.
Materials and Methods 
Study Design
Subjects were screened for participation in a randomized study design in which patients 
themselves served as controls. fMRI was performed at baseline (BL, no medication), 
after oral intake of a single dose of 8 mg GAL with water (Single Dose; SD) and after 
prolonged exposure to GAL (Steady State (SS)); i.e. a 120 hour period (5 days) spread 
over 6 weekdays: 4 mg GAL (first gift, evening of day 1); 4 mg GAL b.i.d. (mornings and 
evenings; 4 consecutive days); 4 mg GAL (final gift, morning of day 6)). The minimum 
serum GAL concentration at 4 mg b.i.d. in healthy controls is 10.6 ± 4.0 ng/ml, with 
maximum levels 30.7 ± 6.2 ng/ml. At this rate, steady state plasma levels are reached 
within 2–3 days (Mannens et al., 2002; Zhao et al., 2002). Timing of scanning sessions 
was such that, on average, plasma levels could be considered equal at the time of 
scanning for SD and SS regimes, i.e. 3 hours after SD and 9 hours after SS regimes. 
BL, SD and SS regimes were randomized across scanning sessions to prevent session 
(e.g. learning) effects from interfering with possible effects of medication. To avoid 
carry-over effects, SD and SS regimes were separated by a washout period of two days 
of zero GAL intake (which is more than 6 times the half-life of galantamine (7.4 hours) 
(Mannens et al., 2002; Zhao et al., 2002). Scanning sessions were exactly one week 
apart and each patient was scanned on the same hour of day during all three sessions. 
If data acquisition failed, the subject’s consent was asked for a fourth and final scanning 
visit, for which the relevant medication regime was readministered, to obtain a maximum 
number of reliable datasets.
Subject recruitment
Thirty healthy elderly MCI patients, aged 54 to 89 years (mean 73.6 ± 7.7) were recruited 
from the Alzheimer Center at the VU Medical Center, Amsterdam, the Netherlands. 
MCI patients were diagnosed using Petersen’s criteria for amnestic MCI, i.e. a slowly 
progressive memory decline without the involvement of any other domain of cognitive 
function, that did not interfere significantly with activities of daily living (Petersen et 
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al., 2001). Before inclusion in the study, elaborate neuropsychological profiling was 
performed during clinical investigation. Inclusion criteria were a mini mental state 
examination (MMSE) (Folstein et al., 1975b) score of 26 or higher, a clinical dementia 
rating (CDR) scale score of 0.5 (Morris, 1993), and a New York University (NYU) 
paragraph recall test-score not exceeding 10 items on delayed recall. Formal education 
was determined on a discrete scale with three levels (1 = low, 2 = middle, 3 = high). 
All patients provided informed consent under supervision of a lawful caretaker during 
a screening visit in which the procedure was explained and contraindications were 
checked. Patients were excluded if they had any significant medical, neurological or 
psychiatric illness, or if they were taking medication or other substances that are known 
to influence cerebral function, including antidepressants and other cholinesterase 
inhibitors. Patients were excluded if their history showed excessive nicotine or alcohol 
intake (> 0.5 packs of cigarettes, > 8 glasses of an alcoholic substance a day), a 
severe allergy to pharmacological substances or their constitutive compounds, or the 
use of any experimental medication within three months prior to enrollment in this trial. 
Exclusion criteria to MRI involved the presence of a pacemaker, metallic implants in 
high-risk areas (i.e. vessel clips) and a history of claustrophobia.
Functional MRI (fMRI)
Data acquisition
Imaging was carried out on a 1.5 T Sonata MR scanner (Siemens, Erlangen, Germany), 
using a standard circularly polarized head coil with foam padding to restrict head 
motion. For fMRI, an echo planar imaging sequence was used (echo time 60 ms, flip 
angle 90°, matrix 64 × 64, field of view 192 × 192 mm), to obtain 21 transverse slices 
(thickness 5 mm, interslice-gap 1 mm). Task stimuli were projected on a screen located 
at the head end of the scanner table via an LCD projector located outside the scanner 
room. Subjects viewed the screen through a mirror located on the head coil. In each 
hand, subjects held an fMRI compatible response-box through which they were able 
to react to task stimuli by pressing a single button using one of their index-fingers. A 
T1–weighted structural MRI-scan was obtained of each subject (MPRAGE; inversion 
time: 300 ms, TR = 15 ms; TE = 7 ms; flip angle = 8°; 160 coronal slices, 1 × 1 × 1.5 
mm voxels).
Paradigms (memory-tasks)
Two paradigms were used to examine different types of memory function. A well-stablished 
face-encoding task was used to cover the intermediate-term episodic memory domain. 
98
Chapter 4: Effects of galantamine challenge on brain function in MCI and AD patients
This task produces activation in visual, parietal, prefrontal, anterior cingulate, and medial 
temporal brain structures bilaterally (Small et al., 1999). A parametric N-letter back task 
was used to examine brain activation during working memory (WM) performance. This 
task activates a combination of frontal and parietal brain structures and the anterior 
cingulate gyri (Braver et al., 1997). Given the hypothetical dichotomy between episodic 
memory (EM) and working memory (WM), an attempt was made to map the effects of 
GAL challenge to alterations in brain activation patterns within distinct brain structures 
and their associated memory systems. Three different but comparable versions of 
each paradigm were constructed and randomized across the scanning-sessions (BL, 
SD, SS). A fourth ‘spare’ version was made in case data-acquisition might fail during 
one of the scanning sessions. All paradigms were practised extensively using dummy 
tasks to ensure that patients mastered the general procedure of task performance 
before scanning (one day before the start of the first session on a laptop computer 
during a home visit: both paradigms; fifteen minutes before the onset of each scanning 
session: n-back task; five minutes before the onset of the first measurements, with 
subject in scanner: face encoding paradigm). During the first 10.5s of each memory-
task, subjects saw a circle indicating time left before the onset of the first condition. To 
avoid investigator’s bias, task performance data were only viewed after all three scan 
visits had been completed. Total time for one scanning session including instructions of 
memory tasks was approximately one hour.
Episodic memory task (face encoding) 
The encoding task consisted of a simple block-design with two alternating conditions: 
Condition 1 (‘ENCOD’) consisted of 4 blocks of 42s each. Each block contained 
6 unfamiliar faces presented sequentially in random order on a black background 
(presentation time 6s, followed by a 1s delay). Male and female faces were balanced 
across the blocks. Condition 2 (‘FIX’) consisted of 4 blocks of 44s each, in which a 
white fixation cross (X) was presented on a black background. The entire task thus 
consisted of 8 alternating blocks of ENCOD and FIX conditions and was preceded by 
a 21s FIX condition. Prior to scanning, subjects were instructed verbally to remember 
the faces for future testing and to classify each face according to its gender by pressing 
one of two buttons (written instructions “Left: male”, “Right: female” also appearing 
alongside the pictures). Mean reaction times for gender discrimination were recorded 
and a performance accuracy-score varying from –1 to 1 (with 0 indicating chance level) 
was calculated by subtracting false answers from correct answers and dividing the 
result by the total number of items (24). Total task duration was 6’12’’minutes.
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Immediately after encoding, encoding success was assessed using a recognition task, 
while subjects were still in the scanner. 24 faces, of which 12 had been shown during 
encoding and 12 were new, were presented sequentially in random order on a black 
background (presentation time 5s for each face, followed by a white fixation-cross 
presented for 3s on a black background). Subjects were instructed verbally to indicate 
whether the presented faces were familiar or unfamiliar by pressing one of two buttons 
(written instructions “Left: familiar” and “Right: unfamiliar” also appearing alongside the 
pictures). Similar performance measures were calculated as for gender discrimination.
Working memory task (N-letter WM back)
This task consisted of a block design with three conditions lasting 40s each, which 
were presented three times (9 blocks) in a pseudorandomized fashion. Each condition 
involved four occurrences of a single, pre-specified target (a letter or letter-combination) 
in a string of 20 letters that were presented sequentially in a pseudorandomized fashion 
on a black background (presentation-time: 1s, followed by a 1s delay). Each condition 
was preceded by a written instruction indicating the target (‘INSTR’) with a duration 
of 10s. Subjects were asked to press a single button using their right index finger 
whenever the target appeared. In Condition 1, the target was the occurrence of the 
letter X (‘X’, testing sustained attention). In condition 2, subjects were instructed to 
respond to any occurrence of two identical letters in a row (‘1-BACK’, testing low WM-
load). Condition 3 involved events where two identical letters were separated by a single 
and randomly chosen letter (‘2-BACK’, testing increased WM-load). A percentage of 
‘hits’ and ‘misses’ was recorded for each subject. Task performance measures were 
calculated separately for X, 1-BACK and 2-BACK WM load conditions (see above). 
Total task duration was 7’41’’ minutes.
Statistical analysis of task performance data
Separate performance scores, each corresponding to different medication regime (i.e. 
BL, SD, SS), were calculated for each patient. A univariate analysis of variance was 
performed using SPSS 9.0, in which measures of task performance were entered as 
dependent variables in an analysis of the medication effect, with ‘subject number’ as 
a random factor (to account for the effect of taking repeated measures from the same 
subject), medication ‘regime’ (3 levels: BL, SD, SS) and ‘test version’ (3 levels: 1, 2, 
3) as fixed factors (to account for within-subject variance attributable to these factors) 
and ‘scan order’ (3 levels: 1, 2, 3) and ‘WM load’ (if applicable; 3 levels: 0, 1, 2) as 
covariates. If a significant effect of a covariate was found, the model was adjusted to 
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contain the relevant covariate as a fixed factor in a subsequent analysis of the medication 
effect. Effects of the factor ‘regime’ were then considered representative of an effect of 
intervention with GAL.
Analysis of functional neuroimaging data
Functional datasets of individual patients were analyzed using FSL (FMRIB’s Software 
Library, www.fmrib.ox.ac.uk/fsl). The first five volumes of each dataset were discarded to 
account for T1-saturation effects. At first level (individuals), the following preprocessing 
was applied: non-brain removal, slice-timing correction using Fourier-space time-series 
phase-shifting, motion correction and spatial smoothing using a Gaussian kernel of 
FWHM 8mm, mean-based intensity normalization of all volumes by the same factor and 
high and low pass temporal filtering (Jenkinson et al., 2002; Smith, 2002). Registration 
of functional neuroimages to high resolution and/or standard images was carried out 
using an intermodal registration tool based on the correlation ratio (Jenkinson & Smith, 
2001). After preprocessing, the following statistics was applied on a voxelwise basis 
on each time series, using local autocorrelation correction (Woolrich et al., 2001): 
signal change during all task conditions was modeled as a box car, which had the same 
alternation frequency as the task conditions, and convolved with a gamma function 
to model the haemodynamic response. The FIX conditions of both the encoding task 
(except for the first FIX-period of 21s) and the INSTR condition of the n-letter back task 
were not modeled, to prevent overspecification of the model. Model-fitting and parameter 
estimation generated whole brain activation maps (Z-statistic images) (Forman et al., 
1995; Friston et al., 1994; Worsley et al., 1992)) for each subject, task condition, and 
medication regime (BL, SD, SS). These images represent average signal change from 
baseline during task performance under these conditions. From face encoding data, a 
single ENCOD (> FIX) contrast (difference between effect sizes of two task conditions) 
was calculated. From n-back data, two contrasts were calculated: 2BACK > X and 
1BACK > X. These contrast maps (with associated maps of signal variance) were fed 
into in a second-level statistical analysis to examine effects of medication intake at group 
level.
At second level (group level), individual contrast maps for a particular condition 
were summed across all subjects and medication regimes (i.e. BL + SD + SS), to 
produce whole brain group maps of average brain activation during that condition (the 
‘main effects’). This was done using a mixed effects (i.e. combined fixed and random 
effects) higher level analysis with clusters determined by Z > 2.3 and a (corrected) 
cluster significance threshold of P = 0.05 (Woolrich et al., 2004; Forman et al., 1995; 
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Friston et al., 1994; Worsley et al., 1992). A second higher-level design was used 
to calculate effects of medication, in which explanatory variables (EVs) were used as 
regressors to explain signal variance. The first two EVs contrasted BL (–1) and SD (1) 
regimes and BL (–1) and SS (1) regimes respectively. Similarly, the next four EVs coded 
for effects of scan order and test version to correct for possible effects of scanning 
session (e.g. learning effects) and test version on signal response. Since data-analysis 
involved the use of multi-level statistics, these possible confounders were removed from 
those of medication intake. The remaining EVs were used to set proper weights to data 
that were derived from the same subject (repeated measures design). Paired inputs 
were identified as such in the model by specifying a separate EV for each subject, 
with values of 1 for all inputs derived from that subject, and 0 otherwise. Thus, within- 
and between-subject variance was modelled by separate EVs. If certain combinations 
(pairs) could not be made (due to missing values), unpaired data was still allowed to 
enter the model. Data were analyzed in a mixed effects analysis at a voxel threshold for 
significant activation determined by Z > 3.1, at uncorrected p (Woolrich et al., 2004; 
Forman et al., 1995; Friston et al., 1994; Worsley et al., 1992). Images were rendered 
on a 3D mean anatomical brain volume of all patients in standard space for display 
purposes (Talairach & Tournoux, 1988). Coordinates of local maxima were extracted and 
fed into the Talairach Daemon Client version 1.1 (Research Imaging Center; University 
of Texas, Health Science Center, San Antonio, USA) for identification of the relevant 
brain structures. If effects of medication were small, the threshold for significant brain 
activation was lowered to Z = 2.3 to view additional, and possibly related, subthreshold 
changes in order to judge whether the observed supra-threshold changes were part of 
a meaningful neural network.
Results
Demographics
Mean age of MCI patients was 73.8 (± 7.7). Education-level was low in 3 patients, 
middle in 15 patients and high in 10 patients. Three patients were left-handed and three 
were smokers. Mean MMSE score was 27.0 (± 1.2) and mean NYU paragraph recall 
score was 3.2 (± 2.9) on delayed recall. CDR was 0.5 by definition.
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Figure 1. 3D-brain rendered images of main effects for encoding and N-letter back WM 
performance. 
Left in the image is left in the brain. Effects are shown at a Z-threshold of 2.3 (cluster corrected p = 0.05) 
for BL, SD and SS regimes respectively. Colour scale extends from Z = 2.3 (orange) to Z = 12.0 (yellow). 
A, B, C: Main effects of encoding contrast. D, E, F: Main effects of 1BACK > X contrast. G, H, I: Main 
effects of the 2BACK > X contrast.
Patient compliance and discontinuation
Data-acquisition was complete in 21 out of 30 patients after a single run. Four patients 
required an extra scan to obtain a complete dataset (three patients had poor compliance 
(i.e. significant errors of intake during either SD or SS regimes), as judged by the 
caretaker’s comment. One patient did not respond to task-stimuli in one session. This 
yielded a total of 25 complete datasets. In three patients, data acquisition was incomplete 
due to a scanner error (1 session, 1 patient) and side effects during two SD regimes (3 
sessions, 2 patients). No data was obtained in two patients (one patient developed a 
mood disorder prior to GAL-intake. A second patient refused to continue the study after 
developing side effects after the first regime (SD). Sessions of incomplete datasets 
were included in the analyses (see M&M). Thus, data from 28 patients was used in this 
study.
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Analysis of functional neuroimages
Face encoding
Main effects of face encoding involved extensive activation in ventral and dorsal 
occipital (visual) areas, bilateral parietal, bilateral frontal and prefrontal areas and the 
anterior cingulate gyri, with a preference for the right hemisphere (Figure 1). Additional 
activation was found in the left and right posterior parahippocampal areas and the 
left posterior hippocampus. Extensive bilateral activation of thalamic structures also 
occurred. Pairwise comparisons of functional maps of SD and SS versus BL regimes 
showed a significant change from baseline for SS regimes only (Figure 2). Table 1 lists 
Z-scores and local maxima for these effects. BOLD signal changes associated with SS 
vs. SD regimes were similar to those observed for SS versus BL contrasts (data not 
shown).
Table 1. Volume, Z-scores and coordinates of peak voxels of local maxima of effects of GAL-
intake (SS > BL) on brain activation patterns related to encoding (ENCOD vs. FIX; Table A.) and 
working memory performance (2BACK > X; Table B.). 
A
N-Vox Z x y z Le/Ri Location
27 4.2 –32 –84 8 L Middle Occipital Gyrus
21 3.7 –36 8 58 L Middle Frontal Gyrus
17 3.7 –44 50 20 L Middle Frontal Gyrus
17 3.9 –40 54 18 L Middle Frontal Gyrus
16 3.7 –24 –30 –4 L Posterior Hippocampus
12 3.9 –44 58 –14 L Middle/Inf. Frontal Gyrus
 9 3.5 2 30 45 R Anterior Cingulate Gyrus
 9 3.3 8 34 42 R Superior Frontal Gyrus
 5 3.3 –64 4 34 L Lingual Gyrus
B
N-Vox Z x y z Le/Ri Location
71 4.1 8 –80 42 R Precuneus
23 4.0 32 44 34 R Middle Frontal Gyrus
 6 3.5 40 50 –16 R Middle Frontal Gyrus
N-Vox: number of voxels in local maximum (voxelsize 2 x 2 x 2mm). Z: Z-score of peak voxel. x, y, z: coordinates 
of peak voxel. Le/Ri: left or right hemisphere.
Significant effects of GAL intake occurred in the left middle occipital cortex, left middle 
frontal gyrus, left posterior hippocampus and right anterior cingulate gyrus (Figure 3). 
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When the threshold for significant brain activation was lowered from Z = 3.1 to Z = 2.3, 
additional activation was observed for SS versus BL regimes in prefrontal structures 
bilaterally, left dorsal cingulate gyrus and left fusiform gyrus.
Peak voxels in the left hippocampus and occipital cortex showed a linear increase 
in activation from BL to SD and SS, as judged by visual inspection (Fig. 3). Areas within 
the left middle frontal cortex showed an increase in activation for SS versus BL regimes 
only.
Figure 2. Axial slices showing effects of medication (SS > BL) on activation patterns 
related to face encoding (A.) and working memory performance (B.). 
Left in the image is left in the brain. Threshold for significant brain activation has been lowered to Z = 2.3 
(uncorrected p) for display purposes. Colour scale extends from Z = 2.3 (orange) to Z = 4.5 (yellow). 
Numbered activation blobs are significant at a Z-threshold of 3.1 (uncorrected p). Mean_struct_MCI = 
average T1-weighted brain of 28 MCI patients. (A) 1. Left middle occipital gyrus. 2. Left middle frontal 
gyrus. 3. Left hippocampus. 4. Right anterior cingulate gyrus. 5. Right middle frontal gyrus. (B) 1. Right 
middle frontal gyrus.; 2. Right precuneus.
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Figure 3. Plots of percentual signal change (from global mean values) for peak voxels of 
various local maxima listed in Table 1.
BL: baseline; SD: single dose; SS: steady state medication regimes. Error-bars show 95% confidence 
intervals of the mean A: ENCOD contrast, left middle occipital gyrus (-32 –84 8). B: ENCOD contrast, left 
middle frontal gyrus (–44 50 20). C: ENCOD contrast, left hippocampus (-24 30 4). D: ENCOD contrast; 
right anterior cingulate gyrus E: 2BACK > X contrast, right middle frontal gyrus (32 44 34). F: 2BACK > 
X contrast, right precuneus (8 –80 42).
N-letter back
Main effects of the N-letter back WM task for 1BACK > X contrast included bilateral 
parietal and prefrontal structures, with a preference for the left hemisphere (Figure 1). 
The 2BACK > X WM condition showed a similar but more extensive pattern of activation 
(Figure 1). Pairwise comparisons of activation maps showed no effect of GAL-intake on 
the 1BACK > X contrast. For 2BACK > X, a significant change in activation patterns 
from baseline was found for SS regimes only (Figure 2). Table 1 lists Z-scores and local 
maxima for these effects. SS versus SD comparisons produced activation changes 
similar to those of SS vs. BL contrasts (data not shown).
Significant effects of GAL intake occurred in the right precuneus and right 
middle frontal gyrus (Figure 3). When the threshold for significant brain activation after 
medication intake was lowered from Z = 3.1 to 2.3, additional activation was observed 
in various structures, including the left and right medial frontal gyri, right visual cortex 
(area V2) and anterior cingulate gyrus.
Peak voxels in the right precuneus and right middle frontal gyrus showed significant 
intensity changes for SS regimes only (2BACK > X; Figure 3). No significant changes in 
percentual signal intensity were found for the X-condition (data not shown).
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Task Performance
Encoding
Mean overall task performance accuracy for male-female discrimination was 0.96 
(± 0.08), with a mean overall reaction time of 1.36s (± 0.38s). No significant effects for 
the factor regime were found on performance accuracy of (p = 0.77). A near significant 
effect was observed of the factor regime on mean reaction time (p = 0.051).
During recognition, mean overall task performance accuracy was 0.45 (± 0.20) 
and mean overall reaction time was 2.27s (± 0.42s). No significant effect of GAL was 
found on recognition accuracy (p = 0.72). No significant effects of regime were found 
on mean reaction time (p = 0.72).
Table 2. Means and standard errors of task accuracy scores and mean reaction times for 
encoding, recognition and N-letter back WM task performance (listed for X, 1BACK and 2BACK 
WM conditions).
Reqim
Baseline Single Steady
Mea Std Mea Std Mea Std
Acc. .96 .10 .97 .06 .97 .07
Rtav 1.41 .38 1.25 .23 1.39 .49
Acc. .37 .16 .49 .20 .48 .23
Rtav  2.28 .42 2.27 .40 2.27 .45
Acc. X .92 .21 .96 .08 .95 .10
Acc. IB .93 .20 .98 .04 .96 .07
Acc. 2B .79 .22 .87 .10 .85 .16
Rtav X .55 .01 .52 .01 .52 .01
Rtav 1B .59 .01 .55 .02 .57 .01
Rtav 2B .71 .02 .68 .02 .71 .02
Means are modified population marginal means (i.e. calculated using the specified linear model). Acc.: 
Accuracy score. RTav: mean reaction time. X: X condition (sustained attention). 1B: 1BACK condition. 2B: 
2BACK condition.
N-letter back
Mean overall task performance accuracy was 0.91 (± 0.16) and mean overall reaction 
time was 0.60s (± 0.15s). Performance accuracy during 2BACK (the highest WM load 
condition) was significantly lower than during 1BACK or X WM load conditions (p < 0.001 
for all regime types), indicating that neural systems were successfully stressed during 
this condition (Table 2). Accuracy scores during X and 1BACK conditions did not differ 
significantly (p > 0.79 for all regime types). After GAL-intake, task accuracy increased 
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(p = 0.004) and latency decreased (p = 0.046) significantly from baseline values. The 
effect on task accuracy was only significant across WM load conditions, but not for each 
WM load condition separately (i.e. X: p = 0.18; 1BACK: p = 0.30; 2BACK: p = 0.053). 
This was also true for task latency (i.e. X: p = 0.20; 1BACK: p = 0.17; 2BACK: p = 0.31). 
No significant effect was found for the interaction regime × WM load on either accuracy 
(p = 0.11) or latency (p = 0.65) scores, indicating that GAL intake did not preferentially 
influence performance accuracy for any particular WM load condition. The increase in 
task accuracy from BL was largest during SS (p < 0.01). The maximum effect on task 
latency occurred after SD intake (p = 0.042).
Discussion
The functional status of the cholinergic system is thought to contribute significantly to 
symptoms in AD (Bartus, 2000; Mesulam, 2004). In advanced Alzheimer’s Disease, 
low levels of cholinergic markers have been found post-mortem (DeKosky et al., 2002). 
The anticholinergic agent scopolamine may induce acute symptoms of moderately-
severe amnesia in healthy controls, making pharmacologically induced memory-loss a 
successful model to study the cholinergic contribution to AD symptomatology (Assal 
& Cummings, 2002). Additionally, cholinergic system dysfunction in AD patients has 
been linked to a decrease in verbal fluency and neuropsychiatric symptoms such as 
mood disorders, psychotic states, and a lack of concentration and mental agility (Assal 
& Cummings, 2002). Restoring acetylcholine levels pharmacologically may significantly 
benefit AD patients (Lanctot et al., 2003; Trinh et al., 2003). Studies examining 
cholinergic system (re)activity in early AD may therefore be of clinical value. This study 
demonstrates the feasibility of using fMRI to detect cholinergic system reactivity in 
elderly patients with MCI.
It is not exactly known how the cholinergic system is able to regulate neural activity. 
Cholinergic stimulation may improve neural information processing by increasing the 
signal-to-noise ratio of neural networks, while cholinergic inhibition has the opposite 
effect (Mesulam, 1996; Little et al., 1998; Rezvani & Levin, 2001). This mechanism 
is however not disease-specific, i.e. when given to healthy controls, cholinomimetic 
drugs may improve attention and memory performance as well (which is why they are 
sometimes referred to as ‘smart-drugs’ (Rose, 2002)). From the small number of studies 
that investigated the anatomy of the human cholinergic system, it is known to originate 
within various nuclei of the basal forebrain, particularly Ch2 and Ch4, from which 
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acetylcholine is transported by discrete bilateral bundles of afferents and distributed 
diffusely across the hippocampal area and entire neocortex respectively (Geula, 1998; 
Selden et al., 1998). The cholinergic system plays an important role in modulating 
brain activity in networks associated with a variety of neural functions, particularly 
arousal, attention and working memory performance (Clarke, 1995; Levin & Simon, 
1998; Rezvani & Levin, 2001). A study by Furey et al. showed that the administration of 
the cholinesterase inhibitor physiostigmine to healthy controls increased activation in 
the (ventral) occipital cortex and reduced prefrontal activation load during spatial WM 
performance, suggesting that cholinergic stimulation increased the efficiency of visual 
perceptive processing and (hence) decreased effortful processing in prefrontal areas 
(Furey et al., 2000). Several other neuroimaging studies have investigated the effects 
of cholinomimetic and anticholinergic substances on brain function in healthy controls 
(Ernst et al., 2001; Kumari et al., 2003; Lawrence et al., 2002; Parry et al., 2003; Sperling 
et al., 2002) and AD patients (Rombouts et al., 2000). These were the first fMRI studies 
to demonstrate alterations in brain activation patterns during memory task performance 
after cholinergic modulation. Cholinergic stimulation increased activation mainly in 
fusiform areas during episodic memory performance (face encoding) (Rombouts et 
al., 2002), while cholinergic inhibition reduced activity in fusiform, hippocampal and 
prefrontal areas (Sperling et al., 2002). Effects of cholinergic enhancement on WM 
related brain activation included (left) prefrontal, cingulate, parietal and occipital regions 
(Ernst et al., 2001; Due et al., 2002; Kumari et al., 2003; Parry et al., 2003; Furey et 
al., 2000; Lawrence et al., 2002). The various study populations generally showed an 
improvement in task performance measures after cholinergic stimulation.
In this study, GAL challenge resulted in a significant signal increase for SS, but not 
SD, versus BL regimes in MCI patients. Pairwise comparisons of SS and SD regimes 
showed similar activation patterns as those for SS vs. BL comparisons, again indicating 
that activation during SD was minimal (Figure 1). This does not mean that SD application 
of GAL had no effect on brain activation. Some regions showed a gradual increase from 
BL for SD and SS regimes (Figure 3). With plasma levels of GAL considered near equal 
for both regimes at the time of scanning (see Materials & Methods), such a difference 
in magnitude of response may be due to the effects of exposure-time to GAL. A longer 
period of exposure may have provided more time for synaptic rearrangement of task-
related networks resulting in more activation when these networks were stimulated (Fujii 
et al., 1999). Since however SD related changes in brain activation were non-significant, 
we will focus on SS versus BL effects only.
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Overall, the observed changes in brain activation after GAL challenge were small in 
number, extent and intensity, even though we scanned a relatively large sample of 
patients (n = 28). This may be due to the fact that scans of elderly patients may show 
greater anatomical and haemodynamic variability than healthy age-matched controls and 
contain more movement artifacts, which may hamper signal detection (D’Esposito et al., 
2003). Also, activation levels may be decreased in MCI patients (Machulda et al., 2003). 
Despite such constraints, increased activation was observed in areas within the left 
prefrontal cortex, left hippocampus and left medial occipital gyrus during performance 
on an episodic memory task (face encoding). When the threshold for significant brain 
activation was lowered (Z = 2.3), effects were found in prefrontal structures bilaterally, 
the (anterior) cingulate gyrus and visual cortex. These structures together have been 
proposed to form a (face) encoding network (Druzgal & D’Esposito, 2001) and previous 
studies have shown that cholinergic modulation may influence this network (Rombouts 
et al., 2002; Sperling et al., 2001). Neuropsychological interpretation of the observed 
effects is difficult, since activation observed during the ENCOD condition was somewhat 
aspecific to episodic memory (additional activation was produced, e.g. visual and 
possibly working memory-related activation). By choosing a very low-level baseline (i.e. 
fixation cross), we aimed to increase contrast (to raise chances of finding significant 
activation changes after GAL treatment), but at the cost of some neuropsychological 
specificity. Medio-temporal and especially hippocampal activation, however, are 
considered specific to episodic memory (Schacter & Wagner, 1999), indicating that 
the observed change in hippocampal activation after GAL challenge may well have 
involved episodic memory performance. This is in line with previous reports saying that 
GAL may influence episodic memory (Raskind, 2003). Task performance measures 
in this study however did not corroborate this finding. Neither attentional measures 
during encoding, nor recognition scores after encoding showed significant changes 
after GAL intake. This may reflect low statistical power for this type of analysis (i.e. small 
sample size and a ceiling effect during male-female discrimination). Alternatively, there 
may be no relation between enhanced activity in the (posterior) hippocampal area and 
increased episodic memory performance. The hippocampal area, however, is among 
the first to show neuropathological changes in Alzheimer’s Disease (Braak et al., 1999) 
and may have decreased activation levels in early AD (Rombouts et al., 2000). The 
observed hippocampal reactivity to cholinergic stimulation may therefore bear some 
clinical relevance.
Effects of GAL-intake on activation patterns during performance on the lower WM 
load condition (1BACK > X) were not significant. Main effects for this task condition 
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involved effect sizes of smaller magnitude than those observed during increased WM 
load performance (2BACK > X), indicating that the lower WM load condition required 
less neural processing. A possible effect of GAL intake on tissue excitability might 
therefore not have become explicit. The 2BACK > X contrast did show an increase after 
GAL treatment (SS) in some areas. Effects mainly included the right precuneus and left 
middle frontal gyrus. Again, this only partly represented areas known to increase their 
activation levels in healthy controls after cholinergic stimulation. When the threshold 
for significant brain activation was lowered, additional effects were found in the middle 
frontal gyrus bilaterally, visual cortex, caudate nucleus and left temporal lobe. Similar 
areas have been reported in healthy controls after nicotine intake, possibly representing 
a cholinergic effect on visual attention (Lawrence et al., 2002). Plots representing 
percentual signal change showed that GAL intake did not significantly alter activation 
levels during the X condition in areas where an increase in the 2BACK > X contrast 
was found. Hence, the enhancement of the 2BACK > X contrast in these areas involved 
a true increase in activation during the 2BACK condition (Figure 3). Task performance 
data showed a highly significant effect of GAL-treatment on task accuracy scores 
(p = 0.004), and a significant decrease in reaction times (p = 0.046), indicating a 
clear effect of GAL intake on neural function associated with this task. This effect 
however was not more pronounced for any of the three WM conditions, suggesting 
that GAL intake consitituted a non-specific effect on (sustained) attentional systems. 
This conclusion is supported by the literature on the functions of the cholinergic system 
(Levin & Simon, 1998; Rezvani & Levin, 2001). Although no effect of GAL intake was 
found on activation levels during the X condition, this does not preclude a role of GAL 
in the enhancement of attentional processing. Rather, performance scores during the X 
condition may not optimally reflect attentional processing and 2BACK > X might be a 
more suitable measure.
The current study used two rather unrelated paradigms, which have independently 
shown reproducible alterations in brain activation in AD as compared to controls (Braver 
et al., 1997; Small et al., 1999). This was done to raise chances of finding significant 
effects of medication intake, but prevented useful comparisons between activation 
levels during encoding and working memory performance (and no randomisation was 
done of the order in which both tasks were administered). Future studies however may 
require to use paradigms that allow tighter comparisons between episodic memory and 
working memory performance.
This study was not placebo-controlled. We should therefore be cautious to 
conclude that the observed changes were due to the effects of GAL alone. Placebo-
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effects however, if present, should probably have occurred in comparable magnitude 
after acute as well as chronic dosage, and the absence of effects after acute dosage 
(but the presence of effects after chronic dosage), suggests that possible placebo 
effects remained sub-threshold. The (highly) significant effect on attentional and WM 
task performance scores when compared to face recognition, further makes it unlikely 
that the findings in this study were solely due to a placebo effect. Effects of task version 
and especially scan order, which were accounted for in this study, may prove significant 
confounders in any study examining pharmacological effects on brain activation. With 
these effects removed, the residual signal changes may be considered more true 
representations of an effect of medication intake.
In conclusion, this study has listed several brain areas in MCI patients that 
show increased activation after GAL challenge. This seems to confirm the feasibility 
of using fMRI to study cholinergic system reactivity in elderly patients with a possible 
cholinergic deficit. Longitudinal studies should determine whether a differential 
response to cholinergic stimulation exists in MCI patients that show further decline 
in mental functions versus patients with more stable functions. Such a differential 
response may point to a role of the cholinergic system in compensating for small 
incipient neurofunctional defects. Furthermore, the spectrum of symptoms and signs 
of MCI patients can be correlated with cholinergic system reactivity, and vice versa. 
This may allow us to determine the relative contribution of the cholinergic system to 
signs and symptoms in early AD. Such knowledge may help to predict clinical decline in 
patients exhibiting such characteristics, and to target these symptoms more selectively 
with specific pharmacological agents.
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Abstract
Most functional magnetic resonance imaging (fMRI) studies examine blood oxygenation 
level dependent (BOLD) signal changes using a single default model of the BOLD 
response to task stimuli. Such studies are therefore biased with respect to signal 
variance explained by that single regressor. The current study examine signal variance 
across a wider range of timepoints, to provide a more complete account of signal 
changes as a result of pharmacological intervention. AD patients (n = 18; age 74.5 
years ± 8.2; MMSE 22.5 ± 2.4) were scanned during performance on a face encoding 
and n-letter back working memory task. Brain function during task performance was 
examined under three different pharmacological conditions: at baseline (no treatment), 
and after acute (single dose) and prolonged exposure (5 days) to galantamine (a 
cholinesterase inhibitor). Significant effects of galantamine intake occurred during face 
encoding only, and after acute galantamine exposure only. When considering signal 
changes using the default model of the BOLD response, acute galantamine challenge 
increased cortical responses when compared to baseline in cingulate areas (Z = 4.4) 
and visual cortex (Z = 3.8). When considering a model based on a smaller-than-default 
delay (5s) of the BOLD response, additional treatment effects (increases in signal 
amplitude) were found in the visual cortex (Z = 3.8). Reconstruction of the average 
BOLD response to task stimuli showed an increase in BOLD signal intensity and a 
decrease in response latency in areas of significant treatment effects. In conclusion, 
accounting for the temporal characteristics of the BOLD response may help to explain 
residual signal variance caused by pharmacological intervention (cholinergic challenge) 
in elderly AD patients, which would otherwise be ignored by standard analyses of such 
effects. Cholinergic challenge increases and quickens the cortical response to task 
stimuli in the visual cortex in AD patients. Such effects may serve as candidate clinical 
markers in studies examining the functional status of the cholinergic system in disease.
Keywords: fMRI; AD; memory; galantamine; challenge study.
115
4.2 Effects of galantamine challenge on brain function in AD patients
Introduction
Most functional magnetic resonance imaging (fMRI) studies use a single default 
hemodynamic response function (HRF) to model blood oxygenation level dependent 
(BOLD) signal response to task stimuli. Since this default model of the hemodynamic 
response has a fixed onset time and latency to peak intensity (usually ~6s), the results 
of such studies are biased with respect to signal variance explained by this single 
default model. By modeling signal changes across a range of different timepoints after 
stimulus onset, it is possible to study residual variance in the data that is otherwise 
not accounted for by standard analyses of signal changes. Studies of the temporal 
characteristics of the BOLD response to task stimuli therefore allow for a more realistic 
view on the neurovacular events that contribute to BOLD signal reactivity. Using 
similar approaches, previous fMRI studies have found differences in BOLD response 
shape and latency between brain regions (Huettel & McCarthy, 2001), task conditions 
(Henson et al., 2002; Kollias et al., 2000) and with aging and disease (D’Esposito et 
al., 2003; Richter & Richter, 2003; Rombouts et al., 2005b). Although their origins 
remain unknown, BOLD signal latency shifts are likely to reflect changes in neural and/
or vascular response latencies under a range of different conditions.
In a previous study, we showed that the BOLD response to task stimuli in 
patients with mild Alzheimer’s disease (AD) is delayed rather than decreased in visual 
cortex, when compared to healthy controls and patients with mild memory complaints 
(Rombouts et al., 2005b). Thus, brain function in AD patients may show disease-
specific changes that may escape detection in standard fMRI analyses. The origin the 
observed BOLD latency shifts changes remains unclear, but may reflect pathological 
changes in vascular reactivity and neurovascular coupling, as well as strictly neurogenic 
effects such as altered (cholinergic) neurotransmission in AD patients, when compared 
to healthy controls (Rombouts et al., 2005b). Such functional changes may serve as 
clinical markers that can be tested for their early diagnostic value, or predictive value 
with respect to disease outcome and response to (cholinergic) treatment. 
The current study used a similar approach to examine the effects of cholinergic 
stimulation in AD patients. In AD, impaired cholinergic neurotransmission is thought 
to contribute significantly to disease symptomatology (Assal & Cummings, 2002; 
Bartus, 2000; Mesulam, 2004). Current therapies against AD largely aim at restoring 
low acetylcholine levels with pharmacological agents (Lanctot et al., 2003; Trinh et al., 
2003). By challenging the cholinergic system in AD patients pharmacologically with 
a cholinergic agent, it may be possible obtain markers of cholinergic system viability 
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that can be tested for their clinical value (Goekoop et al., 2004). In a previous study, 
we showed that even a brief cholinergic challenge with the cholinesterase inhibitor 
galantamine may produce region-, process-, and disease-specific effects on BOLD 
signal reactivity (Goekoop et al., 2005c). By examining the effects of galantamine 
challenge on brain function across a range of different timepoints, it may be possible to 
obtain a more complete view of such effects. This may facilitate research into treatment 
mechanisms, and the predictive value of the observed effects with respect to disease 
outcome and response to cholinergic therapy in AD patients (Goekoop et al., 2004; 
Goekoop et al., 2005c).
Cholinergic treatment is thought to enhance delayed memory performance by 
increasing cortical arousal and attention (Sarter et al., 2003). Cholinergic stimulation 
may improve accuracy scores on delayed memory tasks, and may decrease response 
latency (reaction times) on tasks that require motor responses to task stimuli (Sarter 
et al., 2005). In healthy controls, fMRI studies of cholinergic enhancement have mostly 
shown increases in signal intensity using default models of the BOLD response to 
task stimuli (Goekoop et al., 2004; Saykin et al., 2004; Thiel, 2003). In some studies, 
decreases in signal intensity occurred alongside increases, which were suggested 
to reflect a reduced need of effortful processing as a result of increased automatic 
processing of visual stimuli (Furey et al., 2000), or a reduction in expectation-driven 
(top-down) selective biasing of visual cortex activity (Bentley et al., 2004). So far, only 
two fMRI studies reported effects of cholinergic enhancement in AD patients (Rombouts 
et al., 2002; Goekoop et al., 2005c). These studies showed increases in BOLD signal 
intensity as a result of cholinergic stimulation. To our knowledge, however, no fMRI 
studies have been published that examined the effects of cholinergic stimulation on the 
temporal characteristics of the BOLD response. EEG studies of event-related potentials 
(ERPs) in AD patients have shown that cholinergic enhancement may decrease rather 
than increase response latencies to task stimuli in patients with AD (Werber et al., 
2003; Thomas et al., 2001). We therefore hypothesized that cholinergic challenge 
would increase the amplitude and decrease the latency of the BOLD response to task 
stimuli in the current study.
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Methods 
Study Design
Patients were screened for participation in a randomized study design with patients 
serving as their own controls. As a cholinergic stimulant, we chose galantamine, which 
is a ‘dual mode’ cholinesterase inhibitor with an additional modulatory effect on nicotinic 
receptors that has known therapeutic efficacy and relatively few side effects in AD 
patients (Raskind, 2003). fMRI was performed at baseline (baseline, no medication), 
after oral intake of a single dose of galantamine with water (acute), and after prolonged 
exposure to galantamine (prolonged). Baseline, acute and prolonged regimes were 
randomized across scanning sessions to prevent between-session (e.g. learning) effects 
from interfering with possible effects of medication. Thus, three scanning sessions were 
performed in each patient, with each session corresponding to a different medication 
regime. Scanning sessions for different regimes were exactly one week apart and 
occurred at the same hour of day in each patient. Acute intake involved oral ingestion 
of 8mg galantamine with water. Prolonged exposure involved a 120 hour period (5 
days) of galantamine intake, spread over 6 weekdays, during which period steady state 
plasma levels were reached. On the evening of day 1, a first dose of galantamine was 
given (day 1: 4 mg, oral ingestion of tablet), after which followed 4 consecutive days of 
galantamine intake (day 2-5: 2 x 4 mg of galatamine each day, mornings and evenings; 
4 consecutive days, oral ingestion), and a final dose of galantamine on the morning of 
day 6 (day 6: 4 mg, oral ingestion of tablet). At this rate, steady state plasma levels 
are reached within 2–3 days in healthy controls (with minimum serum galantamine 
concentrations 10.6 ± 4.0 ng/ml and maximum levels 30.7 ± 6.2 ng/ml (Mannens et al., 
2002; Zhao et al., 2002)). To avoid carry-over effects between the regimes, periods of 
acute and prolonged intake were separated by a washout period of at least two days 
of zero galantamine intake, which is more than 6 times the half-life of galantamine (7.4 
hours) (Mannens et al., 2002; Zhao et al., 2002). Scanning sessions were performed 
3 hours after acute (1 x 8mg) and 9 hours after prolonged (2dd 4mg; 5days) exposure. 
Dosage and timing of sessions was such that galantamine plasma levels after acute 
and prolonged exposure could be considered equal on average at the time of scanning, 
which enabled comparisons between treatment effects produced by different exposure 
durations.
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Subject recruitment
The study had the approval of the review board of the committee of medical ethics of the 
VU University Medical Center in Amsterdam, the Netherlands. Twenty elderly AD patients, 
aged 55 to 83 years (mean 74.5; ± 8.2), were recruited from the memory outpatient 
clinic (Alzheimer Center) of the department of neurology. In a previous fMRI study, 
data from the same AD patients was used to examine effects of galantamine challenge 
on brain function during delayed retrieval of information (Goekoop et al., 2005c). 
The current study examined data from these patients to study effects of galantamine 
challenge on brain function during encoding and working memory performance. AD 
patients were diagnosed using NINCDS-ADRDA criteria for AD (McKhann et al., 1984). 
All patients provided informed consent under supervision of a lawful caretaker during 
a screening visit in which the procedure was explained and contraindications were 
checked. Apart from neuropsychological assessment during clinical investigation, AD 
patients underwent additional MMSE (Folstein et al., 1975a), CDR (Morris, 1997) and 
NYU-paragraph recall tests, which were used for cognitive profiling. Inclusion criteria 
were an MMSE of 19 or higher and CDR score of 1.0 or higher. Formal education was 
determined on a discrete scale with three levels (1 = low, 2 = middle, 3 = high). Patients 
were excluded if they had any significant medical, neurological or psychiatric illness 
(other than MCI or AD), or if they were taking medication or other substances that 
are known to influence cerebral function, including antidepressants and cholinesterase 
inhibitors. Patients were excluded if their history showed excessive nicotine or alcohol 
intake (> 0.5 packs of cigarettes, > 4 glasses of an alcoholic substance a day), a 
severe allergy to pharmacological substances or their constitutive compounds, or the 
use of any experimental medication within three months prior to enrollment in the trial. 
Exclusion criteria to MRI involved the presence of a pacemaker, metallic implants in high-
risk areas (i.e. vessel clips) and a history of claustrophobia. Subjects were excluded if 
their structural scan showed signs of overt structural pathology (e.g. high quantities of 
age-related white matter hyperintensities, lacunar infarctions, and cortical atrophy), as 
determined by an experienced neuroradiologist (FB).
Functional MRI (fMRI)
Imaging was carried out on a Siemens Magnetom Sonata 1.5 T scanner (Siemens, 
Erlangen, Germany), using a standard circularly polarized head coil with foam padding 
to restrict head motion. For fMRI, an echo planar imaging sequence was used (echo 
time 60ms, flip angle 90°, matrix 64 × 64, field of view 192 × 192 mm), to obtain 21 
transverse slices (thickness 5 mm, interslice-gap 1 mm). Task stimuli were projected 
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on a screen located at the head end of the scanner table via an LCD projector located 
outside the scanner room. Patients viewed the screen through a mirror located on the 
head coil. If necessary, visual acuity was corrected using MRI-compatible plastic glasses. 
In each hand, patients held an fMRI compatible response-box through which they were 
able to react to task stimuli by pressing the left or right button using their index-fingers. 
A T1-weighted structural MRI-scan was obtained of each subject (MPRAGE; inversion 
time: 300 ms, TR = 15 ms; TE = 7 ms; flip angle = 8°; 160 coronal slices, 1 × 1 × 1.5 
mm voxels).
Face encoding task
A face encoding task was used to examine episodic memory for visuospatial information 
(Small et al., 1999). This task consisted of a simple block-design with two alternating 
conditions: condition 1 (‘ENCOD’) consisting of 4 blocks of 42s each, and condition 2 
(‘FIX’), consisting of 4 blocks of 44s each. Each ENCOD block contained 6 unfamiliar and 
emotionally neutral faces presented sequentially in random order on a black background 
(presentation time 6s, followed by a 1s delay). Male and female faces were balanced 
across the blocks. In each ‘FIX’ block, a white fixation cross (X) was presented on a 
black background. The entire task thus consisted of 8 alternating blocks of ENCOD and 
FIX conditions and was preceded by a 21s FIX condition. Prior to scanning, subjects 
were instructed verbally to remember the faces for future testing and to classify each 
face according to its gender by pressing one of two buttons (written instructions “Left: 
male”, “Right: female” also appearing alongside the pictures). Total task duration was 
6 minutes and 12 seconds. Immediately following encoding, encoding success was 
assessed using a recognition task, while subjects were still in the scanner. 24 faces, 
of which 12 had been shown during encoding and 12 were new, were presented 
sequentially in random order on a black background (presentation time 5s for each face, 
followed by a white fixation-cross presented for 3s on a black background). Subjects 
were instructed to indicate whether a presented face had been shown previously by 
pressing one of two buttons (written instructions “Seen previously?”; “<= Yes ” and 
“=> No” appearing alongside the pictures). Total task duration was 3 minutes and 40 
seconds.
Working memory task 
This task consisted of a block design with three conditions lasting 40s each. 
Each condition involved 4 occurrences of a single, pre-specified target (a letter 
or letter-combination) in a string of 20 letters that were presented sequentially in a 
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pseudorandomized fashion on a black background (presentation-time: 1s, followed by a 
1s delay). During condition 1, the target was the occurrence of the letter X (‘X’, testing 
sustained attention). During condition 2, subjects were instructed to respond to any 
occurrence of two identical letters in a row (‘1-BACK’, testing low working memory 
load). Condition 3 involved events where two identical letters were separated by a 
single other (randomly chosen) letter (‘2-BACK’, testing increased working memory 
load). Each condition was preceded by a written instruction (‘INSTR’) indicating the 
target, with a duration of 10s. Subjects were asked to press a single button using their 
right index finger whenever the target appeared. Each condition was presented three 
times (9 blocks) in a pseudorandomized fashion. A percentage of ‘hits’ and ‘misses’ 
was recorded for each subject. Task performance measures were calculated separately 
for X, 1-BACK and 2-BACK conditions (see above). Total task duration was 7’41’’ 
minutes.
Three different but comparable versions of each paradigm were constructed and 
randomized across the scanning-sessions (baseline, acute and prolonged regimes). All 
paradigms were practised extensively using dummy tasks to make sure that patients 
mastered the general procedure of task performance before scanning: one day before 
the start of the first session, a home visit was scheduled during which all memory 
tasks were practiced on a laptop computer. Five minutes before the onset of the first 
measurements, the face encoding paradigm was practiced while patients were in the 
scanner. During the first 10.5s of each task, patients saw a circle indicating time left 
before the onset of the first condition. Total time for one scanning session including 
instructions of memory tasks was approximately one hour.
Statistical analysis of task performance data
For each patient, performance accuracy scores and mean reaction times were calculated 
separately for performance under each exposure duration (i.e. baseline, acute, 
prolonged). Gender discrimination and recognition accuracy scores were calculated 
by subtracting false answers from correct answers and dividing the result by the total 
number of items (24). Performance scores thus varied from –1 (100% incorrect) to 1 
(100% correct), with 0 indicating chance level (50% correct, 50% incorrect). Accuracy 
scores for n-letter back performance were calculated that varied between 0 (0% correct) 
and 1 (100% correct). Mean reaction times were recorded for all tasks and response 
types separately. A univariate analysis of variance (ANOVA) was performed using SPSS 
9.0, in which measures of task performance were entered as dependent variables in an 
analysis of the medication effect, with ‘subject number’ as a random factor (to account 
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for the effect of taking repeated measures from the same subject), medication ‘regime’ 
(3 levels: baseline, acute, prolonged) and ‘test version’ (3 levels: 1, 2, 3) as fixed factors 
(to account for within-subject effects attributable to these factors) and ‘scan order’ (3 
levels: 1, 2, 3) and ‘working memory load’ (if applicable; 3 levels: 0, 1, 2) as covariates. 
If a significant effect of a covariate was found, the model was adjusted to contain the 
relevant covariate as a fixed factor in a subsequent analysis of the medication effect (i.e. 
effects of factor ‘regime’).
Analysis of functional neuroimaging data
Functional datasets were analyzed using FSL (FMRIB’s Software Library, www.fmrib.
ox.ac.uk/fsl). The first five volumes of each dataset were discarded to account for T1-
saturation effects. At first level (individuals), the following preprocessing was applied: 
non-brain removal, slice-timing correction using Fourier-space time-series phase-
shifting, motion correction and spatial smoothing using a Gaussian kernel of FWHM 
6mm, mean-based intensity normalization of all volumes by the same factor and high 
and low pass temporal filtering (Jenkinson et al., 2002; Smith, 2002). Registration of 
functional neuroimages to anatomic and standard images was carried out using an 
intermodal registration tool based on the correlation ratio (Jenkinson & Smith, 2001). After 
preprocessing, signal change during task performance was analyzed in an event-related 
fashion for encoding tasks, and in a blockwise manner for working memory tasks. For 
face encoding tasks, signal change was modeled by box cars that had the same duration 
and alternation frequency as the individual task stimuli (faces). For n-letter back working 
memory tasks, signal change was modeled as box cars that had the same duration and 
alternation frequency as the corresponding task conditions. The resulting vectors were 
convolved with a gamma function (a default hemodynamic response function (HRF)) to 
model the hemodynamic response, and the result served as a regressor in a general 
linear model analysis to detect significant effects task performance at subject level. The 
FIX condition of the encoding task and the INSTR conditions of the n-letter back task 
were not modeled (i.e. were implicit baseline conditions), to prevent overspecification 
of the model.
In order to examine changes in the shape or latency of the BOLD response after 
cholinergic challenge, we used an analysis technique that has been described earlier 
(Rombouts et al., 2005b). Apart from a default HRF-based model assuming a maximum 
BOLD reponse amplitude at 6 sec after stimulus onset, we included 6 additional temporal 
variants of the default HRF. Each of these additional HRFs assumed a different delay 
of the BOLD response (i.e. MA reached after 5s, 4s, 3s, 2s, 1s, and 0s respectively). 
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Box cars representing task conditions were separately convolved with each of these 
additional HRFs. The resulting regressors were orthogonalized with respect to both 
the first (default) regressor (HRF with MA = 6s) and each of the other regressors, to 
make sure that all seven regressors modeled different aspects of the same data. The 
combination of these regressors modeled the whole of signal variability within a time 
interval between 0 and 6s (positive correlations) and 6 and ~10s (negative correlations) 
from stimulus onset. This method is analogous to an analysis of the temporal derivative, 
but allows visualization of activation changes across a broader range of timepoints.
For each regressor, voxelwise model-fitting with local autocorrelation correction 
(Woolrich et al., 2001) generated 3D images representing average intensity changes 
corresponding to that regressor, as well as corresponding variance images. Thus, for 
face encoding data, seven ENCOD > FIX contrast images was calculated for each 
subject, each corresponding to a different timepoint after stimulus onset. For n-back 
data, activation during X (X), 1-back (1BACK) and 2-back (2BACK) conditions was 
examined at seven different timepoints, along with two contrasts comparing activation 
levels between working memory conditions (i.e. 2BACK > X and 1BACK > X). These 
contrasts were calculated for all runs and sessions of each patient, yielding activation 
images for all patients, task conditions, onset times and exposure durations (baseline, 
acute, prolonged). These images were subsequently carried up to group level, for 
examination of main effects of task performance, and analysis of treatment effects.
Main effects during task performance were calculated by averaging individual 
contrast maps for a particular regressor (MAs 0s – 7s) and treatment condition 
(i.e. baseline, acute, prolonged) in a mixed effects group level analysis with clusters 
determined by Z > 2.3 and a (corrected) cluster significance threshold of P = 0.05 
(Woolrich et al., 2004; Forman et al., 1995; Friston et al., 1994; Worsley et al., 1992). 
To calculate treatment effects, a group level mixed effects repeated measures model 
was used, which examined individual contrast maps for effects of treatment, scanning 
order, test version, and repeated measurements from single subjects (Woolrich et al., 
2004). Analysis was limited to areas showing significant activation changes during task 
performance only (i.e. areas defined by main effects, see above). Treatment effects 
were examined at a voxel threshold for significant brain activation determined by Z > 3.1 
(corresponding to p = 0.001). An F-test was used to detect any effect of cholinergic 
challenge (either acute or prolonged). If present, specific contributions of acute and 
prolonged exposure to this effect were analyzed using pairwise comparisons (T-tests).
Based on group level data, the average BOLD response to task stimuli (face 
encoding) or task conditions (n-letter back) could be reconstructed. For each of the 
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seven regressors modelling signal changes at different post-stimulus onset times at 
single subject level, the amount of signal change explained by that regressor at group 
level (the parameter estimate ‘beta’), was sampled in peak voxels of local maxima of 
significant effects of treatment, yielding a beta for each regressor. Each regressor was 
then multiplied by its corresponding beta, and all multiplied regressors were summed, 
to obtain a reconstruction of the actual BOLD response after stimulus onset. This was 
done for all exposure durations separately (baseline, acute and prolonged exposure), 
allowing visualization of changes in the shape and latency of the BOLD response to task 
stimuli or -conditions under all treatment conditions.
Results
Demographics and results of cognitive profiling
Mean age of the 18 AD patients (11 male, 7 female) was 74.5 (± 8.2) years. Education-
level was low in 7 patients, intermediate in 10 patients and high in one patient. One 
patient was left-handed. Mean MMSE score was 22.5 (± 2.4) and mean NYU paragraph 
recall score was 2.3 (± 1.3) on immediate recall and 0.0 (± 1.0) on delayed recall. Mean 
overall CDR score was 1.6 (± 0.5). These results are representative of mild AD.
Patient compliance and discontinuation
Data-acquisition was complete in 18 out of 20 patients without the need for additional 
scanning sessions. One patient was claustrophobic and another patient withdrew 
consent in the initial stages of the study. Thus, data of 18 patients were available for 
analysis. Patient compliance was good, as judged by pill-counts and the caretaker’s 
comments. Non-compliance occurred in 4 patients. In all but one case, non-compliance 
involved the intake of more galantamine than specified. Since these errors occurred in 
early stages of prolonged regimes only (i.e. day 1–2), an adequate build-up of plasma 
levels was considered to have occurred. Non-compliance was therefore judged not to 
have interfered significantly with plasma levels at the time of scanning. Side effects 
(nausa) occurred in 3 patients after acute intake of galantamine, but did not interfere 
with study participation. One patient did not respond to task-stimuli in a single session 
and this session was discarded. Thus, data of 18 patients (17 complete datasets, 1 
incomplete dataset containing two sessions) was used for the analysis.
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Figure 1. Axial slices showing main effects for face encoding observed using models based 
on the default HRF (MA = 6s), and residual variance explained by additional models based on 
HRFs examining signal changes at earlier timepoints after stimulus onset. 
Effects are rendered on a mean anatomical brain volume of all subjects (Mean_anat_AD). Left in the image 
is left in the brain. Effects are cluster corrected using Z = 2.3 and p < 0.05. Colour scale extends from 
Z = 2.3 (red) to Z = 9.5 (yellow). BL: effects at baseline (no galantamine intake); SD: Effects after acute 
(single dose) intake of galantamine. SS: Effects after prolonged galantamine exposure (5 days, steady 
state plasma levels). (A) Signal variance during task performance explained by default HRF (MA = 6s), 
(B-F) Residual variance explained by regressors based on HRFs with MA = 5–1s, respectively. The final 
regressor (HRF with MA = 0s) did not explain additional variance.
125
4.2 Effects of galantamine challenge on brain function in AD patients
Figure 2. Axial slices showing effects of galantamine challenge on activation patterns during 
face encoding (acute intake > baseline). 
Figure 2. Axial slices showing effects of galantamine challenge on activation patterns during 
face encoding (acute intake > baseline). 
Left in the image is left in the brain. All effects are significant at Z = 3.1. Threshold lowered to Z = 2.3 
(significant areas only) for display purposes. Colour scale extends from Z = 2.3 (orange, dark blue) to Z 
= 4.5 (yellow, light blue). Mean_anat_AD = average T1-weighted brain of 18 AD patients. Red: effects of 
galantamine challenge as captured by a model involving a default hemodynamic response function (HRF) 
with maximum amplitude (MA) at 6s. Activated areas indicate increased signal intensity at default onset 
time compared with baseline. Blue: Residual effects of galantamine challenge as captured by a model 
based on an HRF with MA at 5s (earlier onset time). Activated areas indicate increased signal intensity at 
earlier onset time compared with baseline (and hence a faster response). Arrows point to relevant local 
maxima (Table 1). Coordinates are given at the top of each plot. Plots represent reconstructed average 
BOLD response after stimulus onset, with signal intensity along the vertical axis and time from stimulus 
onset in seconds along the horizontal axis. See text for further details.
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Task Performance: face encoding
Mean task performance accuracy for male-female discrimination was 0.95 (±0.009), 
with mean reaction times of 1.28s (± 0.045s) (Table 2). No significant effects of 
galantamine intake were found on performance accuracy (p = 0.64) or latency (p =  0.81). 
During recognition, mean task performance accuracy was 0.22 (± 0.035) with mean 
reaction times 2.10s (± 0.071). No significant effect of galantamine intake was found 
on recognition latency scores (p = 0.59), but a trend existed for an improvement in 
recognition accuracy scores (p = 0.082), which gradually increased from baseline to 
acute and prolonged exposure.
Task performance: N-letter back
Responses to task stimuli on average were well above chance levels. Mean overall task 
performance accuracy was 0.80 (± 0.25), with a mean overall reaction time of 0.63s 
(± 0.17s) (Table 2). Grouped by working memory load condition, task performance 
accuracy was 0.96 (± 0.04; X), 0.91 (± 0.04; 1BACK) and 0.58 (± 0.04; 2BACK), 
with mean overall reaction time 0.51s (± 0.02s; X), 0.58s (± 0.02s; 1BACK) and 0.76s 
(± 0.02s; 2BACK) respectively. No significant effect of galantamine intake was found 
on task performance accuracy (p = 0.57) or latency scores (p = 0.64).
fMRI analyses: face encoding
At default onset times (MA = 6s), main effects of face encoding involved ventral and 
dorsal occipital (visual) areas, bilateral parietal and prefrontal areas, and the anterior 
cingulate gyri. Extensive bilateral activation of thalamic structures also occurred. 
Additional activation was found in the left and right posterior parahippocampal areas and 
the left posterior hippocampus (Figure 1). This pattern of effects reflects brain function 
during episodic memory performance, and has been widely reported in international 
literature (e.g. (Rugg et al., 2002)). The remaining regressors modelling signal changes 
at deviating onset times explained residual variance in brain function, the amount of 
which grew smaller at shorter onset times (Figure 1).
Overall, significant changes in brain function versus baseline were observed after 
acute, but not prolonged intake of galantamine. Acute versus prolonged comparisons 
produced treatment effects that were highly similar to those observed for acute versus 
baseline comparisons (data not shown), indicating that changes after prolonged treatment 
were minimal. At default onset times (MA = 6s), galantamine challenge increased BOLD 
signal intensity in cingulate, lingual and prefrontal areas when compared to baseline 
(Z > 3.1; Figure 2, Table 1). Additional variance in treatment effects was explained by 
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the regressor involving a HRF with MA = 5s: acute galantamine challenge increased 
BOLD signal intensity in the primary visual cortex (V1) (Z > 3.1; Figure 2, Table 1). None 
of the remaining regressors involving HRFs with earlier onset times explained additional 
variance in treatment effects. Only positive (but not negative) parameter estimates 
were found for each regressor after treatment, indicating that galantamine challenge 
increased signal amplitude at earlier timepoints only (see Materials and Methods). Plots 
representing reconstructed average BOLD responses at baseline, and after acute and 
prolonged treatment with galantamine, showed that galantamine intake affected the 
shape of the BOLD response to facial stimuli when compared to baseline. The increase 
in signal intensity at MA = 5s effectively reduced the latency-to-peak intensity of the 
BOLD response (Figure 2).
Table 1. Volume, Z-scores and coordinates of peak voxels of local maxima for effects of galantamine 
challenge (acute intake > baseline) on brain activation patterns during face encoding.
A.
N VOX Zmax x y z Left/Right Location
87 4.36 14 –26 36 R Cingulate Gyrus
83 4.38 2 –38 50 R Cingulate Gyrus
21 3.92 –2 –58 62 L Cingulate Gyrus / Precuneus
20 3.82 36 –80 0 R Lingual Gyrus
18 3.72 –35 –76 2 L Lingual Gyrus
15 3.8 –50 24 16 L Inferior Frontal Gyrus
B.
N VOX Zmax x y z Left/Right Location
31 3.8 4 –92 –2 R Primary Visual Cortex
29 3.7 0 –68 14 R Primary Visual Cortex
(A) effects of acute galantamine challenge as captured by a model involving a default HRF with maximum 
amplitude (MA) at 6s after stimulus onset. (B) residual effects at earlier onset time (MA = 5s) that are not 
explained by the default model. N-VOX: total number of voxels (volume) of local maximum (voxelsize 2 x 2 
x 2 mm). Z: Z-score of peak voxel. x, y, z: coordinates of peak voxel. Le/Ri: left or right hemisphere. See 
also Figure 2.
fMRI analyses: N-letter back
Main effects during N-letter back working memory task performance included bilateral 
parietal and prefrontal structures for 1BACK and 2BACK working memory conditions. The 
X-condition produced minimal amounts of activation. Comparisons of signal intensities 
between working memory load conditions showed more extensive patterns of activation, 
involving bilateral parietal and prefrontal structures (data not shown). These patterns of 
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effects reflect brain function during n-letter back working memory performance, and 
have been widely reported in international literature (e.g. (Owen et al., 2005)). No 
significant effects of galantamine intake were observed on brain function examined by 
the default model (MA = 6s) for any treatment condition or contrast. Additionally, none 
of the additional regressors explaining residual variance at deviating onset times during 
task performance explained residual variance in treatment effects.
Table 2. Means and standard errors of task accuracy scores and reaction times for encoding, 
recognition and N-letter back working memory task performance (listed for X, 1BACK and 
2BACK conditions). 
Regim
Baselin Single Steady
Mea Std Mea Std Mea Std
Acc. (encod) .94 .02 .97 .02 .95 .02
Rtav (encod) 1.31 .05 1.27 .04 1.28 .05
Acc. (recog) .16 .05 .18 .05 .30 .05
Rtav (recog) 2.10 .08 2.04 .08 2.16 .08
Acc. X (nback) .97 .04 .97 .04 .93 .04
Acc. 1B (nback) .91 .04 .92 .04 .89 .04
Acc. 2B (nback) .58 .04 .59 .04 .56 .04
Rtav X (nback) .52 .03 .51 .02 .51 .03
Rtav 1B (nback) .58 .03 .58 .02 .58 .03
Rtav 2B (nback) .75 .03 .75 .02 .75 .03
Means are modified population marginal means (i.e. calculated using the specified linear model). Acc.: 
Accuracy score. RTav: mean reaction time. X: X condition. 1B: 1BACK condition. 2B: 2BACK condition.
Discussion
Effects of cholinergic challenge with the cholinesterase inhibitor galantamine were 
examined on the shape of the BOLD response of AD patients during memory task 
performance, using different BOLD models to capture variance not explained by a single 
default model. Treatment effects were found on brain function during face encoding, 
but not working memory performance. Effects of galantamine challenge occurred after 
acute intake only. Galantamine challenge increased BOLD signal intensity both at 
default onset time (HRF with MA = 6s) and at earlier onset time of the BOLD response 
(HRF with MA = 5s). These results will be discussed below.
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Effects of galantamine challenge: process-specificity
In contrast to face encoding (Figure 2, Table 1), galantamine challenge produced no 
effects on brain function during working memory performance, despite analyses of 
treatment effects across a number of different contrasts and timepoints after stimulus 
onset. The asymmetric distribution of treatment effects across encoding and working 
memory tasks may be explained by several factors. First, they may reflect differences 
in task design. Since we scanned a population of AD patients, we aimed to minimize 
scanning time by reducing the number of alternating blocks during n-letter back working 
memory performance, and to exclude task conditions requiring working memory loads 
exceeding those required for 2-back performance (from previous experience, we knew 
that higher working memory loads require too much effort of mild AD patients and 
produce chance level accuracy scores). Since n-letter back working memory tasks 
contained more conditions of interest (3) than face encoding (1), face encoding 
paradigms involved more blocks per condition (4 blocks) than n-letter back task (3 
blocks). This may have produced better signal-to-noise ratios during face encoding 
(Z-scores up to 9.5) than for working memory performance (Z scores up to 6.5), which 
may have lowed chances of finding significant effects of treatment.
Alternatively, effects of cholinergic challenge may be process-specific, i.e. may 
preferentially involve face encoding rather than working memory processes in AD 
patients. Process-specificity has been observed previously in pharmacological fMRI 
studies (Honey & Bullmore, 2004; Thiel, 2003) and may reflect the combined effects of 
receptor expression and drug characteristics (e.g. some mental processes may be more 
dependent on specific nicotinergic or muscarinergic receptor subtypes than others (Jann 
et al., 2002)). The current study, however, did not allow for a more detailed analysis of 
the process-specificity of galantamine-induced treatment effects. Face- encoding and 
n-letter back working memory tasks were chosen because of their proven reliability in 
eliciting activation patterns in controls and AD patients (Small et al., 1999; Owen et al., 
2005). These paradigms, however, differ substantially with respect to the information 
content of the presented stimuli (visuospatial information (faces) versus symbolic 
(lexical) information). We therefore refrained from further studies of process-specificity, 
which would require tight statistical comparisons of treatment effects between encoding 
and working memory domains. Future pharmacological imaging studies may require a 
balancing of the number of task conditions and timepoints scanned for each block, and 
keep the information content of encoding and working memory paradigms as similar 
as possible, in order to allow for more detailed studies of the process-specificity of 
pharmacological substances.
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Effects of galantamine challenge: changes in shape and latency of the 
BOLD response
At default onset time (MA = 6s), increased signal amplitude was observed in (posterior) 
cingulate and prefrontal cortices during face encoding. Additional variance was 
explained by a regressor explaining signal variance at earlier onset time (MA = 5s) 
than the default HRF (MA = 6s). This shows that effects of pharmacological treatment 
may be overlooked if standard procedures of fMRI data analysis are used. At MA = 5s, 
an increase in BOLD signal amplitude (relative to baseline) was found in the primary 
visual cortex. Treatment effects at MA = 5s did not overlap with those observed at 
default onset times (MA = 6s), suggesting that effects of galantamine challenge either 
occurred at MA = 5s or at MA = 6s. Reconstruction of average BOLD responses 
after galantamine challenge, however, showed that such sharp distinctions could not 
be made (Figure 2). Amplitude changes could be observed at both timepoints in each 
brain area, but each time reached significance for one timepoint and brain area only. 
This suggests that the effects observed at both timepoints reflect a single phenomenon 
affecting both latency and intensity of the BOLD response. Since BOLD signal intensity 
was increased at earlier onset times, response latency was effectively decreased 
as a result of galantamine challenge. This confirmed our hypothesis that cholinergic 
stimulation increases the intensity and decreases the latency of the BOLD response to 
task stimuli.
Although difficult to interpret from BOLD signal changes alone, the observed 
effects may involve increased arousal, attention and stimulus processing, which are 
well-described effects of cholinergic stimulation (Sarter et al., 2005). Posterior cingulate 
activation has been linked to enhanced visuospatial attention (Mesulam et al., 2001). 
Previous studies of cholinergic stimulation have further shown increases in prefrontal 
and cingulate cortex activation (Thiel, 2003). These structures may interoperate with 
visual cortex to direct (selective) visual attention to potentially relevant stimuli (Small 
et al., 2003). The observed increase in BOLD response intensity at earlier onset times 
(effects at MA = 5s) in the visual cortex may reflect a decrease in neural response-
latency as a result of an increase in stimulus-driven (bottom-up) attentional performance. 
Previous studies have shown that a shift in attention to a (new) stimulus enhances 
cortical reactivity in areas involved in early selection of relevant information, such as 
the visual cortex (Mangun, 1995; Coull, 1998; Bentley et al., 2004). The observed 
effects at MA = 5s may therefore reflect increased early processing of facial stimuli. 
These findings are especially relevant given our previous findings of a delayed cortical 
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response to facial stimuli in the visual cortex of AD patients (Rombouts et al., 2005b). 
Acute galantamine challenge may therefore improve signal intensity at default onset 
time, as well as the temporal characteristics of the BOLD response. The long-term 
therapeutic effects of galantamine treatment on episodic memory in AD patients may be 
secondary to these immediate effects (Sarter et al., 2005).
We should be cautious, however, to conclude that the observed effects are strictly 
neurogenic in nature. The effects of pharmacological substances on brain function may 
involve both vascular, glial and neurogenic effects (Honey & Bullmore, 2004; Logothetis 
& Pfeuffer, 2004). Without the aid of complementary methods, it is not possible to 
attribute the observed BOLD latency shift to any of these three compartments with 
a high degree of certainty (Kollias et al., 2000; Richter & Richter, 2003). Although 
this may be problematic in fundamental studies of the effects of pharmacologcial 
substances on brain function, it is likely to be less of an obstacle to clinical studies 
of neurotransmitter system function, since reactivity of both vascular, glial and neural 
tissues to pharmacological challenge may contain information regarding the functional 
status of the neurotransmitter system under investigation. Clinical studies examining the 
effects of pharmacological intervention on the shape and latency of the BOLD response 
to task stimuli may therefore follow the same pragmatic approach taken in analogous 
studies of latency changes of event-related potentials (ERPs) to oddball stimuli. ERP 
studies in AD patients have shown peak responses of P300 to be delayed by about 
40ms as compared to control subjects (Ball et al., 1989; Polich & Herbst, 2000). P300 
seems especially sensitive to cholinergic changes (Hammond et al., 1987). Cholinergic 
stimulation may cause a (partial) remittance of this P300 delay in AD patients, which is 
shortened by 15–25ms (Werber et al., 2003; Thomas et al., 2001). Both the delay of 
P300 in AD patients and its latency-shift after cholinergic treatment have been proposed 
to serve as clinical markers, which may aid in early (differential) diagnosis of AD and 
may help to predict response to cholinomimetic treatment in these patients (Frodl et al., 
2002; Green & Levey, 1999; Knott et al., 2002; Polich & Herbst, 2000; Thomas et al., 
2001; Werber et al., 2003). Similarly, changes in the shape and latency of the BOLD 
response to task stimuli may provide additional information concerning the functional 
status of the cholinergic system in AD, and have predictive value with respect to disease 
outcome and response to cholinergic therapy.
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Effects of galantamine challenge: dependence on exposure duration
In the current study, activation changes were observed after acute, but not prolonged 
galantamine exposure. With plasma levels considered equal at the time of scanning 
for both acute and prolonged treatment regimes, such differences may be explained 
by effects of receptor (de)sensitization within the context of a cholinergic deficit. In 
AD patients, low acetylcholine levels are thought to be responsible for a significant 
proportion of symptoms (Giacobini, 2004). Low acetylcholine levels may induce 
sensitization of nicotinic and muscarinic cholinergic receptors on recipient neurons, 
resulting in high reactivity to acute galantamine challenge (Erb et al., 2001; Svedberg 
et al., 2002). Similarly, prolonged galantamine exposure may cause desensitization of 
(muscarinic) cholinergic receptors, with low reactivity to cholinergic stimulation (Quick 
& Lester, 2002; Volkow et al., 2001). Thus, the strong reaction to acute challenge with 
galantamine in AD patients may reflect acute nicotinic receptor sensitization in the 
presence of a cholinergic deficit, whereas the non-significant response after prolonged 
galantamine exposure may reflect (muscarinic) receptor desensitization within the context 
of (partially) restored acetylcholine levels. Similar effects of receptor sensitization have 
been suggested to underlie differences in BOLD signal reactivity to nicotine exposure 
between smokers and non-smokers (Ernst et al., 2001) and the varying effect sizes of 
different cholinesterase inhibitors in AD patients (Geerts et al., 2002). Future studies 
may require a combination of molecular imaging techniques (e.g. PET) and phMRI in 
order to link functional changes as a result of pharmacological intervention to alterations 
in receptor expression profiles at the molecular level.
Effects of galantamine challenge: disease-specificity
The results of the current study are difficult to compare with those of other studies, since 
these involved different groups of subjects, cholinergic substances, memory tasks and 
exposure durations (Thiel, 2003; Saykin et al., 2004). In a previous study, however, 
we used the same dosing regimen and analysis methods as reported in the current 
study to examine the effects of galantamine challenge on brain function during delayed 
recognition of emotionally neutral human faces in patients with AD and with mild cognitive 
impairment, which is a disease stage preceding the development of AD (Goekoop et al., 
2005c). We found that the effects of acute galantamine challenge were region-specific, 
process-specific, and disease-stage-specific: hippocampal activation was enhanced in 
AD patients in a manner that favoured encoding of novel information during retrieval, and 
posterior cingulate, temporal and prefrontal activation was enhanced in MCI patients in 
a way that favoured successful retrieval of previously learned information. The differential 
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functional response of MCI and AD patients to galantamine challenge during retrieval 
was thought to reflect differences in the functional status of the cholinergic system 
at different stages of disease, which is in line with recent findings at a molecular and 
clinical level. Such a differential response may be relevant to clinical studies examining 
the differential diagnostic value of such changes, or their predictive value with respect 
to clinical decline and response to cholinergic therapy.
In another study, we used the same design and memory tasks as described in the 
current study to examine the effects of galantamine challenge on brain function during 
face encoding and n-letter back working memory performance in patients with MCI 
(Goekoop et al., 2004). In contrast to AD patients, effects of galantamine challenge 
in MCI patients occurred after prolonged galantamine exposure only. During face 
encoding, effects occurred in lateral visual, hippocampal and prefrontal areas. During 
working memory performance, effects occurred in right precuneus and right prefrontal 
cortex. Thus, MCI and AD patients responded differently to cholinergic challenge 
during face encoding and working memory performance, suggesting a difference in 
the functional status of the cholinergic system between these patient groups. When 
examined statistically, however, the observed differences in BOLD signal reactivity 
between MCI and AD patients were not significant (Z > 3.1; data not shown). Thus, 
the face encoding and working memory paradigms, as described in the current study, 
may be less suitable to study disease-specific effects of cholinergic challenge in a 
clinical setting. Alternatively, disease-specific alterations in brain function as a result 
of cholinergic challenge may themselves be process-specific, i.e. may only become 
apparent during performance under certain task conditions (e.g. delayed recognition 
memory performance). By systematically varying a number of different parameters, it 
may be possible to find disease-specific biomarkers that can aid in the assessment of 
cholinergic system function in early AD.
General considerations
In general, treatment effects reported in the current study were small in both magnitude 
and spatial extent, which may reflect low sample size (n = 18). Similarly, the absence 
of significant effects of galantamine intake on measures of task performance may 
reflect small sample size, since galantamine has a well-establised effects on episodic 
memory performance in AD patients (Raskind, 2003). Additionally, AD patients may 
show more variance in both brain anatomy (atrophy) and the hemodynamic response 
to neural stimulation when compared to healthy controls or MCI patients, which may 
reduce signal-to-noise ratios and hamper detection of significant effects of treatment 
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(Johnson et al., 2000; D’Esposito et al., 2003; Vandenbroucke et al., 2004). Future 
studies may therefore require inclusion of more subjects and corrections for brain 
atrophy (other than standard warping techniques) to enhance sensitivity to effects of 
pharmacological intervention. Since this study was not placebo-controlled, some of 
the observed changes may have represented placebo effects. However, the absence 
of significant effects of galantamine intake on measures of task performance suggests 
that placebo-effects were not a significant confounder in terms of behavior. Since no 
significant effects of galantamine intake were found on brain function after prolonged 
exposure, this suggests that placebo effects remained sub-threshold for this condition. 
By accounting for effects of task version and scan order, the residual signal changes 
may be considered more true representations of an effect of medication intake.
In conclusion, galantamine challenge increased the amplitude and reduced the 
latency of the BOLD response to task stimuli in AD patients during encoding of new 
information into memory. This shows that pharmacological intervention may produce 
effects that are easily missed in standard fMRI analyses. By systematically examining 
the effects of cholinergic challenge on a range of BOLD signal characteristics, it may 
be possible to obtain a set of markers of cholinergic system function that may predict 
clinical decline and treatment response in AD patients.
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Summary
Pharmacological functional magnetic resonance imaging (phMRI) examines the impact 
of pharmacologically induced neurochemical changes on brain function at a system level. 
The current phMRI study directly compared effects of cholinergic stimulation on brain 
function between patients with Alzheimer’s disease and mild cognitive impairment, a 
disease stage preceding the development of Alzheimer’s disease. Brain function during 
recognition of (un)familiar information was examined for changes after exposure to 
galantamine, a cholinesterase inhibitor used for treating memory deficits in Alzheimer’s 
disease. Alzheimer patients (n = 18; age 74.5 years ± 8.2; MMSE 22.5 ± 2.4) and patients 
with mild cognitive impairment (n = 28; mean age 73.6 ± 7.5; MMSE 27.0 ± 1.2) were 
scanned during face recognition under three different conditions: at baseline, and after 
acute and prolonged exposure (5 days) to galantamine. Functional data were analyzed 
in an event-related fashion. In both groups, acute exposure produced strong increases 
in brain activation (Z > 3.1). Prolonged exposure produced less strong effects that 
mainly involved decreases in activation (Z > 3.1). In mild cognitive impairment, acute 
exposure increased activation in posterior cingulate, left inferior parietal, and anterior 
temporal lobe. Prolonged exposure decreased activation in similar posterior cingulate 
areas, and in bilateral prefrontal areas. Effects were stronger for positive (‘familiar’) than 
for negative (‘unfamiliar’) decisions, indicating that the effect was specific to memory 
retrieval. In Alzheimer patients, acute exposure increased activation bilaterally in 
hippocampal areas, whereas prolonged exposure decreased activation in these areas. 
Effects were more pronounced for negative than for positive decisions, suggesting a 
preferential effect on memory encoding. Unique profiles of signal reactivity were found 
in a number of areas, including left inferior parietal lobe and left hippocampus proper. 
The reactivity of posterior cingulate and hippocampal structures to cholinergic challenge 
suggests a key role of the cholinergic system in the functional processes that lead to 
Alzheimer’s disease. The differential response to cholinergic challenge in mild cognitive 
impairment and Alzheimer patients may reflect a difference in the functional status of the 
cholinergic system between both groups, which is in line with recent results showing a 
differential clinical response to cholinergic treatment.
Keywords: fMRI; mild cognitive impairment; Alzheimer’s disease; galantamine; challenge 
study.
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Introduction
Alzheimer’s Disease is characterized by a progressive neurodegenerative process that 
initially affects only the entorhinal cortex and hippocampus in the medial temporal lobe, 
but gradually spreads outward to affect the entire cortical mantle in more advanced 
stages of disease (Braak et al., 1999). Loss of hippocampal function is considered 
a primary factor in causing memory problems in Alzheimer’s disease. Additionally, a 
cholinergic deficit is found that may contribute significantly to memory problems 
(Bartus, 2000; Mesulam, 2004). Apart from symptoms of amnesia, low acetylcholine 
levels have been associated with a variety of other clinical manifestations, including 
impaired verbal fluency and neuropsychiatric symptoms (Assal & Cummings, 2002). 
Current therapies against Alzheimer’s disease largely aim at restoring low acetylcholine 
levels with pharmacological agents (Lanctot et al., 2003; Trinh et al., 2003). Although 
the role of a cholinergic deficit in Alzheimer’s disease has been well established, the 
extent to which cholinergic function is impaired in Alzheimer’s disease, along with the 
time of onset of this impairment, are still subjects of debate. In vivo measurements of 
cholinergic receptor expression at different stages of Alzheimer’s disease using positron 
emission tomography (PET) have shown receptor abnormalities that change with disease 
progression (Nordberg, 2001). Post-mortem studies have shown decreased levels of 
molecular markers of cholinergic function in advanced stages of Alzheimer’s disease, 
but not in mild cognitive impairment, a disease stage preceding the development of 
Alzheimer’s disease. Instead, such markers may be upregulated in MCI, possibly to 
compensate for incipient neurofunctional defects (DeKosky et al., 2002). This suggests 
that cholinergic system function is relatively spared in early stages of Alzheimer’s disease, 
and is gradually affected in more advanced stages of disease. Despite these findings, 
however, the question remains whether the alterations observed at the molecular level 
indeed affect brain function at a system level. Evidence for a difference in cholinergic 
system function between mild cognitive impairment and Alzheimer patients may be 
relevant for subsequent dosage and timing of pharmacological treatment (Freo et al., 
2002; Ackerman et al., 2000; Thiel, 2003; Goekoop et al., 2004; Saykin et al., 2004).
Pharmacological functional magnetic resonance imaging (pharmacological fMRI 
or phMRI) is a technique that is used to study the impact of pharmacologically induced 
neurochemical changes on brain function at a system level (Honey & Bullmore, 2004). 
Since many psychopharmacological substances target specific neurotransmitter 
systems, phMRI may be used to study neurotransmitter system function in both healthy 
subjects and patients. Effects of neurotransmitter depletion or overexpression on 
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brain function and behavior have been studied in healthy controls to model disease 
mechanisms (e.g. (Sperling et al., 2002; Thiel, 2003)). Additionally, the therapeutic 
mechanism of a number of compounds has been studied in patients by examining 
changes in brain function after pharmacological treatment. Effects of pharmacological 
substances on brain function have been found to be region-specific, process-
specific and even genome-specific, and may vary with age and cognitive capacity 
(Honey & Bullmore, 2004). Recent results show that phMRI may successfully predict 
clinical response to pharmacological treatment in patients with major depression, by 
correlating initial changes in brain function to clinical outcome after treatment (Fu et 
al., 2004). Based on such findings, it has been suggested that the cortical response to 
pharmacological challenge is also disease-specific, i.e. reflects the functional status of 
the neurotransmitter system under investigation (Thiel, 2003; Honey & Bullmore, 2004; 
Saykin et al., 2004; Fu et al., 2004; Goekoop et al., 2004). We therefore used phMRI to 
compare changes in brain function as a result of cholinergic stimulation between patients 
with mild cognitive impairment and Alzheimer’s disease. In two previous phMRI studies, 
we examined cholinergic system reactivity in both groups separately while varying a 
number of parameters, including memory tasks and exposure durations (Goekoop et 
al., 2004; Goekoop et al., 2005b). Short periods of exposure to the cholinesterase 
inhibitor galantamine affected brain activation during encoding of unfamiliar information 
in different brain areas in both patient groups, suggesting a differential involvement of 
the cholinergic system. Treatment effects were very small, however. When compared 
statistically, no significant differential response to cholinergic challenge was observed 
between patients with mild cognitive impairment and Alzheimer’s disease (Goekoop et 
al., 2005b).
So far, most phMRI studies of cholinergic stimulation in patients examined brain 
function during encoding and working memory performance. Since the effects of 
cholinergic challenge may be process-specific (Honey & Bullmore, 2004)), cholinergic 
stimulation may differentially affect encoding and recognition stages of memory 
performance. For this reason, we used phMRI to compare effects of cholinergic 
challenge on brain function associated with recognition of previously stored information 
between patients with mild cognitive impairment and Alzheimer’s disease. The current 
study involved the same design and patient groups as reported in our previous studies 
(Goekoop et al., 2004; Goekoop et al., 2005b). A face-recognition task was used in 
which the familiarity of subjects was tested with items that had been presented a few 
minutes before, during encoding. As a cholinergic stimulant we used galantamine, which 
is a cholinesterase inhibitor (with an additional sensitizing effect on nicotinic receptors) 
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that has known therapeutic efficacy in Alzheimer patients (Raskind, 2003). Effects were 
examined after both acute (single dose) and prolonged (5 days) galantamine exposure. 
We hypothesized that cholinergic challenge would differentially affect brain function in 
patients with mild cognitive impairment and Alzheimer’s disease during face recognition. 
If so, this would provide in vivo evidence for a differential involvement of the cholinergic 
system in different stages of disease, with consequences for brain function at a system 
level.
Materials and Methods 
Study Design
Patients were screened for participation in a randomized study design with patients 
serving as their own controls. fMRI was performed at baseline (baseline, no medication), 
after oral intake of a single dose of galantamine with water (acute) and after prolonged 
exposure to galantamine (prolonged). Thus, three scanning sessions were performed in 
each patient, each of which corresponded to a different medication regime. Scanning 
sessions for different regimes were exactly one week apart and occurred at the same 
hour of day for each patient. Acute intake involved oral ingestion of 8mg galantamine with 
water. Prolonged exposure involved a 120 hour period (5 days) of galantamine intake, 
spread over 6 weekdays, during which period steady state plasma levels were reached, 
i.e. 4 mg galantamine (first gift, evening of day 1), 4 mg galantamine b.i.d. (mornings and 
evenings; 4 consecutive days), 4 mg galantamine (final gift, morning of day 6). At this 
rate, steady state plasma levels are reached within 2–3 days in healthy controls (with 
minimum serum galantamine concentrations 10.6 ± 4.0 ng/ml and maximum levels 30.7 
± 6.2 ng/ml (Mannens et al., 2002; Zhao et al., 2002)). Baseline, acute and prolonged 
regimes were randomized across scanning sessions to prevent between-session (e.g. 
learning) effects from interfering with possible effects of medication. To avoid carry-over 
effects between the regimes, periods of acute and prolonged intake were separated 
by a washout period of at least two days of zero galantamine intake, which is more 
than 6 times the half-life of galantamine (7.4 hours) (Mannens et al., 2002; Zhao et 
al., 2002). Scanning sessions were performed 3 hours after acute (1 x 8mg) and 9 
hours after prolonged (2dd 4mg; 5days) exposure. Dosage and timing of sessions was 
such that, on average, galantamine plasma levels after acute and prolonged exposure 
could be considered equal at the time of scanning. This was done in order to facilitate 
comparisons between treatment effects produced by different exposure durations.
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Subject recruitment
The study had approval of the review board of the committee of medical ethics of 
the VU University Medical Center in Amsterdam, the Netherlands. Thirty (30) elderly 
patients with mild cognitive impairment, 9 male, 21 female, aged 73.6; ± 7.7 (range 
54 to 89 years) were recruited from the Alzheimer Center at the VU Medical Center, 
Amsterdam, the Netherlands. Patients with mild cognitive impairment were diagnosed 
using Petersen’s criteria for amnestic mild cognitive impairment, i.e. a slowly progressive 
memory decline without the involvement of another domain of cognitive function, that 
did not interfere significantly with activities of daily living (Petersen et al., 2001). For 
further details, see (Goekoop et al., 2004). Additionally, twenty (20) age matched 
patients with Alzheimer’s disease, 11 male, 9 female, aged 74.5; ± 8.2 (range 55 to 83 
years), were recruited in a similar fashion. Alzheimer patients were diagnosed using the 
NINCDS-ADRDA criteria for Alzheimer’s disease (McKhann et al., 1984). For further 
details, see (Goekoop et al., 2005b). All patients provided informed consent according 
to the declaration of Helsinki under supervision of a lawful caretaker during a screening 
visit in which the procedure was explained and contraindications were checked. 
Apart from neuropsychological assessment during clinical investigation, all patients 
underwent additional MMSE (Folstein et al., 1975a), CDR (Morris, 1997) and NYU-
paragraph recall tests, which were used for cognitive profiling. Formal education was 
determined on a discrete scale with three levels (1 = low, 2 = middle, 3 = high). Patients 
were excluded if they had any significant medical, neurological or psychiatric illness 
(other than mild cognitive impairment or Alzheimer’s disease), or if they were taking 
medication or other substances that are known to influence cerebral function, including 
antidepressants and cholinesterase inhibitors. Patients were excluded if their history 
showed excessive nicotine or alcohol intake (> 0.5 packs of cigarettes, > 4 glasses 
of an alcoholic substance a day), a severe allergy to pharmacological substances or 
their constitutive compounds, or the use of any experimental medication within three 
months prior to enrollment in the trial. Exclusion criteria to MRI involved the presence 
of a pacemaker, metallic implants in high-risk areas (i.e. vessel clips) and a history of 
claustrophobia.
Functional MRI (fMRI)
Data acquisition
Imaging was carried out on a 1.5 T Sonata scanner (Siemens, Erlangen, Germany), 
using a standard circularly polarized head coil with foam padding to restrict head 
motion. For fMRI, an echo planar imaging sequence was used (echo time 60ms, flip 
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angle 90°, matrix 64 × 64, field of view 192 × 192 mm), to obtain 21 transverse slices 
(thickness 5 mm, interslice-gap 1 mm). Task stimuli were projected on a screen located 
at the head end of the scanner table via an LCD projector located outside the scanner 
room. Subjects viewed the screen through a mirror located on the head coil. In each 
hand, subjects held an fMRI compatible response-box through which they were able 
to react to task stimuli by pressing the left or right button using their index-fingers. A 
T1–weighted structural MRI-scan was obtained of each subject (MPRAGE; inversion 
time: 300 ms, TR = 15 ms; TE = 7 ms; flip angle = 8°; 160 coronal slices, 1 × 1 × 1.5 
mm voxels).
Memory-task: face recognition
A face recognition task was administered immediately after a face encoding task. The 
encoding task involved the presentation of four blocks of unfamiliar faces (24 in total) 
alternating with blocks of fixation (Goekoop et al., 2004; Goekoop et al., 2005b). 
During face recognition, 24 faces were presented sequentially in random order on a 
black background, of which 12 had been shown during encoding and 12 were new. 
Each face was presented for a duration of 5s, and was followed by a white fixation-cross 
presented for 3s on a black background. Patients were instructed to indicate whether 
a presented face had been shown previously by pressing one of two buttons. Written 
instructions “Seen previously?”; “<= Yes ” and “=> No” also appeared alongside the 
pictures. Response types (familiar, unfamiliar, none) and response latencies to individual 
stimuli were recorded.
Three different but comparable versions of each paradigm were constructed and 
randomized across the scanning-sessions (baseline, acute and prolonged regimes). 
All paradigms were practised using dummy tasks to ensure that patients mastered the 
general procedure of task performance before scanning. One day before the start of the 
first session, a home visit was scheduled during which all memory tasks were practiced 
on a laptop computer. Five minutes before the onset of the first measurements, the face 
encoding paradigm was practiced again, while patients were in the scanner. During the 
first 10.5s of each task, patients saw a circle indicating time left before the onset of the 
first condition. Total time for one scanning session including instructions of memory 
tasks was approximately one hour.
Analysis of behavioral data
Differences between demographic values and neuropsychological test scores were 
analyzed with SPSS 11.5, using chi-square analysis for discrete parameters (gender, 
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education level, CDR scores), and a multivariate analysis of variance (ANOVA) for 
continuous parameters (age, MMSE, NYU-paragraph scores). Overall accuracy scores 
and mean reaction times during recognition task performance were calculated for 
each patient. This was done separately for performance under each scanning session 
/ exposure duration (i.e. baseline, acute, prolonged). Overall accuracy scores were 
calculated by subtracting false answers (false rejections (FN) + false recognitions (FP)) 
from correct answers (correct rejections (TN) + correct recognitions (TP)), and dividing 
the result by the total number of items (24 if no misses). Accuracy scores thus varied 
from –1 (100% incorrect) to 1 (100% correct), with 0 indicating chance level (50% 
correct, 50% incorrect). For analysis of treatment effects, a mixed effects ANOVA was 
performed in which accuracy scores and response latencies were entered as dependent 
variables, with medication ‘regime’ (3 levels: baseline, acute, prolonged), ‘group’ (2 
levels: mild cognitive impairment and Alzheimer’s disease), ‘test version’ (3 levels: 1, 2, 
3) and ‘scan order’ (3 levels: 1, 2, 3) as fixed factors, and education level (3 levels: low, 
medium, high) and gender (2 levels: male and female) as covariates. ‘Scanorder’ was 
specified as the repeated factor, to account for the effect of taking repeated measures 
from the same subject. Given the large number of possible interactions between these 
terms, Akaike’s information criterion (AIC) was used to calculate an optimal model-
structure, which at an IAC value of –17.0 was found to contain only two-way interactions 
between all terms. Non-significant interactions were eliminated from the analysis in 
a stepwise process (two steps). Effects of the interaction regime*group were then 
considered representative of a differential effect of galantamine treatment on behavior 
in both groups (p < 0.05, Bonferroni corrected for multiple comparisons).
Analysis of functional neuroimaging data
Functional datasets of individual subjects were analyzed using FSL (Smith et al., 2004). 
The first five volumes of each dataset were discarded to account for T1-saturation 
effects. At first level (individuals), the following pre-processing was applied: non-brain 
removal, slice-timing correction using Fourier-space time-series phase-shifting, motion 
correction and spatial smoothing using a Gaussian kernel of FWHM 8mm, mean-
based intensity normalization of all volumes by the same factor and high (0.02 Hz) 
and low pass temporal filtering (Jenkinson et al., 2002; Smith, 2002). Registration 
of functional neuroimages to high resolution and/or standard images was carried out 
using an intermodal registration tool based on the correlation ratio (Jenkinson & Smith, 
2001). After pre-processing, the following statistics was applied on a voxelwise basis 
on each time series, using local autocorrelation correction (Woolrich et al., 2001): 
143
4.3 Differential response to galantamine challenge in MCI and AD patients
signal change during face recognition was modeled in an event-related fashion, using 
separate regressors for TP, TN, FP and FN response types (see above). Type and 
onset time of the events were determined by post-hoc sorting, based on the responses 
given by the individual subjects. Signal variance during fixation (X condition) was not 
modeled, to prevent overspecification of the model. Thus, a unique model of signal 
response was obtained for each individual patient, containing a single regressor for 
each response type and their temporal derivative, which was convolved with a gamma 
function to model the hemodynamic response. Model fitting generated whole brain 
native space images of parameter estimates for each condition, representing average 
signal change during face recognition versus fixation (X), along with corresponding 
variance images. To reduce the size of the analysis, only effects on brain activation 
during correct responses (i.e. true positive and true negative responses) were further 
considered. Thus, the following lower-level contrasts were generated: TP (versus X), TN 
(versus X) , and TP <> TN. TP and TN versus low-level fixation (X) contrasts examine 
general aspects of recognition memory performance, which are biased with respect to 
successful retrieval processes (TP > X) and encoding processes (TN > X), respectively 
(Buckner et al., 2001). TP > TN contrasts specifically examine brain areas where signal 
intensity during successful retrieval of familiar information was significantly stronger 
than signal intensity during successful rejection / encoding of new information. Areas of 
significant signal differences may therefore represent areas associated with ‘successful 
retrieval’. Conversely, the reverse contrast TN > TP examined brain function related to 
‘encoding during attempted retrieval’. Brain areas that show significant effects for these 
contrasts may differ from those involved in either TP or TN (versus X) decisions, thus 
providing additional information concerning specific subcomponent processes during 
retrieval (Daselaar et al., 2003). The corresponding functional images were resampled 
to 2 x 2 x 2 mm in standard space and fed into in a group level statistical analysis 
to examine activation patterns for differences between treatment durations (baseline, 
acute and prolonged exposure).
At group level, average activation maps (‘main effects’) were calculated for all 
lower-level contrasts (see above). This was done for all regimes types in both patient 
groups in a mixed effects higher level analysis (Woolrich et al., 2004), using clusters 
determined by Z > 2.3 and a corrected cluster significance threshold of P = 0.05 (Forman 
et al., 1995; Friston et al., 1994; Worsley et al., 1992). Effects at baseline were then 
tested for significant changes after acute or prolonged exposure (‘treatment effects’). 
Treatment effects were calculated for each group separately, and for their between-
group comparison. This was done in a single group level analysis using a mixed effects 
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‘Triple T-test’ model (http://www.fmrib.ox.ac.uk/fsl/feat5/index.html), which examined 
lower level contrast maps of both groups for effects of treatment, scanning order, test 
version, and the act of taking repeated measurements from single subjects (Woolrich 
et al., 2004; Goekoop et al., 2004; Goekoop et al., 2005b). Separate variances were 
assumed for both patient groups. Treatment effects were examined at a voxel threshold 
for significant brain activation determined by Z > 3.1 (i.e. p = 0.001), and a minimal 
clustersize of 160mm3. An F-test was used to test for any effect of cholinergic challenge 
(either acute or prolonged). If present, specific contributions of acute and prolonged 
exposure were analyzed using pairwise comparisons (T-tests). All group analyses were 
performed in a common reference space (standard space) (Talairach & Tournoux, 1988). 
For display purposes, treatment effects pertaining to a specific group were rendered 
on mean anatomical brain volumes corresponding to that group in standard space. 
Results of comparisons of treatment effects between groups were rendered on a mean 
anatomical brain volume of all patients in standard space.
Results
Demographics & results of cognitive profiling
Table 1 shows the results of demographic and cognitive profiling in mild cognitive 
impairment and Alzheimer’s disease patient groups. Where possible, statistics are 
given to indicate the significance of a difference between the groups.
Patient compliance and discontinuation
Data from 28 patients with mild cognitive impairment (25 complete datasets including 
scans at baseline, and after acute and prolonged exposure, and 3 incomplete datasets) 
and 18 Alzheimer patients (17 complete datasets, 1 incomplete dataset) was used in 
the current study comments (see also Table 1). Compliance was good, as assessed 
by pill-counts and the caretaker’s comments. For further details, see (Goekoop et al., 
2004; Goekoop et al., 2005b).
Task Performance
Table 2 lists numbers and percentages of response types (i.e. TP, TN, FP and FN 
responses) for mild cognitive impairment and Alzheimer groups, specified by regime 
type. Table 3 shows means and standard errors of overall accuracy and latency scores 
during face recognition for each patient group and regime type separately. Information 
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is provided regarding the significance of (differential) effects of galantamine challenge 
in both groups.
Table 1. Demographics and results of cognitive profiling of MCI and AD patients participating 
in this study. 
Demographic Measure MCI AD Significance
Age Mean 73.8 74.5 (F1,44 = 0.181, p = 0.67), 
SD 7.7 8.2
Gender Male 8 11 (Chi-square = 13.2, df = 1, p = 0.0003) 
Female 20 7
Education level Low 3 7 (Chi-square = 15.3, df = 2, p = 0.0005)
Medium 15 10
High 10 1
Handedness Left 3 1 N.P.
Right 25 17
Smoker Yes 3 1 N.P.
No 25 17
NPE
MMSE Mean 27 22.5 (F1,44 = 70.4 , p = 0.0001)
SD 1.2 2.4
CDR Mean 0.5 1.6 (Chi-square = 46.0, df = 2, p = 0.0001)
SD None 0.5
NYU (delayed) Mean 3.2 0 (F1,44 = 16.3, 16.3, p = 0.0002)
SD 2.9 1
NPE: neuropsychological examination. MMSE: mini mental state examination. CDR: clinical dementia 
rating scale. NYU (delayed): New York University paragraph (delayed) recall test. P values, Chi-square or 
F-values and df are supplied to indicate the significance of the difference between both patient groups. 
N.P.: not provided, given small number of cases.
Overall recognition accuracy scores were above chance levels in both patient groups 
(Table 3). Accuracy scores in the Alzheimer group were significantly lower than those in 
the mild cognitive impairment group (F1,46.8 = 31.4, p = 0.0001). When both groups 
were pooled, recognition accuracy was 0.30 (SE 0.35) at baseline, 0.40 (SE 0.037) 
after acute intake, and 0.36 (SE 0.035) after prolonged exposure. A trend was found 
for increased recognition accuracy scores after galantamine treatment (F2,78.4 = 2.6, 
p = 0.08). This effect was largely due to an effect of acute galantamine intake (SE 
0.042, p = 0.080) (Table 3). No significant effects of galantamine challenge were found 
on recognition accuracy in each of the groups separately (Table 3) (Goekoop et al., 
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2004; Goekoop et al., 2005b). No significant effect was observed for the interaction 
regime*group, indicating that galantamine challenge did not differentially affect 
recognition accuracy between patient groups (F2,83.7 = 2.0, p = 0.14) (Table 3). 
Latency scores did not differ significantly between mild cognitive impairment 
and Alzheimer patients (F1,45.9 = 0.123, p = 0.72). When both groups were pooled, 
response latency was 2.28s (SE 0.068s) at baseline, 2.25s (SE 0.070s) after acute 
intake, and 2.31s (SE 0.069s) after prolonged exposure. No effect of galantamine 
intake was found on response latency when groups were pooled (F2,70.4 = 0.78, 
p = 0.46), or in both groups separately (Table 3) (Goekoop et al., 2004; Goekoop et al., 
2005b). No significant effect was observed for the interaction regime*group, indicating 
that galantamine challenge did not differentially affect response latency in both patient 
groups (F2,75.5 = 0.37, p = 0.69) (Table 3).
fMRI analyses
Main effects: mild cognitive impairment and Alzheimer patients
Table 1 lists numbers and percentages of correct and incorrect responses in both patient 
groups (Table 1). Mild cognitive impairment and Alzheimer patients activated roughly 
the same structures during recognition task performance. At baseline (no treatment), 
main effects during correct (TP and TN) responses in both groups involved activation of 
ventral and dorsal occipital (visual) areas, bilateral inferior parietal, (para)hippocampal, 
superior temporal and prefrontal areas and the lateral sulci (Figure 1A, 1B, 1E, 1F). 
Activation patterns of TP and TN decisions differed significantly in both groups (Figure 
1C, 1G). A baseline TP > TN contrast averaged over all subjects showed activation 
bilaterally in primary visual cortex, anterior and posterior cingulate cortex, inferior 
parietal lobes and anterior temporal lobe, whereas unilateral activation was observed 
in right motor cortex, right basal ganglia, left cerebellum, and left inferior, middle and 
superior frontal cortices. The lateralization of activation in right motor-related areas likely 
represents increased motor activity of the left hand and fingers during TP decisions 
when compared to TN decisions. In contrast, only left motor cortex showed increased 
activation in group-level TN > TP contrasts (Figure 1D, 1H).
Treatment effects: mild cognitive impairment
When compared to baseline, acute exposure to galantamine increased brain activation 
in a large number of structures, including (left) posterior cingulate cortex, left anterior 
temporal lobe, left superior parietal, left superior temporal cortex, right frontal lobe and 
cerebellum. These effects were mainly due to activation changes during true positive 
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(TP) decisions (Figure 2A, 2B; Table 4A, 4B), (Z > 3.1). No significant decreases were 
observed after acute galantamine intake. Prolonged exposure produced no significant 
increases in brain activation (Z > 3.1; data not shown). Instead, decreases in brain 
activation were found in (left) posterior cingulate, right middle frontal and bilateral superior 
prefrontal cortex. Again, these effects were mainly due to activation changes during true 
positive (TP) decisions (Figure 2C, 2D; Table 4C, 4D), (Z > 3.1). When effects of acute 
and prolonged effects of galantamine intake were compared (acute <> prolonged), 
the differences were significant (Z > 3.1). Increases after acute intake and decreases 
in similar areas after prolonged exposure summed during these comparisons in areas 
of significant overlap (i.e. posterior cingulate cortex), producing stronger effects (data 
not shown). Significant treatment effects were found on a contrast describing TP > TN 
(but not TN > TP) activation differences. Acute galantamine intake produced strong 
increases in right visual cortex, left parahippocampal cortex, right inferior prefrontal and 
medial prefrontal cortex (Figure 2E, Table 4E) (Z > 3.1). Prolonged intake of galantamine 
decreased brain activation in right caudate nucleus and left putamen (Figure 2F, Table 
4F). Differences between acute and prolonged exposure were significant (Z > 3.1; data 
not shown).
Treatment effects: Alzheimer patients 
When compared to baseline, acute exposure to galantamine increased brain activation 
in a limited number of structures, including the vermis of the cerebellum, right inferior 
temporal gyrus and the parahippocampal areas bilaterally. Effects of response type were 
substantial. When TN items were considered separately, additional treatment effects 
were found in the body of the left hippocampus (Figure 3A, 3B; Table 5A, 5B), (Z > 3.1). 
No significant decreases in brain activation were observed after acute galantamine 
intake. Prolonged exposure produced no significant increases in activation (Z > 3.1; 
data not shown). Instead, a substantial decrease in brain activation was found in right 
(para)hippocampal cortex. Again, these effects were mainly due to activation changes 
during true negative (TN) decisions (Figure 3C, 3D; Table 5C, 5D), (Z > 3.1). When 
acute and prolonged effects of galantamine intake were compared, the differences were 
significant (Z > 3.1). Increases after acute intake and decreases in similar areas after 
prolonged exposure showed a significant overlap in right (para)hippocampal cortex, 
producing stronger effects when compared (data not shown). No significant treatment 
effects were found on contrasts describing TP <> TN activation differences.
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Figure 1. Axial slices showing main effects during face recognition task performance of MCI 
and AD patient groups, for which effects of galantamine treatment were examined. 
Effects are rendered on their respective mean anatomical brain volumes (average T1-weighted brains of 
MCI or AD patients: Mean_anat_MCI, Mean_anat_AD). Left in the image is left in the brain. Effects are 
cluster corrected using Z = 2.3 and p < 0.05. Color scale extends from Z = 2.3 (orange) to Z = 10.5 
(yellow). Panel A: MCI, true positive items (TP); Panel B: MCI; true negative items (TN); Panel C: MCI; 
true positive > true negative items (TP>TN); Panel D: MCI; true negative items > true positive items (TN 
> TP). See also materials and methods. Panel E-H: Same contrasts, involving AD patients. See text for 
further details. Continued on next page.
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Table 4. Volume, Z-scores and coordinates of peak voxels of local maxima for effects of 
galantamine challenge on brain activation patterns of MCI patients during face recognition.
A. TP, acute
Nr. Vox Z-score x y z Left/Right Location
1743 4.77 4 –32 56 Right Posterior cingulate gyrus
843 5.52 60 –66 26 Right Inferior parietal lobe
330 4.99 52 –10 10 Right Precentral gyrus
246 3.92 60 –40 16 Right Superior temporal gyrus
167 4.26 –50 –18 36 Left Precentral gyrus
160 4.5 18 –88 –14 Right Lingual gyrus / cerebellum
148 4.24 –52 30 16 Left Inferior frontal gyrus
146 4.64 2 –12 18 Left Medial septum
143 3.95 –24 –64 22 Left Superior parietal lobe
143 4.4 –56 –54 8 Left Middle temporal gyrus
125 4.15 42 40 –18 Right Middle frontal gyrus
91 4.53 24 –62 –36 Right Cerebellar tonsil
88 3.99 –46 14 22 Left Inferior frontal gyrus
75 3.91 –24 –96 –6 Left Lingual gyrus
72 3.55 24 4 –4 Right Putamen
60 3.67 34 –64 –4 Right Lingual gyrus
57 4.06 34 –76 52 Right Superior parietal lobe
55 3.53 0 –16 6 Right Thalamus
B. TN, acute
Nr. Vox Z-score x y z Left/Right Location
197 4.48 –14 –18 44 Left Posterior cingulate gyrus
133 4.48 -42 –54 64 Left Postcentral gyrus
100 3.88 –24 –84 52 Left Superior parietal lobe
86 3.99 44 42 –18 Right Middle frontal gyrus
66 4.36 –60 –66 28 Left Inferior parietal lobe
66 3.93 –56 –50 10 Left Superior temporal gyrus
51 3.67 –54 –10 10 Left Precentral Gyrus
47 3.75 0 –28 56 Right Posterior cingulate gyrus
33 3.99 –52 32 18 Left Inferior frontal gyrus
32 3.77 –10 –22 22 Left Medial septum
23 3.54 –12 –40 44 Left Precuneus
23 3.62 20 –62 –34 Right Cerebellar tonsil
22 3.75 –8 –6 22 Left Medial septum
20 3.66 32 –16 2 Right Putamen
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C. TP, prolonged
Nr. Vox Z-score x y z Left/Right Location
66 4.09 –30 –4 56 Left Middle frontal gyrus
37 3.56 24 44 –10 Right Middle frontal gyrus
25 3.61 –16 –42 44 Left Posterior cingulate gyrus
25 3.56 20 6 50 Right Middle frontal gyrus
23 3.42 –60 –10 8 Left Superior temporal gyrus
D. TN, prolonged
Nr. Vox Z-score x y z Left/Right Location
81 3.64 24 44 –10 Right Middle frontal Gyrus
36 4.09 –30 –8 58 Left Middle frontal gyrus
23 3.56 20 8 52 Right Middle frontal gyrus
E. TP>TN, acute
Nr. Vox Z-score x y z Left/Right Location
89 3.94 4 54 –8 Right Medial frontal gyrus
73 3.68 20 –76 4 Right Lingual gyrus
53 3.71 24 50 26 Right Superior frontal gyrus
52 3.82 –24 –32 –14 Left Parahippocampal gyrus
51 3.61 2 56 8 Right Medial frontal gyrus
37 3.59 46 –44 –16 Right Middle frontal gyrus
34 3.42 2 –82 36 Right Cuneus
32 3.71 –20 –50 6 Left Parahippocampal gyrus
31 3.75 46 20 8 Right Inferior frontal gyrus
31 3.43 –54 –10 –14 Left Middle temporal gyrus
25 3.64 –42 44 22 Left Middle frontal gyrus
23 3.43 42 -22 8 Right Superior temporal gyrus
F. TP>TN, prolonged
Nr. Vox Z-score x y z Left/Right Location
80 4.02 16 20 20 Right Caudate nucleus
40 3.59 –24 18 10 Left Caudate nucleus
32 3.12 –22 –78 10 Left Cuneus
23 3.56 –56 –4 2 Left Superior temporal gyrus
21 3.82 -28 –38 –14 Left Parahippocampal gyrus
N-Vox: total number of voxels (volume) of local maximum (voxelsize 2x2x2mm; effects at Z = 3.1). Z: Z-
score of peak voxel. x, y, z: coordinates of peak voxel. Le/Ri: left or right hemisphere. (A) TP items, acute 
intake (increases). Only effects with volumes > 400 mm3 (50 voxels) are listed. (B) TN items, acute intake 
(increases). (C) TP items, prolonged intake (decreases). (D) TN items, prolonged intake (decreases). (D) 
TP > TN items, acute intake (increases). F: TP > TN items, prolonged intake (decreases). See text and 
Figure 2 for further details.
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Table 5. Volume, Z-scores and coordinates of peak voxels of local maxima for effects 
of galantamine challenge on brain activation patterns of AD patients during face 
recognition.
A. TP, acute
Nr. Vox Z-score x y z Left/Right Location
33 3.64 0 –40 –12 Right Cerebellar vermis
26 3.52 –36 –20 –24 Left Parahippocampal cortex
23 3.31 33 6 –24 Right Superior temporal gyrus
25 3.82 –70 –26 –20 Left Inferior temporal gyrus
B. TN, acute
Nr. Vox Z-score x y z Left/Right Location
166 4.19 –28 –22 –24 Left Hippocampus
58 3.86 –42 –90 –14 Left Fusiform gyrus
37 3.85 –14 –80 6 Left Cuneus
25 3.82 –70 –26 –20 Left Inferior temporal gyrus
22 3.38 36 –28 –22 Right Parahippocampal gyrus
C. TP,prolonged
Nr. Vox Z-score x y z Left/Right Location
21 3.44 40 –24 –24 Right Parahippocampal gyrus
19 3.37 –46 20 –22 Left Superior temporal gyrus
18 3.21 –28 –22 –24 Left Hippocampus
D N, prolonged
Nr. Vox Z-score x y z Left/Right Location
93 4.44 40 –24 –24 Right Parahippocampal gyrus
44 3.43 –28 –22 –24 Left Hippocampus
26 3.73 18 –72 40 Right Precuneus
22 3.36 –46 22 –22 Left Superior temporal gyrus
N-Vox: total number of voxels (volume) of local maximum (voxelsize 2x2x2mm; effects at Z = 3.1). Z: Z-score 
of peak voxel. x, y, z: coordinates of peak voxel. Le/Ri: left or right hemisphere. (A) TP items, acute intake 
(increases). (B) TN items, acute intake (increases). (C) TP items, prolonged intake (decreases). (D) TN 
items, prolonged intake (decreases). See text and Fig. 3 for further details.
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Treatment effects: mild cognitive impairment versus Alzheimer patients
Visual inspection of treatment effects in both patient groups showed both differences 
and similarities in reactivity to galantamine challenge (Figure 2, Figure 3). In both 
groups, maximum reactivity to galantamine challenge occurred after acute exposure. 
Effects of acute exposure involved increases in activation only. Additionally, both groups 
showed decreases in brain activation after prolonged exposure, which occurred in brain 
areas similar to those showing increases in activation after acute exposure. Effects of 
prolonged exposure were of smaller magnitude than effects of acute exposure. Both 
groups differed in the spatial extent, amplitude and location of treatment effects. The 
mild cognitive impairment group showed a larger number of activation changes than 
the Alzheimer group, which were spread across a larger number of brain structures. 
Activation changes in the mild cognitive impairment group involved cortical (posterior 
cingulate, prefrontal, lateral temporal) and subcortical areas, but not the hippocampal 
areas. In contrast, activation changes in the Alzheimer group mainly involved hippocampal 
areas.
A direct statistical comparison between treatment effects of mild cognitive 
impairment and Alzheimer patients showed significant differences in treatment 
response between both groups. With respect to acute effects of galantamine intake, 
the mild cognitive impairment group produced significantly more activation changes 
than Alzheimer patients in a number of areas, including the left posterior parietal 
cortex (Figure 4A; Table 6A) (Z > 3.1). These effects were found for TP decisions 
only. Conversely, enhancement of hippocampal activation during TN decisions was 
significantly stronger in the Alzheimer group than in the mild cognitive impairment group 
(Figure 4B; Table 6B) (Z > 3.1). No significant between-group differences were found 
in the magnitude of treatment effects described by TP <> TN activation differences. 
Additionally, no differences were found with respect to effects of prolonged galantamine 
intake (Z > 3.1). Thus, significant differences were found in the reactivity of patients with 
mild cognitive impairment and Alzheimer’s disease to cholinergic challenge. Plots of 
percent signal change (relative to global mean signal intensity) in peak voxels of local 
maxima of treatment effects illustrate the significance of the differences in intensity 
changes between both groups (Figure 4).
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Discussion
The current study examined patients with mild cognitive impairment and Alzheimer’s 
disease for a differential response to cholinergic stimulation with the cholinesterase 
inhibitor galantamine by using phMRI with a face recognition task. To our knowledge, 
this is the first event-related phMRI study to directly compare effects of pharmacological 
intervention on brain activation during delayed recognition between patient groups. In two 
previous phMRI studies, we examined effects of cholinergic challenge in mild cognitive 
impairment and Alzheimer patients separately, while they engaged in encoding and 
working memory tasks (Goekoop et al., 2004; Goekoop et al., 2005b). The reactivity of 
mild cognitive impairment and Alzheimer patients to acute and prolonged galantamine 
exposure was examined using identical procedures as described in the current study. 
Overall, treatment effects were small in both spatial extent and magnitude. Patients with 
mild cognitive impairment responded to prolonged galantamine exposure only (both 
tasks), whereas Alzheimer patients responded to acute galantamine challenge only 
(encoding only). Such differences in reactivity to cholinergic stimulation may be due 
to a number of confounding factors (Goekoop et al., 2005b), including a preference 
of galantamine for certain mental processes, and a difference in the functional status 
of the cholinergic system between these groups (i.e. process-specificity and disease-
specificity of galantamine treatment; see below). When treatment effects during 
encoding were compared statistically between both groups, however,, no significant 
differential response to cholinergic challenge was observed between mild cognitive 
impairment and Alzheimer patients (Goekoop et al., 2005b).
Process-specificity
The current study extended our previous research by reporting effects of cholinergic 
challenge in the same patient groups during face recognition. Although identical 
procedures were followed, a larger number of stronger effects was found in both 
groups than observed for face encoding and working memory performance, supporting 
previous findings that effects of cholinergic enhancement are process-specific (Honey 
& Bullmore, 2004; Thiel, 2003). Direct comparisons between treatment effects across 
different memory tasks were not made, however, since these tasks were too dissimilar 
(i.e. block versus event-related designs, lexical versus visuospatial processing) to allow 
meaningful comparisons of cholinergic reactivity across different memory domains. We 
therefore report our findings of the effects of cholinergic challenge separately for all 
memory tasks. Nevertheless, we were able to examine the specificity of galantamine 
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challenge with respect to encoding and retrieval processes by studying brain function 
during retrieval alone. Since our face recognition task contained both novel and familiar 
items, both encoding and retrieval processes occurred during task performance 
(Buckner et al., 2001). By examining brain function during correct hits (TP items) and 
correct rejections (TN items), brain regions that are involved in (successful) retrieval 
and encoding-during attempted retrieval may be studied separately (see materials and 
methods). Although encoding processes during attempted retrieval may differ slightly 
from encoding during attempted encoding (Rombouts et al., 2001; Rugg et al., 2002), this 
methodology allows examination of process-specificity of pharmacological compounds 
with respect to encoding and retrieval processes within the same scanning session, 
which avoids some of the potential confounds that may be introduced by across-task 
or across-session comparisons of treatment effects (e.g. task design, relative timing of 
scanning sessions). If confirmed, a preferential targeting of memory retrieval processes 
rather than memory encoding by galantamine may have some clinical significance. For 
instance, the maximum benefit of cholinergic therapy with galantamine may be limited 
by existing pathology affecting the initial encoding of information. Future studies of drug 
design and development may therefore benefit from information provided by phMRI 
studies, by studying effects of pharmacological treatment in relation to specific neural 
processes. Such studies may help to increase efficacy and reduce side effects of novel 
psychopharmacological compounds.
Mild cognitive impairment
In patients with mild cognitive impairment, acute galantamine challenge enhanced brain 
activation in posterior cingulate cortex, anterior and lateral temporal areas, parietal and 
prefrontal areas, the basal ganglia and in medial septal areas (Figure 2, Table 3), which 
are all known to depend on cholinergic innervation (Selden et al., 1998). Effects were 
stronger during familiar (TP) than for unfamiliar (TN) decisions, suggesting a preferential 
effect on brain activation during retrieval of familiar information. This was confirmed by 
subsequent analyses examining effects of galantamine challenge on brain activation 
during TP > TN decisions. Effects were found for TP > TN decisions in medial and right 
prefrontal cortex, visual cortex and left parahippocampal area, which are part of a well-
described encoding-retrieval network (Simons & Spiers, 2003). Galantamine intake may 
therefore have affected successful retrieval in these patients. No effects were found for 
TN > TP decisions, suggesting that galantamine challenge in mild cognitive impairment 
did not specifically affect the encoding of new pictures during attempted retrieval.
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Posterior cingulate areas showed widespread increases in activation for TP items 
(Figure 2A). In healthy controls, posterior cingulate cortex has been implicated in 
visuospatial attention (Small et al., 2003) and episodic memory performance (Cabeza & 
Nyberg, 2000), whereas anterior and posterior temporal multimodal association cortex 
and inferior parietal cortex may play important roles in episodic memory performance 
(Frankland & Bontempi, 2005). In Alzheimer’s disease, the first neurofunctional 
alterations have been consistently shown to involve hypofunction of posterior cingulate 
cortex (see below). Thus, enhanced brain activation in these areas by galantamine intake 
may signify an enhancement of visuospatial attention and episodic memory. However, 
the observed effects of treatment may also reflect more complex alterations in memory-
related processes (see below).
Table 6. Volume, Z-scores and coordinates of peak voxels of local maxima for differential effects 
of galantamine challenge on brain activation in MCI and AD patients during face recognition.
A. TP, acute, MCI > AD
Nr. Vox Z-score x y z Left/Right Location
295 4.65 –56 –66 26 Left Middle temporal gyrus / inferior parietal lobe
56 3.88 62 –40 –2 Right Middle temporal gyrus
30 3.9 –30 –100 4 Left Cuneus
29 3.55 –52 26 2 Left Inferior frontal gyrus
26 3.75 6 –102 2 Right Cuneus
B. TN, acute, AD > MCI
Nr. Vox Z-score x y z Left/Right Location
25 3.81 –28 –20 –22 Left Hippocampus
N-Vox: total number of voxels (volume) of local maximum (voxelsize 2x2x2mm; effects at Z = 3.1). Z: Z-
score of peak voxel. x, y, z: coordinates of peak voxel. Le/Ri: left or right hemisphere. A: MCI > AD: acute 
galantamine intake produces stronger increases in MCI patients than in AD patients in left superior parietal 
and right lateral temporal cortex. TP items, acute intake. Panel B: AD > MCI: acute galantamine intake 
produces stronger increases in AD patients than in MCI patients in the left hippocampus. TN items, acute 
intake. See text and Figure 4 for further details.
Alzheimer’s disease
In Alzheimer patients, acute galantamine intake increased brain activation mainly in 
(para)hippocampal areas (bilaterally), visual cortex, left fusiform gyrus, and cerebellar 
vermis (Figure 3, Table 5). Effects were dependent on response type, since most 
significant effects of galantamine intake occurred during TN decisions (Figure 3B). 
Although no significant effects were found on brain activation reflected by TN > 
TP comparisons (which may be more specific to encoding processes than TN > X 
162
Chapter 4: Effects of galantamine challenge on brain function in MCI and AD patients
comparisons), this suggests a preferential effect of galantamine intake on brain activation 
involving encoding during attempted retrieval. Cholinergic modulation of brain activation 
in visual areas and fusiform cortex has been observed previously during face encoding 
tasks and may involve alterations in neural processing requirements that are specific 
to perception and processing of facial stimuli (Rombouts et al., 2002; Sperling et 
al., 2001). The increase in hippocampal activation after galantamine intake in these 
patients is remarkable, since hippocampal atrophy is considered the primary deficit 
in Alzheimer’s disease, which is mainly responsible for the observed symptoms of 
memory impairment (Braak et al., 1999). Previous fMRI studies have found decreased 
hippocampal activation in Alzheimer patients when compared to healthy subjects 
(Rombouts et al., 2000; Remy et al., 2005). To our knowledge, this is the first phMRI 
study to demonstrate an enhancement of hippocampal function in Alzheimer patients 
after cholinergic stimulation. Such signal changes may be related to the extent of 
clinical improvement after cholinergic therapy. Future clinical studies may therefore 
want to focus on changes in hippocampal function after cholinergic challenge during 
recognition memory performance, in order to predict treatment response and long-term 
clinical outcome in Alzheimer patients.
Region- process- and disease-specificity
Convergent evidence from functional studies including PET, SPECT and fMRI shows 
that resting state hypometabolism or hypofunction in limbic areas is central to pathology 
in both very early Alzheimer’s disease (i.e. mild cognitive impairment) and mild-to-
moderate Alzheimer’s disease (Matsuda, 2001; Nestor et al., 2003; Greicius et al., 
2004; Rombouts et al., 2005a). In the mild cognitive impairment stage, mainly posterior 
cingulate structures are affected, although sensitive region-of-interest techniques 
have detected hypometabolism in thalamus and hippocampus as well (Nestor et al., 
2003). In more advanced stages of Alzheimer’s disease, the same limbic network is 
affected more extensively, and may show additional hypometabolism in hippocampal, 
temporoparietal and frontal association cortices (Nestor et al., 2003). Although the 
earliest structural changes appear in the medial temporal lobe (entorhinal cortex 
and hippocampus; (Braak et al., 1999)), functional changes first appear in posterior 
cingulate areas (Chetelat et al., 2003). This has lead to the hypothesis that functional 
changes in posterior cingulate areas represent secondary effects of structural changes 
in hippocampal areas (Matsuda, 2001). Indeed, hippocampal and posterior cingulate 
areas are strongly connected through limbic structures such as the thalamus and 
mamillary bodies (Nestor et al., 2003). In a recent study in patients with mild cognitive 
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impairment, posterior cingulate hypometabolism has been related specifically to (deficits 
in) retrieval memory performance, whereas hippocampal hypometabolism was related 
to (deficits in) memory encoding (Chetelat et al., 2003). Hypometabolism in Alzheimer 
patients therefore seems to be region-specific (posterior cingulate versus hippocampus), 
disease-stage specific (mild cognitive impairment versus Alzheimer’s disease), and 
process-specific (recognition versus encoding). These findings show a strong similarity 
with the results from the current challenge study, which show enhancement of posterior 
cingulate activation in mild cognitive impairment related to retrieval, and increases in 
hippocampal activation in Alzheimer’s disease that are likely to be related to encoding 
(see above). Although a definite link between resting state limbic hypofunction and the 
reactivity of posterior cingulate and hippocampal structures to cholinergic challenge 
could not be made in the current (task-related) study, our results show that a cholinergic 
factor may be relevant to hypofunction in posterior cingulate and hippocampal areas as 
observed in early Alzheimer’s disease.
The nature of this possible cholinergic influence and its time of onset remain 
unclear from the present data. Hypometabolism in posterior cingulate (mild cognitive 
impairment) and hippocampal areas (Alzheimer’s disease) may simply reflect a 
hypofunction of the cholinergic system, which would argue for an early involvement 
of cholinergic system dysfunction in Alzheimer’s disease. According to this view, the 
selective enhancement of hippocampal and posterior cingulate areas after galantamine 
challenge may reflect enhanced sensitivity of these structures to cholinergic stimulation 
as a result of cholinergic denervation. Both the hippocampus proper and the posterior 
cingulate gyrus are densely innervated by cholinergic fibers originating from separate 
branches (Ch2 and Ch4, respectively) of the basal forebrain cholinergic system (Selden 
et al., 1998). Selective denervation of (cholinergic) hippocampal afferents, as observed 
in Alzheimer’s disease, may alter both nicotinic and muscarinic receptor expression 
(Nordberg, 2001), producing increased receptor sensitization (Erb et al., 2001; 
Svedberg et al., 2002) and an increased response of brain structures to cholinergic 
challenge (Goekoop et al., 2005b). However, our current results also fit a different 
scenario, where posterior cingulate cortex hypometabolism and recognition deficits 
(as a result of early medial temporal atrophy) are kept partially in check by an intact 
cholinergic system. Hippocampal hypometabolism and encoding deficits (as observed 
in later stages of Alzheimer’s disease) would then reflect a definite failure of cholinergic 
system compensation. According to this view, increased activation in posterior cingulate 
and hippocampal structures after cholinergic stimulation may reflect a partial remission 
from a hypofunctional state of these structures, and cholinergic therapy may simply be 
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an add-on to natural cholinergic system compensation. It is likely that a combination 
of both scenarios, i.e. receptor hypersensitivity and partial compensation, may best 
explain the observed results. Future studies may require to combine molecular imaging 
techniques (e.g. PET) and phMRI in order to relate cholinergic receptor status to signal 
changes in specific brain structures and corresponding clinical phenotypes.
Mild cognitive impairment and Alzheimer’s disease: similarities in cholinergic 
system reactivity
When signal changes in mild cognitive impairment and Alzheimer patients were visually 
compared, both groups showed signal increases after acute intake of galantamine, 
and signal decreases after prolonged exposure (Figure 4, Table 6). In some cases, 
increases and decreases in brain activation as observed for different exposure 
durations involved similar brain areas (Figure 2A,C; 2B,D; Figure 3A,C; 3B,D). The 
reason for this signal behavior is unclear, but may involve effects of nicotinic and 
muscarinic receptor sensitization after galantamine treatment. A strong response to 
acute galantamine challenge may reflect (nicotinic) receptor sensitization under normal 
or hypocholinergic circumstances, as it may occur in mild cognitive impairment or 
Alzheimer’s disease. In contrast, decreased levels of brain activation when compared 
to baseline may represent (muscarinic) receptor desensitization due to prolonged 
exposure to galantamine (Volkow et al., 2001; Quick & Lester, 2002). Similar effects 
of receptor (de)sensitization have been suggested to underlie differential responses in 
smokers versus non-smokers (Ernst et al., 2001), and the modest effects of long-term 
treatment with cholinesterase inhibitors (Geerts et al., 2002). This mechanism seems 
to fit most of our results, including our previous findings in Alzheimer patients during 
face encoding, where effects were observed after acute intake, but not after prolonged 
intake (Goekoop et al., 2005b). However, it does not fit our previous findings in patients 
with mild cognitive impairment during encoding, where effects were only observed after 
prolonged exposure (Goekoop et al., 2004). The origin of this ‘signal deviance’ in mild 
cognitive impairment remains unknown, but can be explained by the actions of several 
factors. Patients with mild cognitive impairment responded selectively to prolonged 
exposure (encoding) and to acute galantamine challenge (recognition). A difference in 
plasma concentrations between acute and prolonged regime types is therefore unlikely 
to fully explain the observed differences (see also materials and methods), since such 
a factor is likely to exert a comparable influence on brain function during encoding and 
recognition. Since patients with mild cognitive impairment responded both to prolonged 
and acute exposure to galantamine challenge, a disease-specific factor (e.g. the 
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absence of cholinergic receptor sensitization in mild cognitive impairment) is not likely 
to give a complete account of these signal changes. Since data-analyses were identical 
for both patient groups, a combination of disease-specific (MCI versus Alzheimer’s 
disease) and process-specific (encoding versus retrieval) factors seems to offer the 
best explanation for signal reactivity in the mild cognitive impairment group with respect 
to different exposure durations.
Other studies have shown increases in brain activation after weeks of treatment 
with different memory tasks and cholinomimetic substances in healthy controls or 
patients (Rombouts et al., 2002; Thiel, 2003; Parry et al., 2003; Saykin et al., 2004; 
Bentley et al., 2004). Since effects of cholinergic therapy may take 6–12 weeks to 
reach their maximum (Scarpini et al., 2003), short term effects of cholinergic treatment 
may represent a transitory state between immediate effects and therapeutic effects 
of a pharmacological substance, be process-specific, compound-specific, disease- 
specific, or may involve some other phenomenon. Future phMRI studies may require 
to investigate more memory tasks, pharmacological substances and timepoints after 
treatment in order to solve these issues.
Mild cognitive impairment and Alzheimer’s disease: differences in cholinergic 
system reactivity
When compared statistically, patients with mild cognitive impairment and Alzheimer’s 
disease differed significantly with respect to their reactivity to cholinergic challenge 
(Figure 4, Table 6). Left hippocampal activation was significantly more enhanced in 
Alzheimer patients than in patients with mild cognitive impairment (Figure 4B, Table 
6B), whereas left anterior and posterior temporal activation was more enhanced in 
patients with mild cognitive impairment than in Alzheimer patients (Figure 4A, Table 
6A). Plots of percent signal change showed unique profiles of cholinergic reactivity in 
both patient groups for a number of brain areas (Figure 4). Overall, these comparisons 
show that mild cognitive impairment and mild-to-moderate Alzheimer patients respond 
uniquely to cholinergic challenge, suggesting that cholinergic system function is 
differentially affected in earlier and later stages of Alzheimer’s disease. This is in line 
with previous findings from post-mortem studies, showing characteristic cholinergic 
changes in mild cognitive impairment and Alzheimer patients at the molecular level 
(DeKosky et al., 2002). The current study shows that such neurochemical alterations 
may eventually affect brain function in living subjects. No significant difference was 
found in posterior cingulate reactivity to cholinergic challenge between mild cognitive 
impairment and Alzheimer patients. This may reflect a lack of power, but may also 
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point to comparable reactivity between both patient groups (i.e. because of smaller 
group size, posterior cingulate reactivity to galantamine challenge may have remained 
sub-threshold in Alzheimer patients). If a cholinergic component is indeed relevant 
to hippocampal and posterior cingulate hypofunction, comparable reactivity of 
posterior cingulate structures to cholinergic challenge would fit previous findings of 
comparable rates of hypometabolism in posterior cingulate structures in mild cognitive 
impairment and Alzheimer patients (Nestor et al., 2003). In contrast, the differential 
response in hippocampal areas may reflect more severe cholinergic system impairment 
in later stages of Alzheimer’s disease, which is not yet present in patients with mild 
cognitive impairment. Since no differential response was found between mild cognitive 
impairment and Alzheimer patients on measures of task performance (Table 3), the 
relationship of the observed effects of treatment with changes at a behavioral level are 
unclear from the current study. This may reflect small sample size and short exposure 
durations rather than a true absence of such effects, since galantamine treatment has 
a well-documented effect on memory retrieval (Raskind & Truyen, 2002). Additionally, a 
trend was found for significant increases in recognition accuracy of galantamine intake 
across subjects (p = 0.08), suggesting that galantamine intake did have an effect on 
recognition accuracy in the current study.
Cholinergic system reactivity: possible clinical relevance
A differential response to cholinergic challenge in patients with mild cognitive impairment 
and Alzheimer’s disease may be clinically relevant. Previous phMRI studies have shown 
that both brain activation at baseline and initial effects of pharmacological treatment 
may successfully predict long-term treatment response and clinical outcome in patients 
with major depression (Davidson et al., 2003; Fu et al., 2004). Similarly, differences 
in cholinergic system reactivity as observed in the current study may to some degree 
reflect the clinical status of patients with memory complaints (Goekoop et al., 2004). 
Interestingly, recent results from clinical trials show that mild cognitive impairment and 
Alzheimer patients respond differentially to long-term treatment with cholinesterase 
inhibitors. Treatment with a number of different cholinergic agonists improves memory 
performance in Alzheimer patients (Lanctot et al., 2003), but seems to have only limited 
effects in patients with mild cognitive impairment (Ihl, 2003; Salloway et al., 2004). 
Such differences in treatment response may reflect underlying differences in the 
functional status of the cholinergic system as suggested by the current study. Follow-
up of mild cognitive impairment and Alzheimer patients should provide a measure of 
disease progression, which may be correlated with the observed effects of galantamine 
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challenge on brain function in order to examine the predictive value of these effects in 
terms of disease outcome and response to treatment. phMRI may prove to be a valuable 
tool in clinical studies, since it offers non-invasive assessment of neurotransmitter 
deficits, and provides additional information concerning effects at system level that may 
not be found with any other technique (Sarter et al., 1996). However, the eventual 
clinical significance of phMRI studies depends strongly on the outcome of within-
subject test-retest reliability studies (Saykin et al., 2004). Although treatment strategies 
can be reconsidered based on results produced at group level, much will depend on 
the ability of clinicians to demonstrate incipient neurotransmitter system dysfunction in 
individual patients.
General considerations
With respect to underlying neural processes, effects of pharmacological challenge as 
measured by fMRI should be interpreted with some caution. fMRI examines changes in 
blood oxygenation level dependent (BOLD) signal intensity, which is an indirect measure 
of neural activity (Matthews & Jezzard, 2004). BOLD signal changes represent changes 
in blood flow, volume and oxygenation as a result of metabolic changes, which are 
secondary to changes in neural activity. Such effects may reflect changes in both neural 
excitation and inhibition (Matthews & Jezzard, 2004). Future studies may therefore 
want to combine electrophysiological techniques (such as EEG) with phMRI in order 
to assess the nature of neural changes underlying the BOLD response. An important 
additional consideration for all phMRI studies is that pharmacological intervention, 
including cholinergic stimulation (Tsukada et al., 2000), may affect vascular tissue as 
well as neural tissue (Honey & Bullmore, 2004). However, such objections are likely 
to be less of an obstacle to clinical studies than to fundamental studies of cholinergic 
system function, since reactivity of both vascular and neural tissues to cholinergic 
challenge may contain information regarding the functional status of the cholinergic 
system in disease.
The current study had some limitations. Differences in cholinergic system function 
between patients with mild cognitive impairment and Alzheimer’s disease were examined 
in a cross-sectional manner. Although time-consuming, future phMRI studies may require 
to examine the development of a cholinergic deficit in time by using longitudinal study 
designs. Comparisons between patient groups in the current study may have suffered 
from bias introduced by group differences in sex and education level (Table 1). Although 
little is known about the effects of gender on brain function, recent studies show that 
such effects may be significant (Cahill, 2003; Lee et al., 2002). Future phMRI studies 
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may therefore require to balance male-female ratios to avoid effects of this possible 
confounder. Additionally, this study was not placebo controlled. Placebo effects may 
therefore have confounded some of the effects of treatment reported in both groups 
separately, although no effects were found at a behavioral level. If present, however, 
placebo effects are likely to have cancelled out in between-group comparisons.
Conclusions
Galantamine challenge affected brain function in posterior cingulate (mild cognitive 
impairment) and hippocampal areas (Alzheimer’s disease), suggesting a key role of 
the cholinergic system in the functional processes that lead to Alzheimer’s disease. A 
differential response to cholinergic challenge was found in mild cognitive impairment 
and Alzheimer patients, suggesting a difference in the functional status of the cholinergic 
system in earlier and later stages of disease. phMRI challenge tests may prove to be a 
valuable instrument to examine the functional status of central neurotransmitter systems 
in disease. Such studies may help to assess neurotransmitter system pathology, monitor 
disease progression, and predict response to pharmacological therapy. In addition, 
phMRI may be used to develop new drugs that target specific aspects of mental 
performance, such as encoding and retrieval processes.
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Chapter 5
General discussion
It is still early days for pharmacological functional magnetic resonance imaging (phMRI), 
but progress is being made with rapid paces. The following sections will discuss the 
empirical chapters of this thesis (Chapters 2-4) within the global context of the clinical 
applicability of phMRI.
5.1  Chapter 2: effects of beta-adrenergic blockade on 
 amygdala function in healthy young subjects
This study aimed to link previous findings of neurotransmission in animals and brain 
function in humans by examining the effects of propranolol intake on amygdala function 
in healthy human subjects. Modulation of amygdala function by means of beta-
adrenergic blockade would demonstrate the dependency of this brain structure on intact 
noradrenergic neurotransmission. More specifically, we hypothesised that propranolol 
intake would decrease amygdala activation during emotional performance as compared 
to placebo.
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Main effects of task performance: emotional encoding
Main effects of task performance in this study showed increasing amygdala activation 
with increasing emotional intensity of the stimuli (i.e. category 1–4 pictures). Signal 
intensity within both amygdala showed a non-linear response (Chapter 2, Figure 5). 
This finding contradicts that of another study, which found a linear increase in signal 
intensity of the amygdala with increasing emotional intensity of presented stimuli (Canli 
et al., 2000). The degree of linearity of the observed response of the amygdala to stimuli 
of increasing emotional intensity was examined by fitting a straight line and a curvilinear 
response through the observed pattern of signal increase. The curvilinear response 
produced a better fit, as judged by its corresponding Z scores, but the linear response 
also significantly explained the observed signal intensity changes (Chapter 2, Figure 6). 
This is not surprising, given the fact that a linear response is a reasonable estimation 
of the curvilinear response used in this analysis. Several reasons are given for the non-
linear response observed in this study, which deserve additional comment.
First, the fact that subjects rated fewer images as category 4 or 3 when compared 
to the number of images rated as category 1 or 2 (Chapter 2, Figure 2) may have 
produced differences in statistical power for estimating corresponding signal intensity 
changes. Within certain limits, however, a lack of statistical power may alter the variance 
of the observed effect size, but not the intensity itself. It should also be noted that the 
number hits for each emotional category decreased linearly with increasing emotional 
intensity in both males and females (Chapter 2, Figure 2). If the number of items analysed 
would indeed affect signal intensity within the amygdala, it may have produced linear 
rather than non-linear effects. Thus, it seems unlikely that a difference in the number of 
items analysed for each condition fully explains the non-linear pattern of brain function 
observed with increasing emotional intensity.
Second, the non-linear relationship may reflect an inverted-U shape, which has 
been observed previously in studies examining dose-response relationships between 
adrenoceptor agonist concentration (drugs) and task performance in rats (Honey 
& Bullmore, 2004). This seems unlikely, however, given the fact that these studies 
concerned drug effects on behaviour. Such effects do not serve well as a means to 
explain normal physiological signal response of human amygdala to stimuli of increasing 
emotional intensity.
Thirdly, the BOLD response may show non-linear tendencies with increasing 
presentation rate, which may be attributed to hemodynamic refractoriness (Mechelli 
et al., 2001). Though this is true, presentation rate is likely to have an equally limiting 
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effect on signal amplitude for all categories of emotional intensity, and not just category 
4. A combination of high presentation rate and emotional intensity may, however, have 
produced hemodynamic refractoriness specifically for category 4 items.
There is no need, however, to attribute the observed non-linear phenomena 
strictly to vascular effects (such as hemodynamic refractoriness). At any level of neural 
organisation, the neural response to an increase in stimulus intensity is characterised 
by a sigmoid shape, which indicates the degree to which continuous waves of electric 
dendritic potential are converted into axonal pulses (Freeman, 2000). The BOLD 
response within the amygdala may therefore show a sigmoid-shaped response to stimuli 
of increasing emotional intensity for strictly neural reasons. When observing signal 
intensity changes with increasing emotional intensity within the placebo group (Chapter 
2, Figure 5), a sigmoid-shape seems plausible. However, it is difficult to infer such a 
shape from a graph that has only four datapoints (i.e. emotional categories). Future 
research should therefore combine fMRI and EEG analyses in animals (and humans) 
to examine the impact of a range of emotionally distressing stimuli on the functional 
response of the amygdala.
Perhaps the most plausible explanation is one that accounts for the fact that 
subjective emotional ratings were used to classify pictures into 4 categories. This 
approach is likely to provide a more direct relationship between the actual emotional 
rating of subjects and their corresponding amygdala activation (Phan et al., 2003). 
However, it creates the possibility that subjects find items from different IAPS categories 
to be of similar emotional value (personally, I had difficulty separating IAPS category 
3 and 4, or 1 and 2 items at times). If the differences that exist between the average 
emotional intensity of pictures that have been assigned to different subjective categories 
are small, a linear relationship between emotional intensity and stimulus category is 
lost. If subjective ratings indeed correspond strongly with amygdala activation, this 
may explain the ‘non-linear’ response of the amygdala to stimuli of increasing emotional 
intensity as observed in our study.
Treatment effects and performance changes
Propranolol intake disrupted the non-linear response to pictures of increasing emotional 
intensity as observed under placebo conditions. A significant decrease in amygdala 
function occurred for category 3 > 1 pictures only. The reasons for this isolated signal 
response are unclear, but several explanations are possible.
First, the response to beta-blockade may reflect an ‘inverted-U shape’ of efficacy. 
Such shapes are observed regularly in neuropharmacological studies examining dose-
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response relationships in animals and humans (Honey & Bullmore, 2004). Both high 
and low doses of a pharmacological substance fail to produce an effect, and maximum 
efficacy is observed for intermediate concentrations, yielding the inverted U. In our 
study, the concentration of propranolol was kept at a single value whereas emotional 
intensity was varied. If higher levels of amygdala activity indeed relate to higher levels 
of beta-adrenergic neurotransmission, a single dose of 80 mg of propranolol may have 
been insufficient to block beta-adrenergic neurotransmission related to the processing 
of images of the highest emotional category. Additionally, propranolol concentrations of 
80 mg may have disrupted normal neurophysiology during exposure to category 1 and 
2 pictures, leading to non-significant changes in signal intensity.
As an alternative, it is possible that adrenergic neurotransmission is only important 
to amygdala function from a certain threshold of emotional intensity onward. Propranolol 
may therefore only affect amygdala function above a certain threshold of amygdala activity 
(i.e. category 2 and up). Such ‘delayed’ effects, however, cannot explain equal amounts 
of brain function for category 4 items under propranolol and placebo conditions. If 
such a threshold exists, a combination with the above suggestion of a dose-response 
relationship would seem to be more likely.
With respect to performance, propranolol intake impaired recognition accuracy 
in women at least until two weeks after drug challenge and encoding of the presented 
pictures. Changes in recognition accuracy as a result of propranolol resembled those 
of signal intensity changes within the amygdala (Chapter 2, Figures 5 and 7), but this 
relationship was not tested directly. In can be concluded, however, that propranolol 
intake decreased memory performance in a way that is likely to have involved decreases 
in amygdala activation.
Decreased amygdala activation: direct or indirect relations with impaired 
noradrenergic neurotransmission?
Decreased amygdala activation as observed in our study may involve direct as 
well as indirect effects of changes in noradrenergic neurotransmission. Since all 
neurotransmitter systems interact at some level (Gu, 2002; Jones, 2003), it is difficult 
to link the observed effects directly to a decrease in noradrenergic neurotransmission. 
As predicted, however, propranolol decreased amygdala activation, whereas increased 
amygdala activation was not observed. This may be additional support for a more 
direct relationship between amygdala function and noradrenergic neurotransmission in 
humans. Future studies may require to measure adrenergic activity in human subjects 
directly using molecular imaging techniques such as PET.
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Gender-specificity of propranolol: amygdala function and performance 
accuracy
Studies have shown that brain function and pharmacological effects on brain function 
may differ between the sexes. Knowledge of such differences may be relevant in terms 
of optimising the design, development and dosing of drugs with respect to a patient’s 
gender (Cahill, 2003). Gender-specificity was therefore examined with respect to main 
effects of task performance (lateralisation of amygdala function), the response of the 
amygdala to propranolol intake, and (propranolol-induced changes in) recognition 
accuracy scores.
Under placebo conditions, women showed significantly more left amygdala function 
in (Category 3 > 1) than men, supporting findings from previous studies suggesting 
a gender-specific lateralisation of amygdala function (Cahill, 2003). Previous studies 
have shown gender-specific effects of propranolol on recognition memory performance 
(Maheu et al., 2004; Strange et al., 2003). In our study, propranolol intake did not affect 
memory scores in males, but decreased recognition accuracy for category 3 pictures in 
females, which seemed to mimic the drop in left amygdala activation for these pictures 
observed in this group. This may indicate a gender-specific effect of propranolol intake 
on memory performance. However, since none of these effects were tested statistically, 
it remains unclear whether gender influenced any of these parameters in a significant 
way.
Gender-specific effects of propranolol intake may reflect the action of a number 
of confounds, including gender differences in the activity of the HPA-axis. Additionally, 
the pharmacokinetics and -dynamics of propranolol may differ between the sexes. 
Such factors may potentate beta-blocker activity in women, which may explain previous 
findings of decreased memory performance after propranolol intake in women, but not 
in men. Future studies may require to use more objective measures of drug action (e.g. 
plasma concentrations) to control for these possible confounds.
Possible clinical relevance 
A consistent finding in studies of emotional memory performance is that emotional 
ratings are independent of the effects of beta blockade (Maheu et al., 2004). Beta-
adrenergic blockade may therefore be used to pharmacologically dissociate specific 
mental processes (e.g. ‘emotional’ and ‘cognitive’ processes). Pharmacological imaging 
studies using propranolol may thus be useful in terms of isolating and localising the 
primary pathological deficit in diseases that are characterised by aberrant function of 
several subcomponent processes (e.g. ‘emotional’ and ‘cognitive’ processes), such 
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as obsessive compulsive disorder (OCD), post traumatic stress disorder (PTSD), or 
major depression. Additionally, the contribution of adrenergic neurotransmission to 
neural function within brain structures supporting psychopathology or personality traits 
can be examined. Such studies may increase our understanding of the dependence 
of various brain areas that constitute axis I (psychopathology) and axis II (personality) 
disorders on specific neurotransmitter systems, which may aid in the development 
of a hypothesis-driven pharmacotherapy for these conditions. Finally, centrally acting 
beta-blockers may be effective in the prevention of psychotrauma. Studies have shown 
that the administration of a single dose of propranolol in subjects at increased risk of 
developing PTSD significantly lowers the chance of negative conditioning at the time of 
a traumatic experience, thereby preventing the development of PTSD (LeDoux, 1998). 
Functional neuroimaging studies of amygdala function may help to identify subjects at 
increased risk of developing PTSD, after which adequate preventive measures can be 
taken.
Conclusion
Propranolol significantly interfered with normal amygdala function in healthy human 
controls. This supports the hypothesis that amygdala function is dependent (either 
directly or indirectly) on noradrenergic neurotransmission. Women (but not men) showed 
a significant decrease in memory performance after propranolol intake (category 3 
items). This may be related to a differential effect of propranolol on amygdala function in 
both sexes. Further studies are necessary to examine the clinical significance of (gender-
specific) effects of beta-adrenergic blockade on brain function in human subjects.
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5.2.  Chapter 3: effects of raloxifene treatment on brain 
 function in healthy elderly males 
The effects of three months of treatment with the selective estrogen receptor modulator 
(SERM) raloxifene were examined on brain function during memory task performance 
in healthy elderly males. This was done to examine the susceptibility of male subjects 
to raloxifene treatment (which may encourage further research into effects of SERMs 
in males) and to examine the treatment mechanism of raloxifene (which may eventually 
contribute to the design and development of new SERMs with less side effects). Two 
studies were performed. Chapter 3.1 describes a study of the effects of raloxifene 
treatment on brain function during encoding of unfamiliar information (faces) into 
memory. Chapter 3.2 describes a similar study examining effects of raloxifene treatment 
on brain function during recognition.
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Main effects of face encoding and –recognition
Main effects of face encoding and –recognition were similar to those observed previously 
using comparable tasks in healthy controls, elderly subjects and patients (Rugg et al., 
2002; Small et al., 1999).
Treatment effects and performance changes
Raloxifene intake affected brain function and performance accuracy, suggesting that 
raloxifene affects mental function in elderly women as well as in males. Future studies 
may therefore want to examine the ability of raloxifene treatment to prevent the onset of 
MCI and AD in males.
Process-specificity of raloxifene
Raloxifene intake produced substantially more treatment effects during face encoding 
than during recognition. A separate analysis showed that treatment effect during face 
encoding were significantly stronger than effects during face recognition, but not vice 
versa (Z > 3.1; data not published), suggesting that its effects on brain function are 
process-specific. Since face encoding data were analysed using a block design and 
recognition data using event-related analyses, such process-specificity may involve 
both encoding versus retrieval processes, and tonic (trait) versus phasic (state) modes 
of neural processing (Duzel et al., 1999; Otten et al., 2002). Future studies should 
therefore aim to maximise similarity between analysis methods in order to examine 
process-specificity of pharmacological substances more specifically with respect to 
different memory domains.
Possible treatment mechanism of raloxifene
phMRI may provide information on treatment mechanisms in several ways. First, the 
spatial configuration of treatment effects may suggest a certain mechanism. Generalised 
and symmetric versus localised and asymmetric effects may indicate effects on arousal 
processes rather than the alteration of specific sub-functions of mental performance. 
Anterior versus posterior effects suggests effects on cognition rather than perception. 
Cortical versus subcortical processes suggests effects on conscious or sensory versus 
unconscious or motor processes, whereas left versus right effects may indicate a 
preference for symbolic rather than visuospatial effects. Such interpretations, however, 
are rather coarse and are not sufficient proof of a particular treatment mechanism (e.g. 
globalised enhancement may reflect vascular as well an neurogenic effects).
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The specificity of phMRI with respect to the behavioural significance of treatment 
effects can be enhanced by making fMRI paradigms and their corresponding contrasts 
‘inherently process-specific’, i.e. the contrast between two conditions has behavioural 
significance of its own. Such contrasts may, for instance, involve ‘tight’ comparisons 
between TP and TN items, which yield information on brain areas involved in processes 
involving successful retrieval or encoding-with-retrieval-attempt (Buckner, 1998; 
Daselaar et al., 2003). Additionally, the behavioural significance of treatment effects 
can be assessed directly through correlations with behavioural measures (3.1). This 
option may be especially suited to enhance the behavioural significance of treatment 
effects on brain function examined by ‘loose’ comparisons between task conditions (i.e. 
conditions of interest (e.g. ‘face encoding’) versus low-level reference conditions (e.g. 
point fixation), which presumably examine more general aspects of mental processes 
that are not very specific). An interesting approach to examining treatment mechanisms is 
the study of direct statistical relationships between signal intensities of treatment effects 
that occur in different functional domains, such as encoding and retrieval processes 
(e.g. between-task connectivity analyses). Since encoding necessarily precedes 
recognition of familiar information, a significant correlation between signal intensities of 
treatment effects during encoding and recognition of familiar (TP) items may indicate 
the existence of a causal relationship between the two (i.e. effects during encoding 
predict those during recognition). Such studies can examine correlations between 
signal intensities of treatment effects within different regions of interest, but can equally 
well be performed in a voxelwise manner. Additionally, cross-modality comparisons 
(e.g. fMRI-EEG/MEG-PET) may help to relate treatment effects as detected by phMRI 
to complementary physiological measures at different levels of neural organisation, 
thus providing a more detailed picture of treatment mechanisms of pharmacological 
substances. Finally, physiological variance in plasma levels of hormones involving 
the hypothalamus-gonadal axis (including estrogen and testosterone) may affect 
BOLD signal reactivity to raloxifene treatment, and act as confounders in analyses of 
treatment effects and –mechanisms. Thus, future phMRI studies may require objective 
measurement of plasma levels of relevant neurochemical and hematological parameters 
and drug concentrations, which can be added as additional regressors in analyses of 
changes in BOLD signal intensity.
Both fundamental studies of treatment mechanisms and clinical studies of 
functional biomarkers depend on the ability to make reliable functional-behavioural 
associations. Although the size of our study group was large to fMRI standards, it 
was too small to perform elaborate correlations of treatment effects with behavioural 
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traits or changes. Future phMRI studies examining functional-behavioural relations 
should therefore involve group sizes that parallel those usually reported in conventional 
behavioural studies (e.g. n > 60).
Our studies have shown that the effects of pharmacological treatment on brain 
function do not necessarily have to be simple. Neurofunctionally, the treatment mechanism 
of raloxifene may involve an increase in signal-to-noise levels (i.e. increased global 
arousal) during initial encoding. This leads to an enhancement of attention and working 
memory performance, which causes downstream effects on posterior hippocampal and 
prefrontal brain function during consolidation and / or delayed retrieval of information. 
Behaviourally, such effects may improve the ability of subjects to discriminate between 
similar stimuli in ambiguous situations (i.e. subjects are less distracted), thus leading to 
increased recognition memory performance. The extent to which the functional effects of 
raloxifene treatment relate to the neuroprotective effects of estrogens (which is thought 
to involve relatively slow metabotropic changes and alterations in hippocampal spine 
formation (Wise et al., 2005)), or immediate effects of raloxifene treatment on brain 
function, remains unclear from the present data. The ability of raloxifene to prevent the 
onset of mild cognitive impairment in elderly women, however, may partly involve such 
neuroprotective qualities (Yaffe et al., 2005). Future studies may require a combination 
of molecular imaging studies and phMRI in order to examine the treatment mechanism 
of pharmacological substances such as raloxifene in more detail.
Possible clinical relevance
phMRI studies of SERM treatment may be used to examine whether substances of 
unknown psychotropic potential affect brain function in humans. The mechanism of 
action of such substances can be examined, and the predictive power of BOLD signal 
intensity changes with respect to clinical and behavioural measures can be assessed.
Conclusion
Raloxifene treatment for three months affected brain function and memory performance 
in elderly males, encouraging further studies into its effects on brain function and mental 
performance. Future studies may require to examine whether raloxifene treatment can 
prevent the onset of MCI and AD in elderly males. Studies of the treatment mechanism 
of raloxifene may help to improve the design and assessment of novel SERMs with 
increased efficacy and less side effects. If it is proven that SERM treatment can 
successfully prevent cognitive decline in males, phMRI of SERM treatment may identify 
brain areas in which functional or molecular changes may predict long-term clinical 
outcome and/or response to SERM therapy.
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5.3 Chapter 4: effects of galantamine challenge on brain 
 function in MCI and AD patients 
Studies presented in Chapter 3 form the main body of this thesis. They examined the 
ability of fMRI to identify brain areas that respond significantly to cholinergic stimulation 
with the cholinesterase inhibitor galantamine in patients with mild cognitive impairment 
(MCI) and Alzheimer’s disease (AD), while they were engaged in memory task 
performance.
Studies reported in Chapter 4.1 (MCI patients) and 4.2 (AD patients) were similar in 
design and rationale (i.e. to study the functional status of the cholinergic system in 
disease). In Chapter 4.1, the feasibility of detecting cholinergic system reactivity was 
explored within the general context of disease-predictability in MCI. In Chapter 4.2, 
effects of galantamine challenge were examined on BOLD signal amplitude across a 
broader range of timepoints than is usual in most model-based fMRI analyses. Such 
explorations may increase chances of finding markers of cholinergic system function 
and disease status in AD patients. Chapter 4.3 examined MCI and AD patients for 
a differential response to galantamine challenge during face recognition. Such a 
differential response may indicate the presence of a difference in the functional status 
of the cholinergic system in MCI and AD patients, which may have consequences for 
subsequent research into diagnostic and treatment strategies.
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Main effects of face encoding, –recognition and working memory 
performance
Functional effects of task performance were similar to those observed previously using 
comparable tasks in healthy controls and elderly patients (Braver et al., 1997; Owen 
et al., 2005; Rugg et al., 2002; Small et al., 2000). For a comparison of brain function 
during face encoding between healthy controls, MCI and AD patients, see (Rombouts 
et al., 2005b). Main effects during performance on all tests were less intense in AD 
patients than in healthy controls or MCI patients. This may reflect the combined effects of 
several factors, including increased hemodynamic and anatomic variance and movement 
artefacts in AD patients when compared to controls or MCI patients. Additionally, AD 
patients had lower task accuracy scores, which may reflect increased distraction, 
disorientation, and overall memory performance. Although such factors may hamper 
detection of significant treatment effects, it is unclear whether they also influence the 
region-, process- and disease-specificity of pharmacological substances.
Treatment effects and performance changes
Galantamine challenge affected brain function and performance accuracy, suggesting 
that even ultra-short durations of galantamine intake may affect brain function and 
behaviour to a degree that allows studies of the clinical significance of these effects.
Process-specificity of galantamine
In both MCI and AD patients, treatment effects during face encoding and working memory 
performance were small and of low magnitude. Effects of galantamine challenge during 
recognition were substantially larger in both patient groups. This suggests that the 
effects of galantamine on brain function are process-specific. Process-specificity was 
not tested statistically, however, since several dissimilarities in task design prevented us 
from making informative comparisons of treatment effects across encoding, recognition 
and working memory domains (Chapters 4.2, 4.3). Face- encoding, -recognition, and 
n-letter back working memory tasks were chosen because of their proven effectiveness 
and reliability in eliciting activation patterns. If possible, however, future studies may 
require to maximise symmetry of design between memory tasks in order to facilitate 
studies of the process-specificity of pharmacological substances with respect to 
different memory domains.
Although process-specificity of galantamine challenge was not examined 
statistically for encoding, working memory and retrieval phases, we were able to study 
process-specificity with respect to encoding and retrieval by examining brain function 
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during retrieval alone (Chapters 3.2, 4.3). Treatment effects during retrieval clustered 
into (MCI – successful retrieval – posterior cingulate), and (AD – encoding-during-
retrieval – hippocampus) associations. Significant differences were found between 
MCI and AD patients within the left hippocampal area. This showed that the reactivity of 
MCI and AD patients to cholinergic challenge was both region- process- and disease-
specific.
Region-specificity of galantamine
Previous studies have shown similar clusters of region- process- and disease-specific 
areas of hypometabolism in MCI and AD patients. The exact nature of this factor remains 
unknown, and could not be further deduced from our studies. Region-specific effects 
of cholinergic challenge may involve effects of receptor sensitisation as well as a partial 
restoring of impaired cholinergic system function. Our findings suggest that a cholinergic 
factor may be important to regional hypometabolism in MCI and AD patients.
Disease-(stage)-specificity of galantamine
The effects of galantamine challenge on brain function during encoding and working 
memory performance were small. Even though visual inspection suggested a difference, 
treatment effects during face encoding and working memory performance were not 
significantly different in MCI and AD patients. Treatment effects during face recognition, 
however, differed significantly between MCI and AD patients. This suggests a difference 
in the functional status of the cholinergic system between different stages of AD, which 
becomes especially manifest during certain mental processes (i.e. retrieval). So far, a 
differential contribution of cholinergic system dysfunction to disease symptomatology 
in AD has been mainly deduced from post-mortem examinations and pharmacological 
models of cholinergic depletion in healthy controls (DeKosky et al., 2002; Mesulam, 
2004). Additionally, a difference in cholinergic system function between early and later 
stages of AD is suggested by recent studies, showing that MCI patients consistently 
show less clinical improvement than AD patients after cholinergic therapy (Ihl, 2003; 
Salloway et al., 2004). Our study confirms the existence of a difference in the functional 
status of the cholinergic system between living MCI and AD patients, and provides the 
location of (some of the) physiological correlates of these differences. Such functional 
effects may serve as biomarkers that relay information concerning the functional status 
of the cholinergic system at various developmental stages of AD. Future studies may 
therefore require further analysis of the clinical significance of the observed effects of 
treatment.
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Dependence on exposure duration
Only immediate effects of galantamine exposure were examined (i.e. single dose and 
five days of exposure). Since effects of cholinergic treatment usually take 4-12 weeks 
to reach their maximum (Scarpini et al., 2003), studies of the immediate effects of 
cholinergic agents are likely to give an incomplete account of therapeutic mechanisms. 
However, it is possible that such effects already bear some information concerning 
cholinergic system function (Davidson et al., 2003; Fu et al., 2004). The presented 
studies therefore qualify as pharmacological provocation (or ‘challenge’) tests. Such 
studies are centred on the general notion that biological systems respond differently 
to external pharmacological influences when they are compromised (Hatzinger, 2000; 
Gijsman et al., 2004). 
A single oral dose of galantamine already produced region- process- and 
disease-specific effects on brain function in elderly patients. This encourages further 
studies of pharmacological challenge tests in a clinical setting, since such tests are 
most valuable if maximum amounts of clinical information can be obtained in minimal 
amounts of time. Treatment effects differed significantly between acute and prolonged 
exposure, indicating that the effects of galantamine on brain function are dependent 
on exposure duration and are likely to develop in time. The responsivity of MCI and AD 
patients to acute and prolonged exposure durations across different memory tasks is 
difficult to integrate into a coherent whole. A significant part of the observed effects 
may be explained by effects of receptor sensitisation and –desensitisation, within the 
context of impaired cholinergic system function. The differential effects of acute and 
prolonged cholinergic challenge, however, may themselves be region- process- and 
disease-specific. Future studies may require to combine phMRI and molecular imaging 
studies (e.g. PET studies examining cholinergic receptor status, second messenger 
pathways and the structural integrity of cholinergic neurons) in order to link cholinergic 
receptor status more firmly to cholinergic system function.
Possible treatment mechanism of galantamine
Given the ultra-short exposure durations, it may not be appropriate to refer to the observed 
effects as “treatment” effects. Rather, they may represent transient neurofunctional and 
behavioural changes that precede the development of more stable effects that eventually 
lead to an improvement of memory performance. Given the fact that functional effects 
of galantamine challenge during retrieval are disease-specific, it may not be possible 
to find a fixed mechanism of action that applies to all patients and disease stages. 
Rather, galantamine may have global effects, which may be similar in both MCI and AD 
patients.
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Although an impressive amount of studies have been published that concern the 
cholinergic system in some way, its function is still unclear. In a recent review, Sarter 
et al. attempted to integrate existing knowledge of cholinergic system function into 
a coherent picture (Sarter et al., 2005). In their view, both stimulus-related neural 
activity and cognitive activity can ‘recruit’ cortical attention systems via basal forebrain 
corticopetal cholinergic projections. Thus, detection of relevant signals can be enhanced 
in a top-down and bottom up fashion, both of which require cholinergic system function. 
As a general mechanism, enhanced cholinergic neurotransmission is said to increase 
signal-to-noise ratios, which facilitates detection of relevant (sensory and cognitive) 
stimuli (see also 5.2). The disruption of cholinergic system function, as observed in 
AD, decreases signal-to-noise levels, leading to decreased detection of relevant 
stimuli, decreased attention, and eventually low working memory and episodic memory 
performance. Increases of cholinergic system activity may increase neural activation 
in any brain area involved in information processing at some point in time. Decreased 
cholinergic system function may decrease brain function during task performance, as 
shown in experimental studies of cholinergic blockade. Increased brain function as a 
result of cholinergic stimulation may, in turn, decrease brain function in remote brain 
areas (e.g. (Furey et al., 2000)). It is therefore difficult to say whether the observed 
effects are directly or indirectly related with changes in cholinergic system function (see 
also 5.1). Apart from immediate effects on cortical arousal and attention, acetylcholine 
may have long-term effects on memory performance through modulation of NMDA-
dependent synaptic plasticity that requires protein synthesis and structural remodelling 
of synapses. A single straightforward effect of cholinergic neurotransmission on brain 
function therefore seems unlikely.
Since we used encoding and working memory tasks that were of limited inherent 
process-specificity (see 5.2), and treatment effects were of such a small magnitude 
as to discourage correlations with neuropsychological or task performance data, our 
ability to examine the mechanism of action of galantamine challenge was limited to 
studies of the location of the various treatment effects (see above, 5.2). Despite the 
limited value of such observations, the location of the observed effects seem to fit 
existing knowledge regarding the actions of the cholinergic system on brain function at 
a system level:
In MCI patients, increased activation in visual, hippocampal and prefrontal areas 
during encoding may reflect enhanced attention, working memory performance and 
face processing. In AD patients, BOLD shape changes as a result of galantamine 
challenge are compatible with an attention-based shift in emphasis to earlier stages of 
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neural processing, reflecting increased use of early selection processes (see 4.3). Both 
functional and behavioural data suggested an effect on working memory performance in 
MCI patients (4.1. 4.2, 4.3). This may reflect increased arousal levels and attention, which 
leads to a cascade of increased working memory and episodic memory performance 
as secondary effects (Sarter et al., 2005). Such effects were not found in AD patients, 
however, suggesting a lack of power (4.3).
When compared to encoding and working memory tasks, the recognition task 
was of greater inherent process-specificity (see above, 5.2). Indeed, the specificity 
of galantamine challenge for successful retrieval processes in MCI patients suggests 
that brain function during recognition was affected more or less independently from 
encoding. This seems to somewhat contradict the general conception of a cascade 
of neural events affecting arousal levels, working memory and episodic memory in a 
pseudoserial order (Chapter 4.1, 5.3.1). In AD patients, however, treatment effects mainly 
involved encoding processes (during attempted retrieval). Studies of direct statistical 
relations between treatment effects on different mental processes (i.e. between-task 
connectivity studies) may help to improve our insight into the mechanism of action of 
cholinesterase inhibitors in different stages of disease (Chapter 3.2).
Regardless of its specific actions in specific brain regions and during different 
stages of memory performance and disease, galantamine may improve brain function 
in general by increasing cholinergic signalling within and between brain areas. The 
differential responses of patients to different exposure durations further suggest 
that receptor sensitisation may be an important factor in the therapeutic efficacy of 
galantamine. First, an immediate response to galantamine enhances brain function in 
sensitised areas. Prolonged exposure (first weeks) then decreases activation in brain 
function, after which a stable therapeutic effect is reached at 6–8 weeks, which is 
likely to be characterised by different functional changes. Future studies may require 
to examine treatment effects across a number of different timepoints after treatment 
onset in order to study the evolution of a therapeutic mechanism of pharmacological 
substances.
Possible clinical relevance
Studies of process-specificity may be important to the design, development and 
clinical testing of new drugs that specifically target certain aspects of memory 
performance (e.g. encoding or retrieval processes), while leaving others unaffected. 
Such studies may help to maximise the efficacy and reduce unwanted side effects of 
pharmacological substances. Studies of region-specificity may improve our knowledge 
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of the pathophysiological mechanisms of AD, which may involve selective encoding 
and retrieval deficits that depend on the functional status of the cholinergic system. 
Studies of disease-specificity of cholinergic substances are interesting particularly 
from a perspective of disease predictability. By performing follow-up on patients that 
have received cholinergic stimulation early in disease (e.g., the MCI stadium), BOLD 
signal reactivity to pharmacological challenge may be compared between groups of 
converters and non-converters, or progressors and non-progressors (Fu et al., 2004). 
A significant difference between both groups may associate cholinergic system activity 
with disease progression or conversion. Additionally, the extent to which BOLD signal 
reactivity to pharmacological challenge can predict long-term response to cholinergic 
therapy in MCI or AD patients can be tested by comparing functional changes between 
groups of responders and non-responders (Mega et al., 2004). Apart from changes in 
BOLD signal amplitude at a fixed timepoint after stimulus onset, changes in the shape 
and latency of the BOLD response may be tested for their clinical relevance (Rombouts 
et al., 2005b). Studies of BOLD signal reactivity to pharmacological challenge may help 
to increase our understanding of the relative contribution of different neurotransmitter 
systems to signs, symptoms and treatment response in a number of different clinical 
conditions.
Conclusion
Ultra-short galantamine challenge affected BOLD signal reactivity in MCI and AD 
patients in a region-specific, process-specific, disease-specific and exposure duration-
dependent manner. These findings may be of indirect, yet important clinical value.
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5.4  Global summary
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phMRI allows studies of the impact of pharmacological substances on brain function at 
a high spatial resolution. Its full potential is still actively explored. So far, phMRI studies 
have mainly involved feasibility studies in animals and humans, and fundamental studies of 
the effects of pharmacological intervention on brain function. The current thesis explored 
the boundary of phMRI research where fundamental studies of pharmacological effects 
on brain function may gradually shift toward clinical applications. The following answers 
can be given with respect to the questions that were raised in the Introduction:
The effects of psychotropic drugs on brain function are small, but can be detected 
using fMRI (Chapters 2-4).
The results of our studies confirm previous findings that the effects of 
pharmacological compounds on BOLD signal response can be region- and 
process-specific (Honey & Bullmore, 2004) (Chapters 3, 4).
We have found evidence that the effects of psychotropic drugs on brain function 
are gender- and disease-specific (Chapters 2, 4). 
Treatment effects may depend on drug exposure duration (Chapter 4): in case of 
cholinergic stimulation, a single oral drug challenge may already produce region- 
proces- and disease-specific effects on brain function (Chapter 4).
We have devised a method to examine the mechanism of action / treatment 
mechanism of drugs on brain function with a high degree of detail (Chapter 3, 
4).
If large groups of patients are included, studies of the early differential diagnostic 
and predictive value of the observed effects are possible (Chapter 4).
The value of these findings for fundamental or clinical neuroscience depends strongly 
on the information content of the BOLD signal. The added value of fMRI over other 
non-invasive imaging techniques lies mainly in its high spatial resolution, reasonable 
temporal resolution and high flexibility of use (see introduction). Such features allow 
researchers to determine where in the brain certain processes occur. Additionally, fMRI 
connectivity studies allow studies of the temporal relationships between brain regions, 
which may solve questions as to where and when these processes occur. For several 
reasons, however, BOLD fMRI may not tell you what actually happens in the brain 
(Donaldson, 2004): BOLD signal changes represent complex interactions between 
neural, neuroglial and vascular factors. Though neural changes are strongly linked to 
changes in BOLD signal intensity, such contributions may include both changes in 
neuronal excitation and inhibition (Logothetis & Pfeuffer, 2004). The use of relative 
1.
2.
3.
4.
5.
6.
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measures of signal intensity changes in task-related fMRI studies further complicates 
interpretation of BOLD signal changes. Since neural processes are essentially non-
linear in nature, linear subtraction of average signal intensities associated with two 
distinct cognitive processes may not always provide a good indication of the degree 
of difference between two neural processes (Sartori & Umilta, 2000). Average signal 
intensity during performance under reference conditions may itself be affected by several 
factors, which may cause researchers to falsely attribute changes in signal intensity 
to conditions of interest (Stark & Squire, 2001). Model-based analyses make further 
assumptions about BOLD signal response (e.g. delay) that are not likely to be true under 
all circumstances (Petersson et al., 1999) (Chapter 4.2). Studies in (elderly) patients 
further complicate fMRI studies because of factors such as atrophy, hemodynamic 
variance and movement artefacts (D’Esposito et al., 2003). Effects of pharmacological 
modulation on BOLD signal intensity are particularly difficult to interpret, since 
pharmacological substances may interact with all factors that contribute to BOLD signal 
reactivity (e.g. neural, glial, vascular factors, age, sex, task performance measures and 
plasma kinetics of drugs) (Honey & Bullmore, 2004) (Chapter 2, 3, 4). Additionally, the 
temporal resolution of conventional BOLD fMRI is limited to a timescale of hundreds 
of milliseconds, which precludes analysis of a large number of neural processes that 
occur below this threshold (Menon et al., 1998). This multitude of interacting features 
that contribute to BOLD signal reactivity makes it impossible to determine the exact 
nature of the various processes underlying BOLD signal changes in phMRI studies. In 
order to provide a comprehensive picture of the effects of pharmacological substances 
on brain function, fMRI therefore needs to be combined with complementary techniques 
that provide additional information, such as molecular imaging techniques (PET) (Rudin 
& Weissleder, 2003), electrophysiological techniques (EEG/MEG) (Hamandi et al., 
2004), and neuropsychological examinations.
As a technique that provides spatial information, findings from phMRI studies 
may be interesting from a fundamental point of view. Studies of region- and process-
specificity of pharmacological substances may reveal the spatial organisation of 
individual brain structures (e.g. amygdala; chapter 2) or neural systems (e.g. encoding, 
recognition, or working memory systems; chapters 3,4) that functionally depend on 
particular neurochemical systems. Thus, our studies suggest that the amygdala 
functionally depend on the beta-adrenergic system during encoding of new information 
into memory (Chapter 2). Additionally, brain function in higher cortical regions seems to 
depend on estrogens during encoding rather than recognition of information (Chapter 
3). Finally, hippocampal and posterior cingulate regions depend on the (nicotinergic) 
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cholinergic system during recognition rather than encoding of novel information, with 
specific subcomponent processes during retrieval being selectively affected depending 
on particular disease stages (Chapter 4). Such findings are difficult to obtain with other 
techniques and may be of important heuristic value for future neuroscientific studies.
As a technique that studies spatiotemporal information, phMRI connectivity 
studies may show to which degree the interaction between spatially separated neural 
systems depends on specific neurotransmitter systems. Connectivity between neural 
systems may be examined within and between individuals with respect to a single 
functional domain (e.g. working memory), and between different functional domains 
(e.g. between-task connectivity studies). In the latter case, studies in which connectivity 
is examined between functional domains that are to some degree separated in time 
(i.e. encoding and delayed retrieval processes) may be of particular interest, since this 
provides a broader view of the time-scale on which pharmacological effects on brain 
function operate (delayed recognition may involve hours, days, or even years). Since 
retrieval of familiar information necessarily follows encoding of that information, between-
task connectivity studies may be used to examine the degree to which brain function at 
timepoint 1 (e.g. encoding, consolidation) causally relates to (predicts) brain function at 
timepoint 2 (e.g. retrieval of familiar information), and how these temporal relationships 
are altered by pharmacological intervention. By varying the treatment duration, and 
studying effects of drugs on brain function at different stages of neural development, 
the timescale of phMRI studies can be further increased. This may provide insight into 
long-term functional interactions that exist between neural systems and their associated 
neurotransmitter systems across periods of weeks, months or even years. Since these 
spatiotemporal relationships may differ with age, gender and disease, knowledge of the 
physiological differences in such relations between subjects may help to understand 
changes in neurotransmitter system function that occur during normal development and 
disease.
Findings from phMRI studies may also be relevant from a clinical point of view. 
phMRI may be used to study the treatment mechanism of pharmacological substances in 
patients in relation to disease-specific mental processes (Chapters 3, 5.2). Knowledge 
of the process-specificity and mechanism of action of psychotropic drugs may improve 
the design, development and clinical testing of new drugs that target some aspects of 
brain function while leaving others unaffected. This may help to maximise the efficacy 
and reduce unwanted side effects of these agents. Conversely, knowledge of the type of 
processes that are affected in disease may affect a clinician’s choice for pharmacological 
therapy with known specificity to these processes.
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Single dose phMRI challenge studies in patients may reveal region- process- and disease-
specific anomalies that may involve the spatial extent and temporal characteristics of the 
BOLD signal (in resting state studies), or the latency and shape of the BOLD response to 
task stimuli (in event-related or blocked studies). Such challenge studies may be a time-
efficient way of assessing the functional status of neurotransmitter systems in disease. 
The fact that BOLD signal changes may partly reflect vascular phenomena should 
not be a great obstacle to studies examining the clinical significance of BOLD signal 
changes, since reactivity of both vascular, glial and neural tissues to pharmacological 
challenge may contain information regarding the functional status of neurotransmitter 
systems in disease.
An important question however, is whether phMRI studies will be able to 
demonstrate clinically informative functional biomarkers in individual patients. To date, 
fMRI has played only a limited role in clinical practice because the combined effects 
of several factors (e.g. low signal-to-noise ratios, use of relative measures, varying 
reproducibility and sensitivity to motion artefacts) so far prevented detection of large 
amounts of robust, quantifiable and clinically meaningful information in single patients 
(Jezzard et al., 2001; Powell & Duncan, 2005). Most fMRI studies therefore report results 
of group analyses. Studies are currently underway that examine the ability of BOLD fMRI 
to demonstrate clinically meaningful markers in individual patients (Small et al., 2002). 
Meanwhile, group studies of treatment effects may already be of clinical relevance to 
individuals. As a heuristic tool, phMRI may be used to identify clinically relevant changes 
in specific brain areas at group level, the equivalents of which can be examined in 
individual patients using techniques that do have the sensitivity and specificity to detect 
neurofunctional events in single subjects (such as qEEG or molecular PET) (Fingelkurts 
et al., 2005; Moresco et al., 2001). Additionally, group level phMRI challenge tests may 
be used to associate disease-specific alterations in neurotransmitter system function with 
specific (profiles of) signs, symptoms and side effects. When recognised in individual 
patients, such clinical profiles may be treated more effectively using pharmacological 
agents that target the associated neurotransmitter systems.
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Future phMRI studies should involve randomised, double blind, placebo controlled cross-
over studies, in which effects of pharmacological intervention are compared between 
patients and control groups that have been extensively profiled using neuropsychological 
investigations and matched for a number of different confounders, including age, gender, 
intoxications, co-morbidity and brain atrophy. If tolerated by subjects and patients, future 
phMRI studies may include objective measurements of drug action (e.g. blood-tests 
or molecular PET before and after each scanning session), which can be entered as 
additional covariates in phMRI analyses of treatment effects. Since treatment effects 
are small, study groups should be large, e.g. > 60 subjects. Adequate knowledge of a 
chemical’s pharmacokinetics and –dynamics should be obtained. These characteristics 
define dosing and timing of drug intake relative to scanning sessions, which are highly 
relevant to the detection of significant effects of treatment.
For task-related phMRI studies in patients, paradigms should be developed that 
tax neural processes (or target brain areas) that are relevant to the disease processes 
under investigation. Since performance scores may differ between different versions of 
a single type of paradigm, paradigms require validation at a behavioural level before they 
are used for imaging purposes. When studying process-specificity of pharmacological 
substances, the content of paradigms (items) and the method of data analysis (event-
related, block, mixed) should be kept as similar as possible, in order to allow tight 
comparisons between different functional domains. Future phMRI studies may require 
to use mixed event-related – block designs (Otten et al., 2002). Such designs allow 
studies of both tonic (trait) and phasic (state) aspects of neural performance, on which 
the effects of pharmacological intervention can be evaluated separately. Apart from 
being of important fundamental interest, studies of process-specificity with respect 
to both tonic and phasic mental processes facilitate comparisons between functional 
domains (different tasks) and pharmacological substances, and raise the probability of 
detecting significant effects of treatment.
Preferably, brain function should be assessed during both task performance 
and non-task (or ‘resting state’) conditions, using both model-based and model-
free analyses, which allow an unbiased view of signal changes and their modulation 
by pharmacological intervention (Beckmann et al., 2003). phMRI cannot do without 
software that allows for advanced group-level repeated-measures analyses that include 
multiple covariates and their interactions. Based on personal experience with SPM 
(Turner et al., 1998), AFNI (Cox, 1996) and FSL (Smith et al., 2004) software, FSL 
seems to be preferable for phMRI studies, since it is one of the few non-commercial 
packages that combines statistical multifacetness and robustness with a user-friendly 
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interface, an excellent mailbase and extensive and clearly written documentation.
phMRI studies are multidisciplinary by nature and therefore benefit from frequent exchange 
of knowledge between physicists, medical doctors, psychologists, pharmacologists, 
statisticians and pharmaceutical industries. Such exchanges should lead to a general 
conception of brain function and clear hypotheses that can be tested using appropriate 
methodologies. The lack of a general conception of brain function currently prevents the 
widespread use of a hypothetical-deductive approach in neuroscience, pharmacological 
imaging studies in particular. Both fundamental and clinical studies may therefore benefit 
from efforts to summarise current knowledge of parameters that contribute to brain 
function into a global network of relationships between all levels of neural organisation 
(i.e. molecular, cellular, network, system, behavioural and social levels). By simulating 
the impact of pharmacological intervention on biological systems at different levels of 
neural organisation, predictions can be made with respect to functional changes that 
can be tested by subsequent experiments.
Since all neurotransmitter systems are interconnected and receive input from 
other neural systems (Gu, 2002; Jones, 2003), pharmacological challenge directed at 
specific neurotransmitter receptors will eventually alter brain function in remote brain 
areas in an aspecific manner. The ability of phMRI to associate brain function within 
neural systems with the activity of specific neurotransmitters is therefore only relative. 
With some modifications, however, connectivity studies may provide more insight into the 
hierarchical relationships between global networks of connected brain regions and their 
associated neurotransmitter systems. In order to disentangle their mutual relationships, 
effective connectivity studies may be used to test specific hypotheses concerning the 
hierarchical relationships between neural systems (Patel et al., 2005; Salvador et al., 
2005) and their dependencies on specific neurotransmitters, by examining changes 
in connectivity patterns as a result of pharmacological intervention. Such studies may 
involve alternated pharmacological stimuli (e.g. cholinergic – dopaminergic – adrenergic 
– serononergic) within single scanning sessions to maximise the heterogeneity of 
connectivity patterns associated with different pharmacological challenges, which may 
facilitate estimation of the relative position of each neurotransmitter system within the 
assumed hierarchy of neural systems.
At present, pharmacological imaging studies are still in their infancy, but 
progress is being made with rapid paces. If developments in conceptual frameworks, 
imaging technology and analysis methods continue to improve at their current pace, 
pharmacological fMRI is likely to become an important instrument in the search for 
biological markers that are of potential clinical interest.
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Dit proefschrift beschrijft de resultaten van een verkennend onderzoek naar een 
nieuwe techniek die gebruikt kan worden om de effecten van geneesmiddelen op 
hersenaktiviteit af te beelden: pharmacologische functionele magnetic resonance 
imaging (farmacologische fMRI of phMRI). Met behulp van deze techniek werden de 
effecten onderzocht van drie verschillende klassen van medicijnen (de bètablokker 
propranolol, de selectieve oestrogeen-receptor modulator (SERM) raloxifene en de 
cholinesteraseremmer galantamine) op hersenaktiviteit van respectievelijk gezonde 
jongere en oudere controles, en patiënten met geheugenklachten. Aan de hand van de 
resultaten van dit onderzoek werd nagegaan in hoeverre phMRI toepasbaar zou kunnen 
zijn in een klinische context.
In hoofdstuk 1 wordt een korte uitleg gegeven van de begrippen MRI, fMRI en 
phMRI. De MRI scanner is al bijna 30 jaar een vast onderdeel van het instrumentarium van 
radiologen. MRI is een volledig non-invasieve scantechniek die artsen in staat stelt om 
haarscherpe, driedimensionale afbeeldingen te maken van de verschillende organen van 
levende patiënten en de eventuele ziekteprocessen die zich daarin afspelen. fMRI is een 
meer recente toepassing van MRI, waarbij de wisselende magnetische eigenschappen 
van de rode bloedkleurstof ‘hemoglobine’ worden benut om zwart-wit contrast te geven 
aan MR plaatjes (Jezzard et al., 2001). Afhankelijk van de mate waarin hersengebieden 
aktief zijn wordt een sterker of minder sterk bloed-oxygenatie afhankelijk (BOLD) MR 
signaal gemeten. De meeste fMRI studies vergelijken de gemiddelde signaalintensiteiten 
van hersengebieden tussen actieve en een minder actieve condities van een bepaalde 
taak, die tijdens het scannen wordt uitgevoerd. Dit levert driedimensionaal plaatjes op van 
het hele brein, waarin de gemiddelde intensiteitsverschillen tussen twee taak-condities 
zijn af te lezen (“contrast plaatjes”). phMRI is een verdere nuancering van fMRI, waarbij 
contrastplaatjes worden onderzocht op toenames of afnames van intensiteitsverschillen 
als gevolg van blootstelling aan een bepaalde farmacologische stof.
Er is nog maar weinig onderzoek gedaan naar de klinische waarde van 
farmacologisch onderzoek door middel van phMRI. De eerste phMRI studies zijn zo’n 
10 jaar oud en betreffen vooral dierexperimenteel onderzoek en haalbaarheidsstudies 
(Shah & Marsden, 2004). fMRI heeft een aantal sterke punten, zoals de non-invasiviteit, 
flexibiliteit en hoge spatiële en goede temporele resolutie, waardoor deze techniek in 
aanmerking komt voor gebruik in de kliniek. fMRI heeft daarentegen ook een aantal 
zwakke punten, zoals een lage signaal-ruis verhouding, het gebruik van relatieve maten 
(contrast plaatjes) en problemen met de interpretatie van het BOLD signaal, die 
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mogelijk een barrière vormen voor een snelle introductie in de klinische praktijk (Jezzard 
et al., 2001). De sterke eigenschappen van fMRI zorgen ervoor dat deze techniek zich 
goed leent voor het beantwoorden van een aantal specifieke vragen ten aanzien van 
de effecten van farmacologische substanties op hersenaktiviteit. Deze vragen stonden 
centraal in dit proefschrift:
Kan fMRI inderdaad effecten van farmacologische substanties op hersenfunctie 
aantonen?
Zijn deze effecten regio- en proces-specifiek?
Reageren bepaalde subgroepen van proefpersonen of patiënten op een 
karakteristieke manier op farmacologische interventie (bijvoorbeeld geslachts- of 
ziekte-specifieke effecten)?
Zijn deze functionele veranderingen afhankelijk van dosis of duur van 
blootstelling?
Kan phMRI worden gebruikt om het werkingsmechanisme van farmacologische 
substanties te verhelderen?
Hebben de gemeten effecten (vroeg- en differentieel-) diagnostische waarde, of 
predictieve waarde voor behandelingssucces en uiteindelijk klinisch beloop?
In hoofdstuk 2–4 van dit proefschrift komen deze vragen één voor één aan bod. Dit 
gebeurt aan de hand van studies van drie verschillende geneesmiddelen (propranolol, 
raloxifene, galantamine; zie boven). Van deze geneesmiddelen is bekend dat zij een 
effect (zouden kunnen) hebben op hersenfunctie tijdens geheugenprestatie. Dit 
doen ze door te interfereren met de overdracht van bepaalde signaalstoffen tussen 
hersencellen, de zogenaamde neurotransmitters. Dit proefschrift beschrijft daarom de 
resultaten van een zestal studies naar drie verschillende neurotransmittersystemen: 
het noradrenerge systeem (met behulp van propranolol), het cholinerge systeem (met 
behulp van galantamine) en het centrale systeem van de geslachtshormonen (met 
behulp van raloxifene). Verschillende groepen van patiënten en controles kregen ieder 
een verschillend geneesmiddel, afhankelijk van de vraagstelling van het onderzoek.
Groepen van gezonde jonge en oudere controles, en oudere patiënten met lichte 
geheugenklachten en de ziekte van Alzheimer werden gescand door middel van fMRI 
tijdens het uitvoeren van speciaal voor dit onderzoek ontwikkelde geheugentestjes 
(paradigmata). Hierdoor waren we in staat om hersengebieden zichtbaar te maken die 
betrokken waren bij verschillende aspecten van geheugenfunctie. Een ‘face-encoding’ 
taak werd gebruikt om hersengebieden zichtbaar te maken die betrokken zijn bij 
1.
2.
3.
4.
5.
6.
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het onthouden van onbekende menselijke gezichten (Small et al., 1999). Een ‘face-
recognition’ taak werd kort daarna afgenomen om de gebieden zichtbaar te maken 
die betrokken zijn bij de succesvolle herkenning van eerder getoonde gezichten, of 
niet-succesvolle herkenning van nieuwe gezichten. Verder gebruikten we een n-letter 
back werkgeheugen taak om hersengebieden te activeren die zich bezig houden met 
de tijdelijke opslag en bewerking van nieuwe informatie (letters of lettercombinaties) 
(Owen et al., 2005). Ten slotte werd een geheugentaak ontwikkeld die tot doel had 
hersengebieden te aktiveren die betrokken zijn bij de opslag van emotioneel geladen 
informatie. Hiertoe werd, in samenwerking met Dr. A.H. van Stegeren and Prof. Dr. 
W.TA.M. Everaerd van de afdeling Klinische en Experimentele Psychologie van de 
Universiteit van Amsterdam, het bestaande International Affective Picture System (IAPS) 
(Lang & Bradley, 1997) aangepast voor gebruik in de MR scanner. Voor deze taak 
werden uitsluitend gebruikt gemaakt van IAPS-plaatjes met een negatieve emotionele 
lading (valentie), zoals verwondingen of verminkingen. Het doel van deze taak was 
stimuleren van de amandelkernen (‘amygdala’): kleine bolvormige structuren aan de 
binnenzijde van de slaapkwab en aan de basis van de hersenen, die specifiek betrokken 
zijn bij het verwerken van (met name) negatief valente stimuli. Vervolgens werden de 
verschillende paradigmata gebruikt om de invloed te onderzoeken van de verschillende 
geneesmiddelen op de hersenaktivatiepatronen van de proefpersonen en patiënten. 
Hiertoe werd gebruik gemaakt van de fMRI expert analysis tool (FEAT) uit het data-
analyse pakket fMRIB software library (FSL) (Smith et al., 2004).
Hoofdstuk 2 beschrijft een studie naar de effecten van de stof ‘propranolol’ 
op hersenfunctie bij gezonde jonge controles tijdens het uitvoeren van de taak die 
het emotionele geheugen test (IAPS voor fMRI). Propranolol is een remmer van de 
(nor)adrenerge neurotransmissie, zoals die wordt verzorgd door beta-adrenerge 
receptoren (een zogenaamde ‘bètablokker’). Uit dieronderzoek is bekend dat 
neurotransmissie in de amygdala met name van noradrenerge aard is (McGaugh, 2004). 
Hoewel het aannemelijk is dat dit bij mensen ook zo is, is de relatie tussen amygdala-
aktiviteit en noradrenerge neurotransmissie bij levende mensen nog niet eerder 
onderzocht. De hypothese bij deze studie was dan ook dat propranolol 80 mg éénmalig 
(tablet per os) de aktivatie van de amygdala tijdens een emotionele geheugentaak ten 
opzichte van een placebogroep zou verminderen.
De placebogroep liet bij toenemende negatieve emotionele intensiteit van 
de plaatjes (4 categorieën) een onevenredige toename van de signaalintensiteit in 
de amygdala zien. Deze ‘non-lineaire respons’ kan verschillende oorzaken hebben, 
variërend van een fysiologische neurale respons tot taakeffecten. Propranolol gaf 
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een significante vermindering van de signaalintensiteit in de amygdala bij categorie 3 
plaatjes, wat in overeenstemming was met de hypothese. In mensen lijkt daarom de 
functie van de amygdala afhankelijk te zijn van intacte noradrenerge neurotransmissie. 
Het blijft echter de vraag of het gemeten effect direct of indirect het gevolg is van 
propranolol-inname. Aangezien het BOLD signaal (zie boven) onvoldoende informatie 
bevat over gebeurtenissen op moleculair niveau zal een definitief antwoord over de aard 
van de neurotransmissie in de amygdala in levende proefpersonen pas gegeven kunnen 
worden door middel van PET studies, of andere vormen van ‘molecular imaging’.
Deze studie probeerde tevens een antwoord te geven op de vraag of de effecten 
van propranolol geslachtsspecifiek zijn. We hebben inderdaad aanwijzingen gevonden 
voor een geslachtsspecifieke lateralisatie van amygdalafunctie onder placebo (vrouwen 
links, mannen rechts). Hoewel mannen en vrouwen niet significant verschilden in hun 
functionele respons op propranolol was de geheugenprestatie van vrouwen twee weken 
na inname van propranolol significant slechter, terwijl dit bij mannen niet zo was. Dit 
lijkt erop te wijzen dat vrouwen inderdaad anders reageren op emotionele stimuli en 
noradrenerge blokkade dan mannen, maar de resultaten moeten worden gerepliceerd 
in grotere studies.
Hoofdstuk 3 beschrijft een studie naar de effecten van de stof ‘raloxifene’ 
(Evista®, Lilly) op hersenfunctie van gezonde oudere mannen tijdens het uitvoeren 
van een face-encoding (3.1) and –recognition taak (3.2). Raloxifene is een selectieve 
oestrogeen receptor modulator (SERM), die gebruikt wordt als middel tegen 
osteoporose (botontkalking) bij postmenopausale vrouwen (Heringa, 2003). Verder 
zou raloxifene een gunstig effect op hart- en vaatziekten kunnen hebben. Aangezien 
mannen, net als vrouwen, oestrogeen-receptoren tot expressie brengen in vrijwel alle 
weefsels zouden de gunstige eigenschappen van raloxifene tot op zekere hoogte ook 
voor mannen kunnen gelden. Van de effecten van SERMs op hersenaktiviteit is echter 
zowel bij mannen als bij vrouwen weinig bekend. Bij oudere vrouwen is inmiddels een 
lichte preventieve werking van raloxifene aangetoond (langdurige behandeling) ten 
aanzien van de ontwikkeling van mild cognitive impairment (MCI; een ziektecategorie 
die voorafgaat aan AD) (Yaffe et al., 2005). Zo’n effect zou ook bij mannen kunnen 
optreden (Bisagno et al., 2003). Om deze reden onderzochten we de effecten van een 
langdurige behandeling (3 maanden) met raloxifene 160mg (1dd1, tablet per os) op 
geheugenprestatie en hersenaktivatiepatronen tijdens het onthouden en het herkennen 
van getoonde gezichten.
Behandeling met raloxifene gaf een sterke toename van hersenaktiviteit tijdens het 
opslaan (encoding) van gezichten, en een lichte toename van hersenaktiviteit tijdens het 
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herkennen van gezichten. De geheugenprestatie van de raloxifene groep bleef constant 
tussen beide scan-sessies, terwijl die van de placebogroep licht daalde. Dit laat zien 
dat er bij mannen wel degelijk effecten van raloxifene op hersenfunctie, en misschien 
ook op gedrag te verwachten zijn. Verder suggereert dit dat de effecten van raloxifene 
‘proces-specifiek’ zijn, dat wil zeggen dat raloxifene bij voorkeur bepaalde processen 
beïnvloedt (encoding) en andere minder (recognitie). Door de behandelingseffecten 
tijdens encoding te correleren met veranderingen in taakprestatie-scores, en door de 
effecten van raloxifene te onderzoeken in relatie tot hersenaktiviteit tijdens het (al of niet 
succesvol) herkennen van getoonde informatie waren we in staat een beter inzicht te 
verkrijgen in het werkingsmechanisme van raloxifene. Een mogelijk werkingsmechanisme 
is er één waarbij raloxifene een toename veroorzaakt van ‘arousal’ (de mate van alertheid) 
van een proefpersoon tijdens het initiële opslaan van informatie (encoding), waarna 
een verminderde afleidbaarheid, een toegenomen werkgeheugen, en/of verbeterde 
consolidatie van geheugensporen uiteindelijk leiden tot een betere herkenning van 
de getoonde plaatjes (ten opzichte van een onbehandelde groep). Aangezien de 
medicatie-effecten klein zijn zal toekomstig onderzoek van de effecten van raloxifene 
op hersenfunctie baat hebben bij grotere groepen deelnemers. Dit laat vervolgens een 
uitgebreider netwerk toe van correlaties tussen neurochemische, neurofysiologische, 
functionele en gedragsgerelateerde maten dat nodig is om een beter inzicht te krijgen 
in het werkingsmechanisme van deze stof. Hieruit zal ook moeten blijken of de gemeten 
functionele effecten inderdaad hun weerslag hebben op geheugen en gedrag. Hoewel 
de onderzochte groep mannen groot was naar fMRI begrippen was hij te klein om 
definitieve uitspraken te doen over veranderingen op gedragsniveau.
Hoofdstuk 4 beschrijft een studie naar de effecten van de stof ‘galantamine’ 
(Reminyl®, Johnsson&Johnsson) op hersenfunctie van oudere patiënten met lichte 
geheugenklachten (mild cognitive impairment (MCI), een voorstadium van de ziekte 
van Alzheimer) en met de ziekte van Alzheimer (AD). Bij AD bestaat er in wisselende 
mate een tekort aan verschillende neurotransmitters, met name acetylcholine. Lage 
concentraties acetylcholine worden voor een belangrijk deel verantwoordelijk geacht 
voor de geheugenklachten (Bartus, 2000), taalklachten en psychische klachten van 
Alzheimer patiënten (Assal & Cummings, 2002). Medicamenteuze therapie met 
cholinesteraseremmers is er daarom op gericht het cholinerge tekort weer aan te vullen. 
Deze ‘cholinerge therapie’ is één van de weinige concrete maatregelen die momenteel 
tegen AD genomen kunnen worden. Cholinerge therapie leidt binnen 4 – 12 weken 
tot een lichte verbetering (5 – 20%) van de geheugenfunctie (Scarpini et al., 2003). 
Ondanks de bewezen effectiviteit is het exacte werkingsmechanisme van cholinesterase-
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remmers (inclusief galantamine) niet goed bekend. Over het algemeen wordt de 
effectiviteit van deze middelen toegeschreven aan een toename van arousal en een 
daardoor verbeterde aandachtsfunctie, met secundaire gevolgen voor werkgeheugen, 
taalfunctie en episodisch geheugen (Sarter et al., 2005). 
In onze studies waren wij speciaal geïnteresseerd in de effecten van een 
zeer kortdurende blootstelling aan galantamine op de hersenfunctie van MCI en AD 
patiënten: effecten van galantamine inname werden onderzocht naar aanleiding van 
een éénmalige dosis van 8mg (tablet 4mg 1dd2 per os) en vijf dagen inname van 8mg 
per dag (tablet 4 mg 2dd1 per os). Aangezien de klinische effecten van galantamine 
pas maximaal zijn na vier tot zes weken (Raskind, 2003) was deze studie niet geschikt 
om het therapeutisch mechanisme van deze stof in zijn volledigheid te onderzoeken. 
De centrale gedachte bij deze studies was dan ook dat de effecten van kortdurende 
stimulatie met galantamine, zoals gemeten met phMRI, al informatie zouden kunnen 
bevatten over de functionele toestand van het centrale cholinerge systeem (volgens het 
principe van de farmacologische provokatietest (zie bijvoorbeeld (Gijsman et al., 2004; 
Travain & Wexler, 1999; Anderson, 1996; Lindsay & Nieman, 2005; Lyon et al., 2004; 
Rush et al., 1996; Hatzinger, 2000)). Recent post-mortem onderzoek op moleculair 
niveau laat zien dat het cholinerge tekort bij MCI patiënten waarschijnlijk minder groot 
is dan bij AD patiënten, aangezien de ziekte in dit stadium nog niet zo ver gevorderd is 
(DeKosky et al., 2002). Als deze verschillen doorwerken tot op het niveau van neurale 
systemen bij levende MCI en AD patiënten, dan zouden de hersenaktivatiepatronen van 
beide patientengroepen op een unieke (ziektespecifieke) manier moeten reageren op 
galantamineprovokatie. Dit kan informatie opleveren over de hersengebieden en neurale 
processen die betrokken zijn bij verschillen in de aktiviteit van het cholinerge systeem. 
Verder zouden dergelijke ziektespecifieke effecten als markers kunnen dienen in klinische 
vervolgstudies, die de mate van achteruitgang van patiënten met geheugenklachten (en 
het succes van cholinerge therapie) proberen te voorspellen op basis van onderzoek 
naar de functionele toestand van het cholinerge systeem.
Hoofdstuk 4.1 beschrijft effecten van galantamine stimulatie bij MCI patiënten 
tijdens het uitvoeren van een face encoding- en werkgeheugentaak. Dit wordt gedaan 
met het oog op de voorspelbaarheid van verdere achteruitgang van geheugenfunctie 
in deze groep. Hoofdstuk 4.2 doet hetzelfde bij AD patiënten, en onderzoekt tevens 
de effecten van galantamine-stimulatie op de vorm van de BOLD respons (zie boven), 
welke ook een markerfunctie zou kunnen vervullen. Hoofdstuk 4.3 vergelijkt de effecten 
van galantamine stimulatie tussen MCI en AD patiënten tijdens het uitvoeren van een 
gezichtsherkenningstaak (face recognition). Eventuele ziektespecifieke effecten zouden 
als markers kunnen dienen in klinische vervolgstudies.
221
Nederlandse samenvatting (Dutch summary)
Zowel MCI als AD patiëntengroepen reageerden op galantamine-provokatie met kleine 
veranderingen van hersenaktivatiepatronen tijdens het uitvoeren van face-encoding en 
werkgeheugentaken (4.1, 4.2). Beide patiëntengroepen vertoonden echter een sterke 
cholinerge reactiviteit tijdens gezichtsherkenning (face recognition). Het feit dat de 
effecten van cholinerge stimulatie op hersenfunctie afhankelijk zijn van de taak die wordt 
uitgevoerd suggereert dat de effecten van galantamine, net als die van raloxifene en 
andere geneesmiddelen, proces-specifiek zijn.
Zowel MCI als bij AD patiënten reageerden zowel op éénmalige als op langduriger 
blootstelling aan galantamine, afhankelijk van het soort taak dat werd afgenomen. 
Verschillen tussen éénmalige en langduringer behandeling waren steeds significant. In 
alle drie de studies traden de meeste effecten op naar aanleiding van een éénmalige dosis 
galantamine. Verder bestonden er aanwijzingen voor een afname van hersenaktiviteit 
naar aanleiding van langdurige behandeling (5 dagen). Dit zou kunnen wijzen op de 
effecten van acute receptorsensitisatie (Maelicke et al., 2001), die vervolgens teniet 
worden gedaan als gevolg van receptor-desensitisatie (Quick & Lester, 2002; Volkow 
et al., 2001)). Deze desensitisatie zou het begin kunnen betekenen van een reeks 
veranderingen die uiteindelijk het gewenste therapeutisch effect opleveren. De effecten 
van galantamine zijn dus inderdaad afhankelijk van de duur van blootstelling aan het 
middel. Dit suggereert dat therapeutische effecten niet onmiddellijk maximaal intreden, 
maar zich ontwikkelen zijn in de tijd. Dit is in overeenstemming met klinische bevindingen 
die laten zien dat de effecten van cholinerge therapie meestal pas maximaal zijn na 4 
– 12 weken (Scarpini et al., 2003). Verder onderzoek van de effecten van galantamine 
op verschillende tijdspunten na aanvang van de behandeling is nodig om een beter 
inzicht te krijgen in het werkingsmechanisme van deze stof.
Galantamine stimuleerde bij MCI patiënten selectief de aktivatie van het 
posterieure cingulum, de temporaalkwab en frontaalkwab tijdens herkenning van oude 
informatie (correcte herkenning), terwijl het bij AD patiënten juist de aktivatie van de 
hippocampus tijdens de opslag van nieuwe informatie tijdens de herkenningspoging 
(correcte verwerping) stimuleerde. De verschillen in cholinerge reactiviteit tussen MCI 
en AD patienten waren significant (Z = 3.1). Dit laat zien dat de effecten van galantamine, 
behalve proces-specifiek, tevens regio-specifiek en ziekte-(stadium)specifiek zijn.
Deze bevindingen zijn opmerkelijk, aangezien ze aansluiten bij bevindingen van 
andere groepen die deels gedaan zijn met behulp van andere technieken. Al eerder 
was gevonden dat functionele en/of metabole afwijkingen bij MCI en AD patiënten 
regio- proces- en ziektespecifiek zijn volgens een patroon dat nauw aansluit bij onze 
bevindingen  (Matsuda, 2001; Chetelat et al., 2003; Nestor et al., 2003; Rombouts 
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et al., 2000). Uit onze studie blijkt nu dat voor dergelijke clusters van relaties een 
cholinerge factor van belang kan zijn. Tot nu toe was het belang van een verminderde 
functie van het cholinerge systeem bij het ontstaan van AD voornamelijk gebleken uit 
post-mortem onderzoek. Onze resultaten suggereren dat het cholinerge systeem in 
levende patiënten een belangrijke rol speelt bij het ontstaan van deze ziekte, en dat er, 
afhankelijk van het ziektestadium, specifieke hersengebieden en –processen betrokken 
zijn bij de gevonden cholinerge tekorten.
Een tweede opmerkelijke bevinding is dat een éénmalige dosis van galantamine in 
beide patiëntengroepen al tot zo’n grote heterogeniteit aan responsen leidt. Deze ‘ziekte-
specifieke’ respons op galantamineprovokatie zou van klinische betekenis kunnen zijn. 
Klinisch onderzoek laat zien dat AD patiënten over het algemeen gunstiger reageren dan 
MCI patiënten op een behandeling met cholinesteraseremmers (Lanctot et al., 2003; 
Ihl, 2003; Salloway et al., 2004). Zulke verschillen in klinische respons zouden kunnen 
berusten op de verschillen in functionele respons zoals die uit onze studie naar voren 
komen. Deze functionele verschillen zouden op hun beurt weer een moleculaire basis 
kunnen hebben (DeKosky et al., 2002) (zie boven). Uit recent phMRI onderzoek blijkt 
inderdaad dat de initiële veranderingen van hersenaktivatiepatronen naar aanleiding 
van farmacologische interventie met een serotonine heropnameremmer voorspellend 
zijn voor het klinisch beloop van patiënten die lijden aan depressie in engere zin (Fu 
et al., 2004). De reactiviteit van MCI en AD patiënten op cholinerge provokate zou op 
een vergelijkbare manier het klinisch beloop of respons op cholinerge therapie kunnen 
voorspellen. Er is dus verder onderzoek nodig om de klinische waarde vast te stellen 
van cholinerge provokatietests bij patiënten met mild cognitive impairment en de ziekte 
van Alzheimer.
Aangezien de effecten van galantamine uitsluitend werden onderzocht naar 
aanleiding van korte blootstellingsduren was het niet mogelijk therapeutisch mechanisme 
van galantamine in zijn volledigheid te onderzoeken. De specificiteit van galantamine 
voor hersenfunctie tijdens gezichtsherkenning lijkt echter de gangbare theorie van een 
cascade van verhoogde arousal, aandacht, werkgeheugen of episodisch geheugen 
(Sarter et al., 2005) enigszins tegen te spreken. De effecten van galantamine op 
hersenfunctie kunnen echter nog steeds (soms met enige moeite) in een context van 
verhoogde arousal en aandacht worden geïnterpreteerd.
Hoofdstuk 5 bevat een samenvatting van alle bevindingen en suggesties voor 
verder onderzoek met behulp van phMRI. Op de vragen die gesteld werden in de 
inleiding  (hoofdstuk 1) kunnen nu de volgende antwoorden gegeven worden:
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Effecten van geneesmiddelen op hersenfunctie zijn klein, maar kunnen inderdaad 
worden gemeten met behulp van fMRI (hoofdstuk 2-4).
De resultaten van ons onderzoek sluiten aan bij die van eerder onderzoek waaruit 
blijkt dat de effecten van geneesmiddelen op hersenfunctie regio-specifiek en 
proces-specifiek kunnen zijn (Honey & Bullmore, 2004) (hoofdstuk 2-4).
De effecten van geneesmiddelen op hersenfunctie kunnen tevens geslachts- en 
ziekte-(stadium)-specifiek zijn (hoofdstuk 2,4).
Onze studies tonen aan dat deze effecten afhankelijk zijn van de duur van 
blootstelling aan het farmacologische agens: in het geval van cholinerge stimulatie 
leidde een éénmalige dosis galantamine al tot regio- proces- en ziektespecifieke 
effecten (hoofdstuk 4).
We hebben een methode ontwikkeld om de effecten van geneesmiddelen 
op hersenfunctie tijdens geheugenfunctie te onderzoeken in relatie tot 
gedragsveranderingen en specifieke hersenprocessen (hoofdstuk 3).
Indien grote groepen patiënten geïncludeerd worden zijn uitgebreide studies 
naar de klinische (vroegdiagnostische en predictieve) waarde van de gemeten 
effecten zeer goed mogelijk (hoofdstuk 4,5).
De waarde van deze bevindingen voor fundamenteel of toegepast (klinisch) onderzoek 
hangt sterk af van het informatiegehalte van de BOLD respons. De meerwaarde van 
fMRI is vooral gelegen in de hoge spatiële resolutie en de flexibiliteit van de techniek 
(zie boven). Hiermee kan men relatief gemakkelijk onderzoeken waar bepaalde neurale 
fenomenen zich afspelen. Daarnaast kunnen connectiviteits-studies helpen een indruk 
te verschaffen van de verbondenheid van de verschillende neurale systemen in de ruimte 
en de tijd. Hiermee kunnen tot op zekere hoogte ook vragen worden beantwoord over 
het waar en wanneer van neurale processen. Aangezien BOLD fMRI echter indirecte en 
vaak relatieve maten van neurale functie levert, en er vele verschillende factoren bijdragen 
aan BOLD signaalintensiteit, is het lastig om aan de hand van BOLD fMRI alleen uit te 
vinden wat er nu precies gebeurt in de hersenen. Bovendien heeft BOLD fMRI een 
beperkte temporele resolutie, wat het onmogelijk maakt om de vaak snel verlopende 
neurale processen in détail te onderzoeken. Voor een completer beeld van neurale 
processen in ruimte en tijd en op verschillende schalen van neurale organisatie zijn dus 
combinaties van technieken nodig. Met name combinaties van fMRI studies met studies 
van genetische profielen (receptoren, second messenger systemen), receptorprofielen 
(door middel van molecular imaging technieken zoals PET), elektrofysiologische 
fenomenen (EEG/MEG) en studies van gedragsveranderingen (neuropsychologie) 
lijken hierbij interessant.
1.
2.
3.
4.
5.
6.
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In deze context kunnen de bevindingen van phMRI studies interessant zijn voor 
fundamenteel onderzoek naar hersenfunctie. Studies van regio- en proces-specificiteit 
kunnen behulpzaam zijn bij het bepalen van de mate waarin verschillende hersenstructuren 
(zoals de amygdala) of neurale systemen (zoals die betrokken zijn bij (tijdelijke) opslag 
en herkenning van informatie) voor hun functioneren afhankelijk zijn van bepaalde 
neurotransmitter systemen. Connectiviteitsstudies kunnen zelfs een indruk verschaffen 
van de mate waarin de verbondenheid tussen neurale systemen (in de ruimte en de tijd) 
afhankelijk is van bepaalde vormen van neurotransmissie. Door de blootstellingsduur 
aan geneesmiddelen te variëren, of effecten van geneesmiddelen te bepalen met 
een interval (weken, maanden, jaren) kan een indruk verkregen worden van de mate 
waarin de neurotransmitter-afhankelijkheid van bepaalde neurale systemen varieert in 
de tijd. Verschillen in zulke afhankelijkheidsrelaties zoals die zouden kunnen optreden 
tussen geslachten of leeftijdsgroepen kunnen helpen een indruk te verschaffen over 
de rol van verschillende neurotransmitter systemen tijdens de normale ontwikkeling en 
veroudering.
phMRI studies zouden ook van klinisch belang kunnen zijn. phMRI kan worden 
gebruikt om het werkingsmechanisme van psychotrope geneesmiddelen te onderzoeken 
(zoals bij raloxifene, hoofdstuk 3), wat vervolgens weer informatie kan opleveren 
over de aard van het ziekteproces dat wordt gecorrigeerd. Studies van de regio- en 
proces-specificiteit van geneesmiddelen kunnen helpen bij het ontwikkelen van 
farmaca die meer gericht inwerken op specifieke (ziekte)processen (hoofdstuk 3,4). 
Dit zou mogelijk de effectiviteit van geneesmiddelen kunnen verhogen en het aantal 
bijwerkingen verminderen. Farmacologische provokatietests zouden ziektespecifieke 
functionele veranderingen kunnen identificeren die van vroeg diagnostische, 
differentieel-diagnostische en/of prognostische waarde kunnen zijn, of het succes van 
farmacotherapie kunnen voorspellen. De vraag is natuurlijk in hoeverre phMRI in staat 
is om klinisch relevante functionele biomarkers aan te tonen in individuele patiënten. 
Toekomstig onderzoek zal moeten uitwijzen in hoeverre de lage signaal-ruisverhouding 
en de reproduceerbaarheid van deze techniek een barrière vormen voor het gebruik van 
phMRI in de klinische praktijk (Jezzard et al., 2001; Powell & Duncan, 2005). Ondertussen 
kunnen groepsstudies al resultaten leveren die van klinisch belang zouden kunnen zijn 
voor individuele patiënten: met phMRI provokatiestudies zouden bijvoorbeeld relaties 
kunnen worden gelegd tussen bepaalde klinische verschijnselen en een afwijkende 
reactiviteit van centrale neurotransmittersystemen. Zijn zulke relaties eenmaal gelegd, 
dan kunnen patiënten die zich presenteren met de bewuste symptomen of afwijkingen 
worden behandeld met een gerichte farmacotherapie.
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De medicatie-effecten die wij vonden waren vrij klein. Toekomstige phMRI studies 
zouden daarom baat kunnen hebben van het includeren van grotere groepen patiënten 
om sterkere effecten te kunnen vinden. Deze medicatie-effecten zouden vervolgens 
in relatie gebracht kunnen worden met een uitgebreid netwerk van relaties tussen 
neurochemische, neurofysiologische, gedragsmatige en klinische waarnemingen om een 
beter inzicht te krijgen in de betekenis van deze effecten voor fundamenteel en klinisch 
onderzoek. De ontwikkelingen in de methodologie van fMRI staan ondertussen niet 
stil. Er is inmiddels een arsenaal aan nieuwe analysemethoden beschikbaar gekomen, 
zoals model-free analyses (Beckmann & Smith, 2005), hierarchical connectivity studies 
(Patel et al., 2005; Salvador et al., 2005) en gecombineerde EEG/fMRI technieken 
(Hamandi et al., 2004), die van belang zouden kunnen zijn voor toekomstig phMRI 
onderzoek. Ook al staat farmacologische fMRI nog in de kinderschoenen, er wordt met 
grote stappen vooruitgang geboekt. Het is dus waarschijnlijk dat phMRI, in combinatie 
met andere technieken, een belangrijk bijdrage zal gaan leveren aan de zoektocht naar 
biologische markers met een bruikbare klinische waarde.
Amsterdam, 1-11-2005.
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Graag wilde ik, in pseudochronologische volgorde, de volgende personen bedanken:
Prof. Barkhof, beste Frederik, ik wilde je hartelijk bedanken voor de mogelijkheid die 
je me hebt geboden onderzoek te doen in het VU Medisch Centrum. Ik ben er meer 
dan dankbaar voor dat jullie me uiteindelijk hebben aangenomen. Je optimisme en 
relativeringsvermogen zorgden altijd voor een frisse kijk op de complexe problematiek 
van mijn onderzoek. Je heldere theoretische én pragmatische commentaar op mijn 
studies heb ik als erg prettig ervaren. Je was altijd aanwezig met goed advies, en toen 
mijn drie jaar bij de neurologie om waren heb je ‘de ideale bijbaan’ (IAC werk) voor 
me geregeld, om een soepele overgang naar de eindfase van de promotie mogelijk te 
maken. Ik wilde je bedanken voor al je inspanningen en het prettige contact gedurende 
de afgelopen vier-en-een-half jaar.
Prof. Scheltens, beste Philip, ik wilde je graag hartelijk bedanken voor de mogelijkheid 
die je me hebt geboden onderzoek te doen bij het Alzheimercentrum van het VUMC. 
Hoewel ik het je soms erg lastig heb gemaakt met allerlei declaraties van taxikosten, 
computers, harddrives en studiekosten heb ik je in vier-en-een-half jaar tijd nooit je 
goede humeur zien verliezen. Ik wil je bedanken voor het prettige contact, je goede 
commentaar op m’n stukken, de gezellige borrels en etentjes, symposia en congressen, 
voor de verlenging van mijn driejarige promotieduur, en je zachte edoch dwingende 
aansporingen om het werk binnen 4 jaar af te maken.
Dr. Rombouts, beste Serge. Geen enkel neuropathologisch proces zal mij er nog van 
kunnen weerhouden om jou te herinneren als “the Man, the Myth, the Legend” -zoals 
je het zelf nogal eens pleegde uit te drukken - ‘who told me everything he knew - and 
more’. Jarenlang hebben we elkaar dagelijks gezien en hebben we dagelijks gelunched, 
terwijl de gesprekken die we daarbij voerden lang niet altijd van een luchtig karakter 
waren. fMRI als vakgebied bleek wereldwijd nog half in de prehistorie te verkeren: geen 
leesbaar boek, pasgeboren scanners, hoekige software, recalcitrante hardware en een 
delicaat soort conceptuele wanorde op werkelijk alle fronten. De eerste 2.5 jaar van 
mijn promotietraject kenmerkten zich daarom door perioden van soms maanden achter 
elkaar, waarin we ons vrijwel dagelijks geconfronteerd zagen met weer nieuwe problemen 
op het gebied van data management en –analyse. Hierdoor was het soms wekenlang 
onmogelijk om bepaalde rekenprocedures af te ronden. Ondertussen tikte de termijn 
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van 3 jaar onderzoek rustig door. Op het hoogtepunt van de frustratie vergeleek ik deze 
‘Mission Impossible’ soms met die van de ‘Knights who say Ni’ van Monty Python, die 
de Graalridders opdragen dikke bomen om te hakken met gezouten haring. Na 2.5 
jaar kwam je gelukkig met een kersvers analysepakket op de proppen (FSL) dat ons in 
staat stelde onze problemen grotendeels op te lossen. Ik denk dat dit de voorwaarde is 
geweest voor het feit dat er nu een boekje ligt dat ik kan verdedigen.
Terwijl we al behoorlijk opgesloten zaten in ons fMRI-universum zaten we ook nog eens 
op dezelfde kamer, wegens ruimtegebrek in het VUMC. Dit is voor ons allebei niet 
altijd even makkelijk geweest. Gelukkig wist je de moeilijke momenten steeds weer op 
te vangen met een humorvolle anekdote. Ik wil je hartelijk bedanken voor je goede en 
betrokken begeleiding en het prettige contact. Ik hoop dat je een prachtig onderzoek 
gaat opzetten in het LUMC en dat we snel nog eens een biertje kunnen gaan drinken. En 
als ik dan ooit m’n geluk weer eens ga beproeven in de fMRI, dan zou ik je graag weer 
om advies komen vragen.
This thesis leaned heavily on the expertise of our ‘guys in Oxford’, the members of the 
fMRIB team who are responsible for developing, maintaining and freely distributing FSL 
(www.fmrib.ox.ac.uk/fsl/). I would especially like to thank Dr. Stephen Smith, head of 
the FSL team, for his clear advice on data analysis. FSL flatly outperforms any software 
package we tried in terms of statistical robustness, flexibility, options for data analysis 
and userfriendlyness. Additionally, I’d like to thank professor P.M. Matthews, head of the 
department of Neurology, Center for Functional Magnetic Resonance Imaging of the 
Brain (fMRIB), Oxford, UK, for taking part in my promotion committee.
Dr. Kuijer, beste Joost, als tweede kamergenoot ben je de stille getuige geweest van 
vrijwel al onze onderzoeksactiviteiten. Je rust, analytisch vermogen en uitgebreide kennis 
op het gebied van MR aangelegenheden zijn daarbij een grote steun geweest. Als 
‘systeembeheerder’ tegen wil en dank heb je in de eerste jaren de nukken van de Linux-
bak dragelijk weten te houden. Als ik nieuwe software nodig had, of als er aanpassingen 
moesten worden gemaakt in scripts of instellingen, dan was een oplossing nooit ver 
weg. Je hebt regelmatig meegedacht over de manier van verwerven en verwerken van 
functionele data in het kader van mijn studies. Ook voor andere onderzoekers (neurologie 
en cardiologie) bleek je een grote steun. Ik wil je bedanken voor een aangename vier 
jaar. Ook wilde ik Petra Pouwels en Mark Hofman bedanken voor de vele lunches die 
we als directe collega’s met elkaar genoten hebben.
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Sander Daselaar, Willem Machielsen, Richard Lazeron, Odile van den Heuvel, Steven 
Scholte, jullie waren de senior fMRI promovendi toen ik begon. Sander en Richard 
hebben me nog flink op weg geholpen met het programmeren van paradigmata en 
automatisering van data-analyse in SPM, waarvoor veel dank. Steven wilde ik vooral 
bedanken voor de vele uitjes, etentjes, borrels en feestjes en discussies, waarom ik erg 
veel plezier heb gehad. Ik hoop ik dat we elkaar nog vaak kunnen spreken.
Graag wilde ik mijn collega-onderzoekers van de afdeling neurologie (Alzheimer, MS), 
radiologie en statistiek bedanken voor de gezellige momenten:
Esther Pelgrim, beste Esther. Onze verschillende onderzoeken betroffen hetzelfde 
geneesmiddel en dezelfde farmaceut, met alle verwikkelingen van dien. Het was de 
periode 11 september, Bush, Irak, Pim Fortuyn, etc. etc. etc. Voor alle junioronderzoekers 
is het prettig om hun onderzoeksaktiviteiten te kunnen zien in het licht van een globale 
infrastructuur, en je hebt me daarbij erg geholpen. Ook Niki Schoonenboom en Ilse van 
Straaten wilde ik bedanken voor de gezelligheid en succes wensen met de opleiding 
neurologie.
Verder natuurlijk Ingeborg Bosma, Laura van de Pol, Femke Bouwman, Alida Gouw, 
Wiesje van der Flier, Yolande Pijnenburg, Wouter Henneman en Sophie Ponten 
(neurologie Dementie), en Jolijn Kragt, Jessica Nielssen, Bas Jasperse en Jack Zwemmer 
(neurologie MS), Hugo Vrenken, Giorgos Karas, Jeroen Geurts, Tijmen Korteweg, 
Jasper Sluimer en António Bastos Leite (radiologie MS en Alzheimer) en Dirk Knol 
(medische statistiek). Dankzij jullie was onderzoek doen een complex maar gezellig uitje 
tussen twee opleidingen door. Ik wens jullie veel succes met jullie promoties en hoop 
jullie snel weer te kunnen spreken.
In het kader van de galantamine-studie (GAL-NED-10) wilde ik met name Alexia 
Loots, Deborah Brouwer en Gosia van Dinter van Janssen-Cilag in Tilburg, Dr. Hugo 
Geerts van In Silico Biosciences in Berwyn, Pennsylvania, USA, en Dr. Luc Truyen 
van Johnsson&Johnsson pharmaceutical Research and Development, Titusville, New 
Jersey, USA, bedanken voor de prettige samenwerking.
In het kader van de raloxifene studie (RALMAN) wilde ik Dr. E.J.J. Duschek, Prof. 
C. Netelenbos en A. Nicolaas-Merkus van de afdeling Endocrinologie in het VUMC 
bedanken voor de prettige samenwerking.
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Dr. Duschek, beste Erik, als onvervalst dokter in witte jas kwam je regelmatig bij ons 
‘experimentelen’ langs om poolshoogte te nemen over de vorderingen van de studie. 
Samen hebben we het eerste RALMAN-stuk geschreven. Ik heb erg veel gehad aan 
je praktische benadering, en de efficiëntie waarmee je met Ans de proefpersonen 
rekruteerde en screende.
Mw. Nicolaas, beste Ans, met volle overgave heb je de 30 raloxifene-mannen gerekruteerd 
en telefonisch ondervraagd. Bedankt voor de snelheid en nauwkeurigheid waarmee dit 
gebeurde en het prettige contact.
Prof. Netelenbos, beste Coen, ik wilde je bedanken voor het ongekende enthousiasme 
waarmee je voortdurend onze studies hebt benaderd. Je energieke houding en optimisme 
waren een belangrijke stimulans om ermee door te gaan en er wat moois van te maken. 
Ik wil je bedanken voor deelname aan mijn promotiecommissie.
In verband met de propranolol studie (BETAMYG) wilde ik Dr. A.H. van Stegeren en 
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Figure 3. (A) Amygdala activation was significantly higher when subjects watched emotional CAT3 pictures 
than the neutral CAT1 pictures under placebo condition. Two large clusters in left and right amygdala were 
visible in this contrast (local maxima: right amygdala at coordinates 18, 0, –14; Z = 4.49; P<0.005;left 
amygdala at coordinates -16, –8, –12; Z = 5.05, P < 0.01). (B) No activation passed the threshold (of Z = 
2.3, P < 0.05) when subjects had taken the betablocker. (C) Interaction between emotional intensity of 
CAT3 contrasted with CAT1 pictures x pill effect: fMRI scans showing remaining amygdala activation during 
CAT3 pictures when activation with betablockade is subtracted from activation with placebo, projected 
on the average transverse anatomical images. This is literally picturing the difference in activation, shown 
in the histogram of Figure 5 for CAT3 pictures, of clusters that pass the threshold (* = P < 0.05; cluster 
corrected). An independent radiologist identified this significant activation to be present in the left 
amygdala (maximal activation cluster on coordinate x = –16; y = –8; z = –12; Z = 3.63, cluster corrected P 
< 0.05). Right in images is left in brain.
Figure 4. (A) In the placebo condition amygdala activation was significantly higher during the most 
emotional CAT4 pictures when compared with the activation during the neutral CAT1 pictures (local 
maxima in right amygdala at coordinates 10, –2, –12; Z= 4.22, p< .005 and in the left amygdala at –8, –10, 
–12; Z= 4.17, p< .01). (B) A comparable image appeared with beta-blockade for CAT4 pictures: significant 
clusters were found in right and left amygdala (local maxima: right amygdala at coordinates: 22, –6, –18; 
Z = 4.56, p< .005 and in the left amygdala at –16, –8, –16; Z=4.16, p< .01). Betablockade appeared not to 
affect amygdala activation for this contrast.
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Figure 6. (A) Predefined contrasts used on first level to test amygdala activation pattern: A linear contrast 
as well as a nonlinear (inverted-U shape) contrast was entered in the FSL analysis. A significant fit of a 
curvilinear relationship between stimuli and activation pattern in the amygdala under placebo condition 
(B) more than under betablocker condition (C) was found. (B) Higher-level activation in the placebo group 
fitting to the nonlinear contrast: Significant cluster corrected activation (thresholded at Z = 2.3, P < 0.05) 
in right and left amygdala was identified (local maxima in R amygdala at coordinates: 20, 0, −16; Z = 
5.1, P < 0.005 and in L amygdala at −16, −8, −12; Z = 5.2, P < 0.005). (C) Higher-level activation in the 
betablocker group fitting to this same nonlinear contrast: A cluster in the right amygdala was found (local 
maximum at x, y, z = 24, −4, −18; Z = 3.52, P < 0.05).
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Chapter 3.2
Figure 1. Axial slices showing main effects during face recognition rendered on a mean anatomical 
brain volume of all subjects. Left in the image is left in the brain. Effects after cluster correction at Z 
= 2.3 and p < 0.05. Colour scale extends from Z = 2.3 (red) to Z = 8.3 (yellow). Effects during correct 
hits (TP), correct rejections (TN) and TP <> TN activation differences. Baseline: brain activation at 
baseline. Treatment: brain activation after three months of treatment. Ral: raloxifene group. Plac: 
placebo group. Visual inspection suggests an enhancement of activation after raloxifene treatment 
for TP items. See also text and Table 2.
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Figure 2. Axial slices showing effects of raloxifene treatment on brain function during TP and TN responses 
(correct hits and correct rejections). Functional maps are rendered on a mean anatomical brain volume 
of all subjects (Mean_anat_RALMEN). Left in the image is left in the brain. Colour scale extends from 
Z = 2.3 (orange) to Z = 4.0 (yellow) for display purposes. No significant effects were observed after 
placebo intake (data not shown). (A) Raloxifene group, TP items, contrast TR > BL. When compared to 
baseline, raloxifene treatment significantly increases brain activation in parahippocampal and right inferior 
prefrontal cortex. Effects are significant at Z > 3.1. (B) Raloxifene group, TN items, contrast TR > BL (RAL). 
Effects are not significant at Z > 3.1, but are highly similar to treatment effects during TP responses at Z 
> 2.3. C. Raloxifene group versus placebo group, TP items, contrast (TR > BL (RAL)) > (TR > BL (PLAC)) 
(interaction). Increased activation is observed in parahippocampal cortex and right inferior prefrontal 
cortex (areas listed in Table 3). Effects are significant at Z > 3.1. (D) Raloxifene group versus placebo 
group, TN items, contrast (TR > BL (RAL)) > (TR > BL (PLAC)) (interaction). Effects are not significant at Z 
> 3.1, but are highly similar to treatment effects during TP responses at Z > 2.3. The strong resemblance 
of treatment effects on TP and TN contrasts suggests a general effect of raloxifene treatment on brain 
function during recognition, rather than a selective effect on encoding or retrieval processes (see text). 
Plots: Graphs depicting the interaction between mean percent signal change of raloxifene and placebo 
groups at baseline and after treatment, as observed in peak voxels of local maxima of significant effects of 
treatment. Two reference voxels have been sampled in peak voxels of local maxima during face recognition 
in similar slices (10, –76, 16) and (2 –82 4), showing no significant interaction after treatment. Means and 
standard deviations (errorbars) are shown. Arrows indicate the corresponding clusters of activation. See 
also text and Table 3.
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Figure 2. Axial slices showing effects of medication (SS > BL) on activation patterns related to face 
encoding (A) and working memory performance (B). Left in the image is left in the brain. Threshold for 
significant brain activation has been lowered to Z = 2.3 (uncorrected p) for display purposes. Colour 
scale extends from Z = 2.3 (orange) to Z = 4.5 (yellow). Numbered activation blobs are significant at a 
Z-threshold of 3.1 (uncorrected p). Mean_struct_MCI = average T1-weighted brain of 28 MCI patients. A: 
1. Left middle occipital gyrus. 2. Left middle frontal gyrus. 3. Left hippocampus. 4. Right anterior cingulate 
gyrus. 5. Right middle frontal gyrus. B: 1. Right middle frontal gyrus.; 2. Right precuneus.
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Chapter 4.2
Figure 1. Axial slices showing main effects for face encoding observed using models based on the default 
HRF (MA = 6s), and residual variance explained by additional models based on HRFs examining signal 
changes at earlier timepoints after stimulus onset. Effects are rendered on a mean anatomical brain volume 
of all subjects (Mean_anat_AD). Left in the image is left in the brain. Effects are cluster corrected using Z 
= 2.3 and p < 0.05. Colour scale extends from Z = 2.3 (red) to Z = 9.5 (yellow). BL: effects at baseline (no 
galantamine intake); SD: Effects after acute (single dose) intake of galantamine. SS: Effects after prolonged 
galantamine exposure (5 days, steady state plasma levels). A. Signal variance during task performance 
explained by default HRF (MA = 6s), B-F. Residual variance explained by regressors based on HRFs with MA 
= 5-1s, respectively. The final regressor (HRF with MA = 0s) did not explain additional variance.
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Figure 2. Axial slices showing effects of galantamine challenge on activation patterns during face 
encoding (acute intake > baseline). Left in the image is left in the brain. All effects are significant at Z = 3.1. 
Threshold lowered to Z = 2.3 (significant areas only) for display purposes. Colour scale extends from Z = 
2.3 (orange, dark blue) to Z = 4.5 (yellow, light blue). Mean_anat_AD = average T1-weighted brain of 18 AD 
patients. Red: effects of galantamine challenge as captured by a model involving a default hemodynamic 
response function (HRF) with maximum amplitude (MA) at 6s. Activated areas indicate increased signal 
intensity at default onset time compared with baseline. Blue: Residual effects of galantamine challenge as 
captured by a model based on an HRF with MA at 5s (earlier onset time). Activated areas indicate increased 
signal intensity at earlier onset time compared with baseline (and hence a faster response). Arrows 
point to relevant local maxima (Table 1). Coordinates are given at the top of each plot. Plots represent 
reconstructed average BOLD response after stimulus onset, with signal intensity along the vertical axis 
and time from stimulus onset in seconds along the horizontal axis. See text for further details.
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